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A B S T R A C T
Background
Despite advances in treatment, the increasing and ageing population makes heart failure an important cause of morbidity and death
worldwide. It is associatedwith high healthcare costs, partly driven by frequent hospital readmissions.Diseasemanagement interventions
may help to manage people with heart failure in a more proactive, preventative way than drug therapy alone. This is the second update
of a review published in 2005 and updated in 2012.
Objectives
To compare the effects of different disease management interventions for heart failure (which are not purely educational in focus), with
usual care, in terms of death, hospital readmissions, quality of life and cost-related outcomes.
Search methods
We searched CENTRAL, MEDLINE, Embase and CINAHL for this review update on 9 January 2018 and two clinical trials registries
on 4 July 2018. We applied no language restrictions.
Selection criteria
We included randomised controlled trials (RCTs) with at least six months’ follow-up, comparing disease management interventions to
usual care for adults who had been admitted to hospital at least once with a diagnosis of heart failure. There were three main types of
intervention: case management; clinic-based interventions; multidisciplinary interventions.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Outcomes of interest were mortality due to heart failure, mortality
due to any cause, hospital readmission for heart failure, hospital readmission for any cause, adverse effects, quality of life, costs and
cost-effectiveness.
Main results
We found 22 new RCTs, so now include 47 RCTs (10,869 participants). Twenty-eight were case management interventions, seven
were clinic-based models, nine were multidisciplinary interventions, and three could not be categorised as any of these. The included
studies were predominantly in an older population, with most studies reporting a mean age of between 67 and 80 years. Seven RCTs
were in upper-middle-income countries, the rest were in high-income countries.
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Only two multidisciplinary-intervention RCTs reported mortality due to heart failure. Pooled analysis gave a risk ratio (RR) of 0.46
(95% confidence interval (CI) 0.23 to 0.95), but the very low-quality evidence means we are uncertain of the effect on mortality due
to heart failure. Based on this limited evidence, the number needed to treat for an additional beneficial outcome (NNTB) is 12 (95%
CI 9 to 126).
Twenty-six case management RCTs reported all-cause mortality, with low-quality evidence indicating that these may reduce all-cause
mortality (RR 0.78, 95% CI 0.68 to 0.90; NNTB 25, 95% CI 17 to 54). We pooled all seven clinic-based studies, with low-quality
evidence suggesting they may make little to no difference to all-cause mortality. Pooled analysis of eight multidisciplinary studies gave
moderate-quality evidence that these probably reduce all-cause mortality (RR 0.67, 95% CI 0.54 to 0.83; NNTB 17, 95% CI 12 to
32).
We pooled data on heart failure readmissions from 12 case management studies. Moderate-quality evidence suggests that they probably
reduce heart failure readmissions (RR 0.64, 95%CI 0.53 to 0.78; NNTB 8, 95%CI 6 to 13).We were able to pool only two clinic-based
studies, and the moderate-quality evidence suggested that there is probably little or no difference in heart failure readmissions between
clinic-based interventions and usual care (RR 1.01, 95% CI 0.87 to 1.18). Pooled analysis of five multidisciplinary interventions gave
low-quality evidence that these may reduce the risk of heart failure readmissions (RR 0.68, 95% CI 0.50 to 0.92; NNTB 11, 95% CI
7 to 44).
Meta-analysis of 14 RCTs gave moderate-quality evidence that case management probably slightly reduces all-cause readmissions (RR
0.92, 95% CI 0.83 to 1.01); a decrease from 491 to 451 in 1000 people (95% CI 407 to 495). Pooling four clinic-based RCTs gave
low-quality and somewhat heterogeneous evidence that these may result in little or no difference in all-cause readmissions (RR 0.90,
95% CI 0.72 to 1.12). Low-quality evidence from five RCTs indicated that multidisciplinary interventions may slightly reduce all-
cause readmissions (RR 0.85, 95% CI 0.71 to 1.01); a decrease from 450 to 383 in 1000 people (95% CI 320 to 455).
Neither case management nor clinic-based intervention RCTs reported adverse effects. Two multidisciplinary interventions reported
that no adverse events occurred. GRADE assessment of moderate quality suggested that there may be little or no difference in adverse
effects between multidisciplinary interventions and usual care.
Quality of life was generally poorly reported, with high attrition. Low-quality evidence means we are uncertain about the effect of
case management and multidisciplinary interventions on quality of life. Four clinic-based studies reported quality of life but we could
not pool them due to differences in reporting. Low-quality evidence indicates that clinic-based interventions may result in little or no
difference in quality of life.
Four case management programmes had cost-effectiveness analyses, and seven reported cost data. Low-quality evidence indicates that
these may reduce costs and may be cost-effective. Two clinic-based studies reported cost savings. Low-quality evidence indicates that
clinic-based interventions may reduce costs slightly. Low-quality data from one multidisciplinary intervention suggested this may be
cost-effective from a societal perspective but less so from a health-services perspective.
Authors’ conclusions
We found limited evidence for the effect of disease management programmes on mortality due to heart failure, with few studies
reporting this outcome. Case management may reduce all-cause mortality, and multidisciplinary interventions probably also reduce
all-cause mortality, but clinic-based interventions had little or no effect on all-cause mortality. Readmissions due to heart failure or
any cause were probably reduced by case-management interventions. Clinic-based interventions probably make little or no difference
to heart failure readmissions and may result in little or no difference in readmissions for any cause. Multidisciplinary interventions
may reduce the risk of readmission for heart failure or for any cause. There was a lack of evidence for adverse effects, and conclusions
on quality of life remain uncertain due to poor-quality data. Variations in study location and time of occurrence hamper attempts to
review costs and cost-effectiveness.
The potential to improve quality of life is an important consideration but remains poorly reported. Improved reporting in future trials
would strengthen the evidence for this patient-relevant outcome.
P L A I N L A N G U A G E S U M M A R Y
Disease management programmes for heart failure
Review question
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We investigated the effects of disease management programmes on death from heart failure or from any cause, hospital readmissions
for heart failure or for any cause, adverse effects, quality of life and cost-effectiveness, in adults who had been admitted to hospital at
least once for heart failure.
Background
Heart failure affects a person’s quality of life, is a frequent cause of hospital admission and has a high risk of death. Traditional drug
therapy is the main treatment, but people may benefit from additional support from disease management programmes that aim to
provide ongoing support rather than crisis management. Such programmesmay be run by specialist nurses, as clinic-based interventions,
or by multidisciplinary teams. Community-based support of this kind could help to keep people out of hospital by improving day-to-
day symptom management and providing an ‘early warning system’ for changes requiring medical attention.
Selection criteria
We conducted a comprehensive search for all studies investigating heart failure-specific disease management interventions for adults
who had been admitted to hospital at least once for heart failure (evidence current to 9 January 2018).
Results and conclusions
We included 47 studies, with a total of 10,869 participants. Twenty-eight studies were case management interventions, seven were
clinic-based models, nine were multidisciplinary interventions and three could not be categorised as any of these. The average age of
the people in most of the studies was between 67 and 80 years old, although 10 studies had younger participants on average, and one
included mostly very elderly people. Most trials were in Europe and North America, but others took place in China, Taiwan, Iran and
Japan.
We found limited evidence for an effect on mortality due to heart failure, as few studies reported this outcome. There was some evidence
that casemanagementmay reduce all-causemortality, andmultidisciplinary interventions probably do, but clinic-based studies appeared
to have little or no effect on this. Readmissions due to heart failure and due to any cause were probably reduced by case management
interventions. Clinic-based interventions probably make little or no difference to heart failure readmissions and may result in little or
no difference in readmissions for any cause. Multidisciplinary interventions may reduce the risk of readmission for heart failure or any
cause.
Only two studies mentioned adverse events, both stating that none occurred. Many studies measured quality of life, but it is difficult to
draw conclusions for any effect because they tended to report this in different ways and did not report it for all their participants. Data
on costs and cost-effectiveness were limited, but indicated a slight benefit of disease management programmes, mostly due to reduced
hospital readmission costs.
Quality of the evidence
The quality of evidence was very low for mortality due to heart failure, low to moderate for all-cause mortality, low to moderate for heart
failure readmissions, and all-cause readmissions, moderate for adverse events (where available), low to very low for quality of life and
low to moderate for costs. The quality of evidence is important as it impacts on how certain we can be in the effect of the intervention
on the outcomes we are interested in. For example, if the evidence is of very low quality, we cannot be certain of the intervention’s
effect.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Case management compared to usual care for heart failure
Patient or population: adults with heart failure
Setting: community
Intervention: case management
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care Risk with case man-
agement
HF mortality - - - - - Not reported
All- cause mortality
Follow-up: median 12
months
Study populat ion RR 0.78
(0.68 to 0.90)
6903
(26 RCTs)
⊕⊕©©
Low1,2
Case management may
reduce all-cause mor-
tality.
NNTB 25 (95% CI 17 to
54)187 per 1000 146 per 1000
(127 to 168)
HF readmissions
Follow-up: median 12
months
Study populat ion RR 0.64
(0.53 to 0.78)
2528
(12 RCTs)
⊕⊕⊕©
Moderate3
Case management
probably reduces HF
readmissions: NNTB 8
(95% CI 6 to 13)
3 addit ional studies had
data that could not be
included in the meta-
analysis361 per 1000 231 per 1000
(191 to 282)
All- cause
readmissions
Follow-up: median 10.5
months
Study populat ion RR 0.92
(0.83 to 1.01)
4539
(14 RCTs)
⊕⊕⊕©
Moderate4
Case manage-
ment probably reduces
all-cause readmissions
slight ly: NNTB 26 (95%
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CI NNTH 204 to NNTB
12)
6 addit ional studies had
data that could not be
included in the meta-
analysis
491 per 1000 451 per 1000
(407 to 495)
Adverse effects - - - - None of the included
studies reported ad-
verse ef fects
Quality of life (MLHFQ
mean score at end of
follow-up)
Follow-up: median 6
months
Analysis 1.13 includes 8 studies, six of which
show a broadly posit ive ef fect of case manage-
ment intervent ions, however, 2 small studies in-
dicate that QoL may actually be lower in the
case management groups. High heterogeneity
precludes pooling these studies in a meta-anal-
ysis. 3 other studies also reported MLHFQ but
for unclear or reduced numbers of part icipants.
There was lit t le evidence for any dif ference be-
tween groups in studies that did not report ML-
HFQ, but only used the EQ-5D, SF-8, SF-36 or
KCCQ tools
- 1595
(8 RCTs)
⊕©©©
Very low5,6,7
A lower score indicates
better quality of lif e on
the MLHFQ.
We are uncertain about
the ef fect of case man-
agement on QoL.
Costs and cost-effec-
tiveness
Follow-up: median 6
months
Cost-ef fect iveness analyses of 3 intervent ions
generally suggest small CE benef its over usual
care, but another one reported a cost of EUR
3746 per QALY gained with case management
compared with usual care
7 case management studies reported the costs
of their programmes, although the wide range
in dates and locat ions of studies complicates
interpretat ion: 2 reported higher costs for inter-
vent ion groups; 4 reported lower costs (generally
af ter taking readmission costs into account); and
1 reported no dif ference in costs
- 2369
(11 RCTs)
⊕⊕©©
Low8,9
Case management may
reduce costs and im-
prove cost-ef fect ive-
ness slight ly
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CE: cost-ef fect iveness; CI: conf idence interval;HF: heart failure;MLHFQ: Minnesota Living with Heart Failure Quest ionnaire; NNTB/H: number needed to treat for an addit ional
benef icial/ harmful outcome; QALY: quality-adjusted lif e year; QoL: quality of lif e; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1We could include only 11 of the 26 studies in the sensit ivity analysis, and this showed a stronger posit ive ef fect than the
main analysis. Downgraded once for risk of bias.
2Funnel plot is slight ly asymmetric. Downgraded once for possible publicat ion bias.
3Funnel plot is asymmetric and suggests publicat ion bias - downgraded by one level.
4Conf idence Interval includes the null as well as a small ef fect. Downgraded once for imprecision.
5Unclear or high risk of attrit ion bias for majority of studies for this outcome. Study was not blind and this outcome was self -
assessed. Downgraded by two levels for risk of bias.
6High heterogeneity, and although subgroups dif fer, there remains high heterogeneity in 6-month follow-up studies.
Downgraded once for inconsistency.
7Downgraded once for imprecision as reported results vary widely.
8Only 4 studies had cost-ef fect iveness analysis; 7 others reported costs which were hard to generalise. Downgraded once for
indirectness of evidence.
9There was variat ion in the direct ion of ef fect for cost studies. Downgraded once for inconsistency.
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B A C K G R O U N D
Description of the condition
Worldwide approximately 26 million adults are living with heart
failure (Bui 2011; Savarese 2017), and the condition is increas-
ingly common in both economically developed and economically
developing countries (Ponikowski 2014; Roger 2012). The crude
prevalence of heart failure is typically around one to two per cent
in the general population (Lloyd-Jones 2010; Ponikowski 2014).
Both the incidence and prevalence of heart failure increase with
age, with data from the USA indicating that the incidence of heart
failure approaches 21 per 1000 population for those aged 65 and
over (Benjamin 2017). The AmericanHeart Association estimates
that the heart failure incidence rate doubles for each 10-year in-
crease in age from 65 to 85 years of age for men (Benjamin 2017;
Karmali 2014), and triples for women between the ages of 65 to
74 and 75 to 84 (Benjamin 2017; Lackland 2012).
Most people with heart failure are elderly. In the English andWelsh
National Heart failure audit the median age of patients discharged
from hospital with a diagnosis of heart failure was 80 years - with
66% aged over 75 years and 30% aged over 85 years (NICOR
2013).With an aging population, an increasing number of people
will be at risk of heart failure. In the UK, for example, Conrad
2018 reported that a decline in age- and sex-standardised heart
failure incidence was seen between 2002 and 2014, but, due to the
increase in size and age of the population, the estimated number
of prevalent cases increased by 23%, from 750,127 in 2002 to
920,616 in 2014.
Despite the fact that in many countries survival has improved in
recent years, the condition carries a substantial risk of death world-
wide: 17% to 45% of people admitted to hospital die within one
year (Ponikowski 2014). In high-income countries, chronic heart
failure accounts for more than 10% of deaths (Kaur 2017). For
low- and middle-income countries, the proportion is substantially
higher, with 28% of deaths being due to chronic heart failure Kaur
2017. In addition to the risk of death, the condition has a pro-
found impact on patients’ quality of life (Bekelman 2007; Juenger
2002; Stewart 1989).
A primary diagnosis of heart failure accounts for one to two per
cent of all admissions in economically developed countries and
for one to three per cent of all healthcare expenditure in Europe,
North America, and Latin America (Ponikowski 2014). The total
annual cost of heart failure to the UK National Health Service
is around GBP one billion (2% of the total NHS budget), and
most of this cost (approximately 70%), is incurred by hospital
admissions (Lancet 2011; NICE 2012). The estimated cost of
treating heart failure was USD 30.7 billion in the USA in 2012,
expected to rise to USD 69.7 billion by 2030 (Benjamin 2017).
Description of the intervention
Drug therapy is the mainstay of treatment for heart failure, al-
though invasive procedures and devices are indicated for some pa-
tients, and patients are usually managed with a combination of
medications and lifestyle advice (NICE 2010). The management
of people with heart failure has evolved from a traditional model,
with its emphasis on crisis intervention, towardsmuchmore proac-
tive, preventative disease management models. These care models
offer ’aggressive care’ in hospital, home or clinic (Riegel 2001).
Riegel proposed three types of heart failure disease management
models (Riegel 2001), and we have used her typology to identify
appropriate types of intervention to include in this review.
• Case management, defined as “the active management of
high-risk people with complex needs, with case managers
(usually nurses) taking responsibility for caseloads working in an
integrated care system” (DoH 2004)
• Clinical interventions such as enhanced or novel service
provision (for example the introduction of a specialist nurse led
heart failure clinic)
• Multidisciplinary interventions such as disease management
interventions, defined as “a system of coordinated healthcare
interventions and communications for populations with long-
term conditions in which patient self-care is significant” (Royal
College of Physicians 2004)
In addition to different settings such “clinical service interven-
tions” may differ in their components, duration, intensity and the
number and type of healthcare professionals involved.
How the intervention might work
Early hospital readmission in people with heart failure is extremely
common. In the USA almost 30% of patients are re-hospitalised
within 90days of discharge (Gheorghiade 2013). In the EuroHeart
Failure survey, which included 24 countries, 24% of people admit-
ted with confirmed or suspected heart failure were readmitted to
hospital within 12 weeks - heart failure was the principal cause of
readmission (20% of readmissions), and contributed to a further
16% of readmissions (Cleland 2003). More recently, Toback 2017
reports that 17% to 27% of people hospitalised with heart fail-
ure will be readmitted within 30 days of discharge (Ghosh 2016;
Jencks 2009).
Disease management interventions might reduce the risk of read-
mission to hospital by providing ongoing, direct support to pa-
tients post-discharge. Facilitating earlier contact with specialists
and improving symptom monitoring could help manage patients
in their own homes and avoid the need for frequent emergency
hospital readmissions.
Why it is important to do this review
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The ESC 2016 guidelines (ESC 2016), recommend multidisci-
plinary care, but state that there is no evidence that non-pharma-
cological, non-device or surgical interventions on their own im-
prove mortality, morbidity or quality of life. The current review
therefore provides a useful overview of the impact of such disease
management programmes on patients’ quality of life, risk of hos-
pital readmission, and risk of mortality. We have also attempted
to include data on cost-effectiveness and costs, where this infor-
mation is available for the included studies.
Since the previous update of the review, there have been a number
of new studies published in this area. There are nowRCTdata from
a broader range of countries and populations than were available
for the Takeda 2012 update, and inclusion of this should widen
the generalisability of findings.
O B J E C T I V E S
To compare the effects of different disease management interven-
tions for heart failure (which are not purely educational in focus),
with usual care, in terms of death, hospital readmissions, quality
of life and cost-related outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with a mini-
mum of six months’ follow-up in the review. Both individually
randomised and cluster-randomised trials were eligible for inclu-
sion. Cross-over trials could be feasible in this area, so would be
included if any were identified. However, we did not identify any.
Studies reported as full text, those only published as abstracts, and
unpublished data were all eligible for inclusion.
Types of participants
This review focused on adults aged 18 years andover, whohadbeen
admitted at least once to secondary care with a diagnosis of heart
failure. We focused on people who had been hospitalised for heart
failure, because they represented a group at high risk of frequent
readmission. We excluded studies dealing principally with people
with cardiac disorders other than heart failure, or with heart failure
arising from congenital heart disease, or valvular heart disease, or
both. Where a study in the last updated review (Takeda 2012)
included only a subgroup of relevant participants, we included
the study if the majority of participants met the inclusion criteria.
For studies identified in the most recent update, we contacted
authors to source data for the relevant subgroup. Where this was
not possible, we included the study if the majority of participants
were eligible.
Types of interventions
We included clinical service disease management interventions
(defined as inpatient, outpatient or community-based interven-
tions or packages of care), directed specifically at people with heart
failure. This excluded the simple prescription or administration of
a pharmaceutical agent(s) to people with heart failure. Interven-
tions could include or exclude patients’ relatives or carers.
We used the typology of Riegel 2001 to classify studies for this
review, as described in the Background section: case management,
clinic-based interventions, and multidisciplinary interventions.
We did not include the following types of interventions in this
review.
• Interventions that were purely educational in focus,
without any follow-up phone calls or interaction between the
patients and provider.
• Interventions that only consisted of exercise programmes.
• Interventions described as cardiac rehabilitation
programmes, unless they also had case management elements.
Cardiac rehabilitation was defined as a structured programme
offered to individuals after a cardiac event to aid recovery and
prevent further cardiac illness. Cardiac rehabilitation
programmes typically achieve this through exercise, education,
behaviour change, counselling and support, and strategies that
are aimed at targeting traditional risk factors for cardiovascular
disease (Taylor 2010).
• ’Generic’ interventions, not exclusively aimed at people
with heart failure, directed at reducing readmission or morbidity
in populations of older people with a variety of long-term
conditions.
• Solely telemedicine interventions, where telemedicine is
defined as the “transfer of physiological data via digital cable e.g.
electrocardiograph (ECG), blood pressure (BP), weight, pulse
oximetry (SPO2), respiratory rate and medicine
administration)”, as these were the focus of another Cochrane
Review (Inglis 2015).
• Interventions that only consisted of structured telephone or
videoconferencing support, including computer-assisted
education and monitoring, as these were in another systematic
review (Clark 2007).
We did not exclude interventions that included structured or
unstructured telephone or videoconferencing support alongside
other non-telemedicine components, such as attendance at a clinic
or home visiting.
The comparator of interest is ’usual care’, and we acknowledge
that variation in local practice could introduce heterogeneity to
the review. We collected data on how usual care was described in
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the published reports, as a source of information to explore this
possibility.
We have conducted three comparisons for this review:
• case management interventions versus usual care
• clinic-based interventions versus usual care
• multidisciplinary interventions versus usual care
We have provided a narrative summary to describe separately any
studies that we could not classify as one of these three types of
intervention.
Types of outcome measures
We extracted outcomes for the longest available follow-up. Re-
porting of one of these outcomes was not an inclusion criterion
for the review. We included mortality due to heart failure as well
as all-cause mortality in an attempt to identify the impact of heart
failure-specific interventions, which may be masked by deaths
from other causes if the emphasis is on all-cause mortality (Sasieni
2017).
Primary outcomes
• Mortality due to heart failure (where this is reported
separately from all cardiac causes)
• All-cause mortality
• Readmissions due to heart failure (where this is reported
separately from all cardiac related readmissions)
• All-cause readmissions
• Adverse effects
Secondary outcomes
• Health-related quality of life, using a validated instrument
• Costs or cost-effectiveness
Where studies reported multiple quality-of-life assessments, we
have prioritised the Minnesota Living with Heart Failure Ques-
tionnaire (MLHFQ), as this was the most widely reported instru-
ment.
Search methods for identification of studies
Electronic searches
We searched the following databases for this update on 9 January
2018 (search strategies in Appendix 1):
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, issue 1) in the Cochrane Register of Studies;
• Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 9
January 2018);
• Embase (Ovid, 1980 to 2018 Week 02);
• CINAHL Plus with Full Text (EBSCO, 1937 to 9 January
2018);
• DARE Issue 2 of 4, 2015 (Cochrane Library) - no longer
updated.
The RCT filter for MEDLINE is the Cochrane Highly Sensitive
Search Strategy for identifying trials in MEDLINE: sensitivity-
maximising version, and for Embase, we applied terms as recom-
mended in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Lefebvre 2011). We applied no language restrictions.
We also searched two clinical trials registries on 4 July 2018 (search
terms in Appendix 1):
• ClinicalTrials.gov (www.clinicaltrials.gov);
• WHO International Clinical Trial Registry Platform
(ICTRP, apps.who.int/trialsearch/).
We did not search some previously searched databases for this
update, as limited resources meant we had to restrict searches to
the major databases.
Details of the searches for the previous versions of the review can be
found in the respective publications (Takeda 2012; Taylor 2005).
Searching other resources
In addition, we screened lists of included studies from relevant
systematic reviews. We contacted study authors to clarify reported
information or to obtain unpublished data.
Data collection and analysis
Selection of studies
Two review authors independently assessed the title and abstract
of each reference ( AT, ST or NM for this 2018 update). Two
authors independently assessed the full texts of all potentially el-
igible papers retrieved ( AT, ST or NM for this 2018 update)
and coded them as ’retrieve’ or ’exclude’. For non-English lan-
guage papers, which appeared to be eligible for inclusion on the
basis of the title and abstract, we sought the assistance of peo-
ple with appropriate language skills via Cochrane TaskExchange
( taskexchange.cochrane.org/). We resolved any disagreements
about eligibility by discussion between at least two authors (AT,
NM), with a third author (ST) being consulted where we could
not reach consensus. For studies with multiple publications, we
collated these so that each study rather than each report was the
unit of interest in the review. We recorded the selection process in
detail and described it in a PRISMA flow diagram (Liberati 2009;
Figure 1).
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Figure 1. Study flow diagram for 2018 update
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Data extraction and management
We developed a new data extraction form for this update, piloted
by two review authors (NM, AT). Three review authors (AT, NM,
ST), conducted the data extraction for studies published since
the 2012 publication. One review author extracted study char-
acteristics and a second author checked them, and two review
authors independently extracted outcomes. An exception to this
was Salehitali 2009, where a volunteer (FS), with Persian language
skills, kindly carried out data extraction and assessed risk of bias.
This could only be compared against the English language abstract
by a second review author.
Where we were unclear about issues arising from their published
papers we attempted to contact the study authors for clarification.
We extracted the following information from included studies.
• Methods: study design, total duration of study, number of
study centres and location, study setting and date of recruitment
• Participants: number randomised, number lost to follow-up
or withdrawn, number analysed, mean age, age range, gender,
severity of condition, diagnostic criteria, comorbidities, inclusion
criteria, and exclusion criteria
• Interventions: intervention, comparison
• Outcomes: primary and secondary outcomes specified and
collected, and time points reported
• Notes: study funding, and notable conflicts of interest of
study authors
For this update, one review author (AT), transferred data into the
Review Manager 5 (RevMan 5) file (Review Manager 2014). A
second review author (NM), double-checked that data had been
entered correctly by comparing the data presented in the systematic
review with the trial reports.
Assessment of risk of bias in included studies
Two of three review authors (AT, ST, NM), assessed all new and
previously included studies by using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2017). We resolved any disagreements by discussion or by involv-
ing a third review author. We assessed the risk of bias according to
the following domains:
• random sequence generation
• allocation concealment
• blinding of participants and personnel
• blinding of outcome assessment (assessed separately for
objective and subjective outcomes)
• incomplete outcome data
• selective outcome reporting
• other bias
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgment in the ’Risk of bias’ table.
Categorising the interventions
We used Riegel’s heart failure disease management models (Riegel
2001), to group the different interventions for synthesis as follows.
Case management models
Casemanagementmodels consist of intensemonitoring of patients
following discharge from hospital, this is usually done by a nurse
and typically involves home visits or telephone calls, or both.
Clinic-based intervention models
Clinic-based intervention models involve outpatient clinics for
heart failure. They are usually run by cardiologists with a special
interest in heart failure or by specialist nurses using agreed proto-
cols to manage medication.
Multidisciplinary models
Multidisciplinary models offer a holistic approach to the individu-
als’ medical, psychosocial, behavioural and financial circumstances
and typically involve several different professions working in col-
laboration. The gap between hospitalisation, other healthcare de-
livery systems (e.g. skilled nursing facilities, hospice), and home is
bridged by a teamof individuals knowledgeable about heart failure
and committed to patient care.
Measures of treatment effect
We analysed dichotomous data as risk ratios (RR) with 95%
confidence intervals (CI) and continuous data as mean differ-
ences (MD) with 95% CIs. For quality of life, we prioritised the
widely reported Minnesota Living with Heart Failure Question-
naire (MLHFQ). On this scale, a lower score indicates a better
quality of life. We considered a change of five points to repre-
sent a clinically meaningful difference (Rector 1995). For out-
comes where a pooled RR was calculated, we calculated the num-
ber needed to treat for an additional beneficial/harmful outcome
(NNTB/NNTH), following methods outlined in the Cochane
Handbook for Systematic Reviews of Interventions (Schünemann
2017) and using the online calculator NNT Online. We used the
assumed risk with control from the ’Summary of findings’ table
as the ’assumed comparator risk’. Where the RR was greater than
one, the CI for the NNTB includes a NNTH and a NNTB, due
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to inclusion of the null. For example, a NNTB of 15 could have
a CI spanning from a NNTB of 8 to a NNTH of 223.
Unit of analysis issues
One study (Jaarsma 2008), had two intervention arms and a single
control arm. Since the interventions were of different types (one
case management and one clinic-based intervention), we treated
these as separate comparisons, and as such, they never appear to-
gether in the samemeta-analysis.We have therefore used the whole
control arm for both comparisons. Had the two intervention arms
of this study appeared within the same meta-analysis, we would
have halved the control arm and used half for each comparison,
to avoid double counting. For trials that reported at multiple time
points, we have used the longest follow-up. We included two clus-
ter-RCTs (Doughty 2002; Thompson 2005). Doughty 2002 ran-
domised at the GP level, but then presented results at the partic-
ipant level. Whilst this would usually present a unit of analysis
problem, we accepted the study author’s reasoning that the me-
dian number of participants per GP was 1.5, so the influence of
clustering was small. We also carried out sensitivity analysis that
excluded this study. Thompson 2005 only contributed quality-of-
life data in a format that could not be pooled in the meta-analysis,
so we did not re-analyse this.
Dealing with missing data
We contacted study authors to verify key study characteristics
where these were unclear, for example, whether or not participants
had been hospitalised for heart failure. We also attempted to ob-
tain missing numerical outcome data from study authors where
possible (e.g. when a study was identified as abstract only). Where
this was not possible, we considered whether themissing data were
likely to introduce serious bias. If we did not consider the data
to be missing at random, we planned to explore the impact of
including such studies using sensitivity analysis for primary out-
comes. Since the only outcome with considerable attrition was
quality of life (a secondary outcome), this was not required. We
used the RevMan 5 Calculator to calculate missing standard devi-
ations from P values where required, and noted this in footnotes
to the forest plots (ReviewManager 2014).We have not made any
assumptions about missing data, so if study authors only reported
available case data, for example for quality of life, we have used
the number of responders as the denominator, not the number of
people randomised.
Assessment of heterogeneity
We anticipated a high degree of heterogeneity due to differences in
interventions, usual care definitions, and participant groups. We
visually inspected forest plots to see if directions of effect differed
between studies, and to assess the degree of overlap between stud-
ies. We calculated the I2 statistic (Higgins 2003) to formally mea-
sure heterogeneity, using the following guide from the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2017):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity
In all cases, we considered the magnitude and direction of effects
and the strength of evidence according to the P value from the Chi
2 test when interpreting the I2 value. In particular, we considered
the substantial uncertainty associated with its value when there
were only a small number of studies in the meta-analysis (Higgins
2017).
Assessment of reporting biases
For outcomes reported by at least 10 trials, we constructed funnel
plots to assess possible publication bias (Sterne 2017).
Data synthesis
We analysed the data using Cochrane Review Manager software,
RevMan 5.3 (Review Manager 2014). Where possible and appro-
priate, we combined the trial results statistically using meta-ana-
lytic methods. Given the high degree of heterogeneity expected in
the studies due to differences in interventions, usual care defini-
tions, and participant groups, we applied a random-effects model
for the meta-analyses. We used the Mantel-Haenszel method to
pool risk ratios, and the inverse variance method to combine stud-
ies reporting health-related quality of life (to allow inclusion of a
study that only reported the mean difference between treatment
arms but not the group-specific data).
GRADE and ’Summary of findings’ tables
We created three ’Summary of findings’ tables, one for each disease
management intervention (case management, clinic-based inter-
ventions and multidisciplinary interventions). We used methods
and recommendations described in Section 8.5 (Higgins 2017)
and Chapter 12 (Schünemann 2017) of the Cochrane Handbook
for Systematic Reviews of Interventions, and used GRADEpro GDT
software to generate the tables (GRADEpro GDT 2015).
Each table includes all five primary outcomes and the two sec-
ondary outcomes. Two review authors (AT, NM) used the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to independently
assess the quality of the body of evidence relating to the stud-
ies that contributed data to the meta-analyses for each outcome.
Where there were studies that reported the outcomes in a way that
we could not meta-analyse, we added a narrative description to
12Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the table. We describe justifications for downgrading decisions in
footnotes to the table and in the section Quality of the evidence .
Subgroup analysis and investigation of heterogeneity
We carried out subgroup analysis by length of follow-up (compar-
ing studies with six months’ or less follow-up against those with
over six months’ follow-up). We also assessed the impact of de-
livery of the intervention using subgroup analysis by particular
professional groups (for example pharmacists, specialist nurses).
For primary outcomes with at least 10 studies we undertook a
random-effects meta-regression using the ’metareg’ command in
Stata, weighting studies by the standard error (SE) of the log RR,
to assess whether particular intervention components were more
strongly associated with positive outcomes. We only undertook
meta-regression for case management studies, due to a lack of
sufficient trial numbers for the other categories of intervention.
Sensitivity analysis
We undertook two sensitivity analyses, for the primary outcomes
only.
• To explore the impact of the cluster-randomised control
trial (Doughty 2002), by comparing the results with and without
this study, for the only outcome that included this trial (clinic-
based intervention versus usual care, all-cause mortality).
• To restrict the analyses to only those studies at low risk of
bias in the key domains of random sequence generation and
allocation concealment, and at low or unclear risk for incomplete
outcome data (attrition bias). We considered blinding separately
for objective and subjective outcomes separately, but since quality
of life was only a secondary outcome we did not undertake
sensitivity analyses for this outcome. We have therefore not
included blinding as a domain for our sensitivity analysis.
We considered a sensitivity analysis exploring the impact of miss-
ing data. The most common area for missing data was in qual-
ity-of-life assessments (either missing standard deviation, which
had to be imputed, or large numbers of participants missing from
analyses). As this was a secondary outcome, we did not undertake
sensitivity analysis for missing data.
R E S U L T S
Description of studies
Results of the search
Figure 1 describes the search process for this update and the pre-
vious publication. The searches for this updated review retrieved
7910 records from the databases and 1109 records from the clini-
cal trials registries. After deduplication 6883 records remained for
screening. We excluded 6631 records based on title and abstract
screening and assessed 252 full-text papers for inclusion.
Based on assessment of the full texts, we excluded 160 references
reporting 124 studies. We also moved a previously excluded ab-
stract to a linked new full publication marked as ’awaiting classi-
fication’, and linked a previously excluded cost-effectiveness anal-
ysis to one of our included studies. Adding these to the previously
excluded 93 studies (103 references) gives a total of 217 excluded
studies (261 references).
We found 22 new studies for inclusion (61 references) and an ad-
ditional two references for a previously included study. In addition
to the previously included 25 studies (32 references) this gives a
total of 47 included studies (95 references), with a total of 10,869
participants.
We also identified 12 new ongoing studies (14 references) and 15
new studies that are awaiting classification (18 references). For this
update, we reassessed all studies previously listed as ongoing or
awaiting classification,moving themeither to included or excluded
studies where possible.
Included studies
Control participants received ’usual’ or ’routine’ care in the ma-
jority of studies. In some studies, small additional components
were mentioned. For example, both control and intervention par-
ticipants received a programme of ’optimised’ medical care after
discharge from the index hospitalisation in Del Sindaco 2007,
and guideline-standard management was described in Lang 2018.
In two studies (Leventhal 2011; Tsuchihashi-Makaya 2013), all
enrolled participants received comprehensive discharge education
using an information booklet. Other studies alsomentioned infor-
mation sheets or short education sessions at discharge (Bekelman
2015; Bernocchi 2017; Gonzalez-Guerrero 2014). In others, a fol-
low-up phone call or outpatient adjustment to medication was
standard care (Chen 2018; Ong 2016). Dunbar 2014 mentioned
an “attention control” component of telephone calls on the same
schedule as the intervention participants, with information about
the trial but no heart failure-specific information.
Just over half (25) of the studies were carried out at single centres,
and 22 were multicentre studies. Six studies took place at two
centres (Agren 2012; de Souza 2014; Kasper 2002; Kwok 2008;
Lopez 2006; Thompson 2005); 13 at three to nine centres (Atienza
2004; Bekelman 2015; Berger 2010; Bernocchi 2017; Brotons
2009; DeBusk 2004; Dunbar 2014; Holland 2007; Kimmelstiel
2004; Naylor 2004; Ong 2016; Stromberg 2003; Tsuchihashi-
Makaya 2013), and three at 10 or more centres (Cavusoglu 2017;
Jaarsma 2008; Tsuyuki 2004).
All the studies were led by professionals from secondary or tertiary
care. None of the 47 interventions were delivered in exactly the
same way by the same type of personnel, although some were very
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similar and all the interventions had overlapping content (seeTable
1). The interventions varied in site, intensity and duration (see
Characteristics of included studies). Length of follow-up ranged
from six months to two years.
Inclusion and exclusion criteria
The studies differed in their inclusion and exclusion criteria.
All of the studies identified participants during or following an
index hospital admission, or confirmed that participants had
been previously hospitalised for heart failure. Participants in
Gonzalez-Guerrero 2014 had acute heart failure according to Eu-
ropean Society of Cardiology (ESC) criteria. Two studies specifi-
cally enrolled people with particular comorbid conditions; people
included in Bernocchi 2017 had to have both heart failure and
chronic obstructive pulmonary disease, and those in Dunbar 2014
had to have both heart failure and diabetes.
Two studies excluded people with diastolic heart failure or heart
failurewith preserved systolic function (Blue 2001;Tsuyuki 2004).
Several of the studies mentioned excluding people with valvu-
lar heart disease requiring surgery (DeBusk 2004; Del Sindaco
2007; Doughty 2002; Holland 2007; Jaarsma 2000; Kasper
2002; Mejhert 2004; Stewart 1999a), or excluded people await-
ing cardiac surgery (Atienza 2004; Holland 2007; Jaarsma 2008;
Thompson 2005). Agren 2012 excluded people currently under-
going cardiac surgery, and Tsuchihashi-Makaya 2013 excluded
people with end-stage heart failure. Four studies specifically ex-
cluded heart failure associated with acute myocardial infarction
(Blue 2001; de Souza 2014; Ducharme 2005; Kasper 2002), and
one excludedheart failure associatedwith cor pulmonale (Nucifora
2006). Leventhal 2011 excluded people with severe myocardial or
valvular obstructive disease. The presence of serious comorbidity
or other terminal illness was a common exclusion criterion, and
most of the studies excluded people discharged to long-term care
facilities, such as nursing homes. Clark 2015 excluded people with
New York Heart Association (NYHA) class IV heart failure.
The participants enrolled in the studies
The majority of studies (36 of 47) had between 100 and 350
participants. Ong 2016 randomised 1437 people, the COACH
study, reported by Jaarsma 2008, randomised 1049 and Bekelman
2015 randomised 392 people. Seven studies (Chen 2018; Clark
2015; Krumholz 2002; Lang 2018; Leventhal 2011; Rainville
1999; Shively 2013) randomised fewer than 100 participants.
For the majority of the 47 included studies, the mean or median
age of participants was between approximately 67 and 80 years old.
Participants in nine studies were considerably younger on average,
with median or mean ages under 65 years (Capomolla 2002;
Cavusoglu 2017; Chen 2018; Clark 2015; de Souza 2014;Dunbar
2014; Kasper 2002; Mao 2015; Mehralian 2014). The mean age
of participants in Gonzalez-Guerrero 2014 was approximately 85
years old.
The severity of heart failure ranged across studies, with the major-
ity (N = 37) of the studies reporting a summary statistic for partic-
ipants’ baseline NYHA class. The percentage of participants with
moderate (class III) or severe (class IV) heart failure ranged from
under one per cent in Tsuchihashi-Makaya 2013, approximately
6% in Brotons 2009 and 16% in Lopez 2006, to 75% or more
in 14 of the studies (Berger 2010; Blue 2001; Chen 2018; Del
Sindaco 2007; Doughty 2002; Ducharme 2005; Jaarsma 2000;
Mao 2015; Ong 2016; Rainville 1999; Salehitali 2009; Stromberg
2003; Thompson 2005; Wierzchowiecki 2006). The mean (SD)
NYHA class in Gonzalez-Guerrero 2014 was 2.5 (0.7) in the in-
tervention arm and 2.3 (0.8) in the control arm. Mehralian 2014
reported that the most prevalent class was III (67.3% of the in-
tervention group and 82% of the control group had this level of
disease).
Fewer than half of the studies were carried out in Europe (N = 23).
Others took place in the USA (N = 11), China (N = 3), Canada
(N = 2), Australasia (N = 2), Iran (N = 2), and one each in Japan,
Brazil, Taiwan and Turkey. Seven of the studies therefore took
place inWorld Bank-defined upper middle-income countries, and
the rest in high-income countries (World Bank 2018).
As would be expected in the generally elderly participants of these
studies, many people had comorbid conditions. For example, of
the 38 studies reporting diabetes, the proportion of people with
this comorbidity ranged from11% (Agren 2012; Leventhal 2011),
to the majority (Bekelman 2015; Mao 2015), or even 100% (
Dunbar 2014), as this was an inclusion criterion for that study.
Twenty-one studies were publicly funded, two by charities (
Jaarsma 2000; Yu 2015a), and four by a combination of public
and charity funds (Cline 1998; Leventhal 2011; Mejhert 2004;
Ong 2016). A further two studies were funded by charity and
industry (Jaarsma 2008; Kimmelstiel 2004), and three more by
a combination of charity, public, and industry support (Holland
2007; Krumholz 2002; Tsuchihashi-Makaya 2013). Five stud-
ies were solely industry-funded (Berger 2010; Doughty 2002;
Ducharme 2005; Kasper 2002; Thompson 2005), and two more
were supported by both industry and public funding (Brotons
2009; Tsuyuki 2004). The remaining nine studies did not re-
port their funding sources (Bohmer 2011; Capomolla 2002; Del
Sindaco 2007; Mehralian 2014; Nucifora 2006; Rainville 1999;
Shively 2013; Stewart 1999a).
Categorising the interventions
We used Riegel’s classification (Riegel 2001), to group the inter-
ventions based on the content and nature of the interventions as
they were described in the papers. In practice there appears to be
considerable overlap between these disease management models
and it was not always easy to classify them. Table 1 summarises
some of the similarities and differences between the interventions.
One intervention involved a day hospital, heart failure-manage-
ment programme (Capomolla 2002), and was difficult to cate-
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gorise. Two more did not fit into any of the classifications. Agren
2012 was an educational and psychological support intervention,
andShively 2013was a self-management support intervention.We
considered that the remaining interventions fell predominantly
into the following groups:
• 28 studies and the intensive intervention arm of Jaarsma
2008 were variations on the case management approach.
• We classified seven studies as clinic-based intervention
models (but with aspects of case management, i.e. telephone
follow-up; Bohmer 2011); Cline 1998; Doughty 2002; Jaarsma
2008 (basic intervention arm); Mejhert 2004; Stromberg 2003;
Thompson 2005)
• Nine studies had a multidisciplinary approach (Bekelman
2015; Bernocchi 2017; Cavusoglu 2017; Chen 2018; Del
Sindaco 2007; Ducharme 2005; Gonzalez-Guerrero 2014; Mao
2015; Wierzchowiecki 2006). Of these, Gonzalez-Guerrero
2014 was unusual in that the intervention took place in a
geriatric day care hospital, but since the intervention involved a
multidisciplinary team we included it in this group.
We also attempted to classify the studies according to the key per-
son delivering the intervention. A specialist nurse was responsible
for delivering the intervention in 19 of the studies (Berger 2010;
Blue 2001; Brotons 2009; Clark 2015; Cline 1998, Dunbar 2014;
Jaarsma 2000, Jaarsma 2008 (basic intervention), Kasper 2002,
Kimmelstiel 2004, Krumholz 2002 Lang 2018; Leventhal 2011;
Naylor 2004, Nucifora 2006; Stewart 1999a, Stromberg 2003,
Thompson 2005; Tsuchihashi-Makaya 2013). A pharmacist pre-
dominantly delivered the intervention in three studies (Holland
2007; Lopez 2006; Rainville 1999), and a nurse or a commu-
nity nurse in 11 (Agren 2012; Aldamiz-Echevarria 2007; DeBusk
2004; de Souza 2014;Kwok2008;Mehralian 2014;Mejhert 2004;
Ong 2016; Salehitali 2009; Shively 2013; Yu 2015a). In 13 of the
studies, the intervention appeared to be delivered by two or more
professionals, although this did not necessarily mean they met
the Riegel 2001 formal classification for multidisciplinary mod-
els, (Bekelman 2015; Bernocchi 2017; Bohmer 2011; Capomolla
2002; Cavusoglu 2017; Chen 2018; Del Sindaco 2007; Doughty
2002; Ducharme 2005; Gonzalez-Guerrero 2014; Jaarsma 2008
(intensive intervention); Mao 2015; Wierzchowiecki 2006). The
intervention described by Atienza 2004 was delivered by a cardi-
ologist, and Tsuyuki 2004 describes the research co-ordinator as
being responsible for delivering the intervention.
Content of the interventions as described in the published
reports.
Table 1 lists the components of the interventions as described in
the published papers. Overall there appeared to be little difference
in reported components between the three groups of interven-
tions. However, it may be that the reports of the components of
the different interventions were not detailed enough or systematic
enough to confidently make this comparison.
Telephone follow-up
The majority (40 out of 47) of the studies in the updated review
included telephone follow-up or help-line access for participants.
Education
Education delivered to participants, and in some cases, carers, ap-
pears to have been a major component in 31 of the studies in-
cluded in this review. The education typically covered the diag-
nosis, symptoms and treatment of heart failure, and when to seek
expert help.
Self-management
The majority (N = 33) of the interventions actively sought to
promote better patient self-management, and participants were
sometimes given heart failure diaries or notebooks to aid self-
management.
Weight monitoring
Thirty of the studies mentioned daily or regular weight monitor-
ing, or the importance of weight monitoring. Participants in these
studies were often given charts or diaries in which to log their
weight.
Sodium restriction or dietary advice, or both
Thirty-one of the studies mentioned participants receiving dietary
advice, often from the nurse at a home visit.
Exercise recommendation
Just under half (N = 23) of the studies mentioned advice about
exercise in stable heart failure or exercise promotion.
Medication review
Study reports mentioned that there was the opportunity to review
participants’ medications as part of the disease management pro-
gramme in 25 of the studies.
Social support and psychological support
Only aminority (N =10) of the studies specifically offered social or
psychological support to participants included in the intervention.
15Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Excluded studies
As shown in Figure 1, we excluded 217 studies in 263 references.
Of these, 75 described an intervention other than a specific heart
failure diseasemanagement programme, and15didnot have ’usual
care’ as a comparator. We excluded a further 21 studies because
they had under six months’ follow-up, and 46 because they were
not RCTs. heart failure hospital admission was not an inclusion
criterion for 35 of the excluded studies, and 17 had the wrong
participants. We excluded a further eight papers for other reasons.
Risk of bias in included studies
Our risk of bias assessments are summarised in Figure 2 and Figure
3.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
Allocation
The majority of studies (N = 35) reported adequate methods of
random sequence generation, andwe judged them to be at low risk
of bias for this domain. It was unclear if the remaining 12 stud-
ies had used appropriate randomisation methods or not, as they
gave insufficient details in the publication, beyond ’randomised’
(Bohmer 2011; Capomolla 2002; Cavusoglu 2017; Clark 2015;
DeBusk 2004; Del Sindaco 2007; Mehralian 2014; Mejhert
2004; Nucifora 2006; Salehitali 2009; Tsuchihashi-Makaya 2013;
Wierzchowiecki 2006). We did not judge any studies to be at high
risk of bias for random sequence generation.
We assessed only 18 studies as having a low risk of selection bias
relating to adequate allocation concealment. The majority (N =
28) did not describe this so we judged them to have an unclear
risk for this domain. We assessed one study (Del Sindaco 2007),
as having a high risk of bias, as eligible patients were randomised,
and informed consent was then given on the basis of information
relevant to the allocated study group, so selection bias is likely if
people could have withheld consent if they did not like their group
allocation.
Blinding
For completeness, we assessed ’blinding of participants and per-
sonnel’. However, all studies were at high risk of performance bias
due to the nature of the interventions. This has an impact on the
visual impact of overall risk of bias in Figure 2 and Figure 3, which
perhaps detracts from the more meaningful differences between
studies.
We assessed detection bias separately for objective outcomes, and
the subjective, participant-reported outcome, quality of life. For
objective outcomes, we assessed 30 of the studies as having a low
risk of detection bias. For 13 studies, it was unclear whether or
not outcome assessors were blinded to group allocation (Atienza
2004; Bekelman 2015; Bohmer 2011; Doughty 2002; Dunbar
2014; Lopez 2006; Mejhert 2004; Nucifora 2006; Rainville
1999; Salehitali 2009; Tsuchihashi-Makaya 2013; Tsuyuki 2004;
Wierzchowiecki 2006). We considered four studies to be at high
risk of bias for this domain (Capomolla 2002; Cavusoglu 2017;
Clark 2015; Shively 2013).
We assessed themajority of studies (N = 31) as being at high risk of
detection bias for subjective outcomes, since the unblinded nature
of the trials meant that assessments of quality of life could be
influenced by knowledge of treatment allocation. The 16 studies
assessed as low risk did not report quality of life.
Incomplete outcome data
We assessed half of the studies as having a low risk of attrition bias
(N = 24). It was unclear in 18 studies whether or not attrition bias
was likely to affect the results. We considered five of the studies
to be at high risk of attrition bias; two were particularly affected
by low levels of completion for quality-of-life assessments (Agren
2012; Wierzchowiecki 2006), two had a noticeably higher attri-
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tion rate in the intervention group than in the usual-care group
(Jaarsma 2000; Yu 2015a), and Leventhal 2011 was stopped early
after only 42 of the required 300 participants had been recruited,
so outcome data could not be collected appropriately.
Selective reporting
It was difficult to assess this domain for many of the older stud-
ies, as trial registrations were not available in many cases. We as-
sessed the majority of studies (N = 38) as being at unclear risk
of reporting bias, as we could not identify published protocols or
trial registrations for these. We assessed six studies as being at low
risk of reporting bias (Bernocchi 2017; Dunbar 2014; Lang 2018;
Nucifora 2006; Ong 2016; Thompson 2005), since publications
reported all expected outcomes. We considered de Souza 2014;
Gonzalez-Guerrero 2014; Tsuchihashi-Makaya 2013 to be at high
risk of reporting bias, as there were differences in outcomes listed
in protocols or trials registries and those published.
Other potential sources of bias
There were no other potential sources of bias noted for 31 of the
studies. We assessed the risk of other bias in 13 studies as unclear
(Agren 2012; Bohmer 2011; Chen 2018; Cline 1998; Doughty
2002; Krumholz 2002; Mehralian 2014; Nucifora 2006; Shively
2013; Stewart 1999a; Stromberg 2003; Tsuchihashi-Makaya
2013; Wierzchowiecki 2006).
We suspected a high risk of other bias for three studies. The NCT
record for Berger 2010 suggested that this study had been termi-
nated, but gave no reason for early stoppage. Participants in the in-
tervention arm also had more severely reduced left ventricular sys-
tolic function at baseline. Not all of the intervention group in the
trial by Capomolla 2002 received all the components of the inter-
vention. Mao 2015 gave participants in the trial guideline-based
medications in addition to the disease management programme,
and post-hoc analyses that adjusted for this indicated that there
was no evidence for the disease management programme lowering
all-cause death rates once the effect of the medication had been
accounted for.
Effects of interventions
See: Summary of findings for the main comparison Case
management compared to usual care for heart failure; Summary
of findings 2 Clinic-based intervention compared to usual care
for heart failure; Summary of findings 3Multidisciplinary disease
management programmes compared to usual care for heart failure
We have presented the results of Capomolla 2002 separately be-
cause of the unique characteristics of both the intervention and
the participants it was directed at (see Characteristics of included
studies Table). This was a day hospital programme that offered a
number of tailored therapies and specialist support (cardiovascular
risk stratification, correction of risk factors for haemodynamic in-
stability; intravenous therapy; laboratory examinations). Similarly,
two other studies (Agren 2012; Shively 2013), had unusual inter-
ventions that did not fit into any of the three categories of disease
management programmes, so could not be included in meta-anal-
yses of themain interventions. Agren 2012 was an educational and
psychological support intervention, and Shively 2013 was a self-
management support intervention. Results of these three studies
are presented under ’Other’ in the section below.
Case management versus usual care
Mortality due to heart failure
None of the case management studies reported deaths due to heart
failure.
All-cause mortality
Twenty-six studies reported all-cause mortality (RR 0.78, 95%
CI 0.68 to 0.90; participants = 6903; studies = 26; I2 = 30%,
low-quality evidence; Analysis 1.1). The median follow-up was 12
months. Lang 2018 reported that there were no deaths in either
arm, so we could not add this study to the meta-analysis. Results
suggest that case management may reduce all-cause mortality. The
NNTB is 25 (95% CI NNTB 17 to NNTB 54), so you could
expect one death from any cause to be averted for every 25 people
treated.
The forest plots and statistical tests did not suggest that there was
important heterogeneity. Subgroup analyses by length of follow-
up and by person delivering the intervention did not indicate any
differences between subgroups (P = 0.22; P = 0.93, respectively).
We undertook sensitivity analysis, which limited the meta-analy-
sis to only those studies at low risk of bias for randomisation and
allocation concealment, and at low or unclear risk for incomplete
outcome data (attrition bias). RR 0.67 (95% CI 0.55 to 0.82;
participants = 3514; studies = 11; I2 = 32%), indicates a stronger
effect, with people receiving case management interventions hav-
ing on average a 33% lower risk of all-cause mortality than people
receiving usual care (Analysis 1.4).
Metaregression did not indicate that any individual intervention
components were particularly associated with the success of the
intervention (Table 2).
The funnel plot in Figure 4 was slightly asymmetrical, which may
indicate some publication bias, so resulted in downgrading of the
evidence.
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Figure 4. Funnel plot of comparison 1. Case management vs usual care, outcome: 1.1 All-cause mortality -
main analysis
Readmissions to secondary care due to heart failure
Twelve case management studies reported data on heart failure
readmissions (RR 0.64, 95%CI 0.53 to 0.78; participants = 2528;
studies = 12; I2 = 51%, moderate-quality evidence; Analysis 1.5).
The median follow-up was 12 months. Case management prob-
ably reduces heart failure readmissions, with the risk of readmis-
sion for heart failure being approximately 36% lower in people
participating in a case management programme compared with
those receiving usual care. The NNTB is 8 (95% CI NNTB 6 to
NNTB 13), so you could expect one heart failure readmission to
be averted for every eight people treated.
Statistical tests indicated that there may be substantial heterogene-
ity for this outcome. However, subgroup analysis by length of
follow-up did not indicate any difference between subgroups (P
= 0.33). Subgrouping by person delivering the intervention did
suggest that there was a difference between groups (P = 0.002),
but some subgroups contained few studies. There was strong evi-
dence for an effect in the studies with a specialist nurse (RR 0.58,
95% CI 0.47 to 0.70). The ’other’ category also showed a strong
effect, notably in Atienza 2004, where the intervention was pri-
marily delivered by a cardiologist. The subgroups of studies led by
non-specialist or community nurses, or bymultidisciplinary teams
(within the case management framework), did not show evidence
of an impact on heart failure readmissions, although there were
only single studies in these groups.
Restricting the analysis of heart failure readmissions to just those
studies at low risk of bias for randomisation, allocation conceal-
ment and low or unclear risk of attrition, gave a similar effect to
the main analysis (RR 0.62, 95% CI 0.50 to 0.77; participants =
741; studies = 4; I2 = 0%; Analysis 1.8).
Three studies reported data in a way that meant that we could not
include them in the meta-analysis of heart failure readmissions.
Kimmelstiel 2004 reported the mean (SE) number of hospitali-
sations for heart failure per patient-year to be 0.74 (0.10) in the
intervention group and 0.73 (0.10) in the control group, RR 1.02,
P = 0.93. Brotons 2009 reported the mean number of heart failure
readmissions per patient to be 1.01 in the intervention arm and
1.3 in the control group. Aldamiz-Echevarria 2007 reported the
total number of unplanned heart failure readmissions to be 55 and
57 in the intervention and control arms, respectively.
The funnel plot in Figure 5 is asymmetrical, suggesting possible
publication bias.
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Figure 5. Funnel plot of comparison 1. Case management vs usual care, outcome: 1.5 HF readmissions -
main analysis
Additional Table 2 shows the results of the meta-regression. The
RR for heart failure readmission in interventions with a strong
education component was smaller than the RR for interventions
that were not largely educational (ratio of risk ratios (RRR) 0.65,
95% CI 0.46 to 0.93; P = 0.02). This would suggest that on aver-
age, the RR for case management versus usual care in studies with
a strong educational component was only 0.65 times the size of
the RR for interventions without a strong educational component
versus usual care. Since a lower RR indicates fewer heart failure
readmissions, this would suggest that a strong educational com-
ponent is an advantage.
There was some evidence from the meta-regression that a self-
management component may have some slight association with a
lower ratio of RR (RRR 0.72, 95% CI 0.48 to 1.07; P = 0.09), but
the CI indicates that there may be no real difference. Conversely,
interventions with a weightmanagement component may actually
have higherRR than thosewithout (RRR1.53, 95%CI1.07, 2.18;
P = 0.03). There may be other differences between studies that are
not captured by the meta-regression of individual components,
however, so it is important not to over-interpret these findings.
All-cause readmissions to secondary care
Fourteen casemanagement studies reported data on all-cause read-
missions in a format that we could include in the meta-analysis
(RR 0.92, 95%CI 0.83 to 1.01; participants = 4539; studies = 14;
I2 = 43%, moderate-quality evidence; Analysis 1.9). The median
follow-up was 10.5months. Results suggest that case management
probably slightly reduces all-cause readmissions. The NNTB is 26
(95% CI NNTH 204 to NNTB 12), so you could expect one
readmission for any cause to be averted for every 26 people treated
- however theCI ranges from one person potentially being harmed
(i.e. one additional readmission) for every 204 treated, to one per-
son avoiding readmission for every 12 people treated.
The I2 result means that moderate heterogeneity may be present.
Subgroup analysis by length of follow-up did not indicate any dif-
ference between studies with six months’ follow-up and those with
longer than six months follow-up (P = 0.19). There was evidence
of a difference between subgroups of studies depending on who
primarily delivered the intervention (P = 0.09). Notably, the stud-
ies where a specialist nurse delivered the intervention found that
readmissions for any cause were fewer in the case management
groups (RR 0.85, 95%CI 0.73 to 0.99). There was only one study
where a pharmacist led the intervention, and Lopez 2006 reported
lower readmissions in this intervention group (RR 0.68, 95% CI
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0.45 to 1.03).
Sensitivity analysis restricting to studies at low risk of bias in key
domains found similar results to the main analysis (RR 0.87, 95%
CI 0.74 to 1.02; participants = 2217; studies = 6; I2 = 42%;
Analysis 1.12).
Six other studies reported data on all-cause readmissions, but not in
a format that could be included in the meta-analysis. Kimmelstiel
2004 reported that the mean (SE) number of hospitalisations per
patient-year was 1.48 (0.14) in the case management group and
1.40 (0.13) in the usual-care group, RR 1.05, P = 0.70. Nucifora
2006 reported that the mean (SD) readmissions per patient were
0.8 (1.2) for both arms. Aldamiz-Echevarria 2007 reported the
total number of unplanned readmissions (not per patient), to be
125 and 118 in the intervention and control arms, respectively.
Holland 2007 reported that 72/169 intervention participants and
70/170 control group had no emergency hospital readmissions
within six months. The mean (95% CI) number of readmissions
per person in Dunbar 2014 was 0.67 (0.46 to 0.87) in the inter-
vention group and 0.95 (0.63 to 1.33) in the control group; P =
0.21. Salehitali 2009 reported a higher rate of readmissions for any
cause in the control group compared with the case management
group (intervention 1.65 ± 1.01, control 2.74 ± 1.07; P = 0.01).
Metaregression (Table 2) indicated that the only individual inter-
vention component that showed any particular impact on the RR
was weight management, which appeared to result in a RR of case
management versus usual care that was approximately 33% higher
for interventions that included this component (ratio of RR 1.32
(1.09, 1.60); P = 0.008).
The forest plot in Figure 6 is broadly symmetrical so does not
suggest publication bias affects this outcome.
Figure 6. Funnel plot of comparison 1. Case management vs usual care, outcome: 1.9 All-cause
readmissions - main analysis
Adverse effects
No case management studies reported adverse effects.
Health-related quality of life
Eight studies with a total of 1595 participants reported MLHFQ
data in a format that could be incorporated into a meta-analysis.
The median follow-up was six months. Holland 2007 only re-
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ported themean difference between groups, not the actual data, so
we used the generic inverse variance method for the meta-analy-
sis. Where studies additionally reported another outcome (such as
EQ-5D, SF-36), we did not included these results in this section
to avoid double counting such studies.
Analysis 1.13 shows the eight studies on a forest plot, but due
to high heterogeneity (I2 = 76%), we have not shown the pooled
effect as it is not meaningful. Subgroup analysis indicated that
there may be a difference between studies reporting at six months
and those with longer follow-up (P = 0.01). However, this looks
to be due to the inclusion of two small studies that reported better
improvement in quality of life in the usual-care group than in the
case management group, both of which had the shorter period of
follow-up. High attrition for this outcome led to us downgrading
the GRADE rating. As our methods planned only to conduct
sensitivity analysis for primary outcomes, we did not explore the
impact of high attrition for this secondary outcome.
Three other studies reported using the MLHFQ tool, but did not
report results in a way that could be incorporated into the meta-
analysis. In a randomly selected subsample of 68 participants,
Stewart 1999a reported the median (interquartile range (IQR))
change in MLHFQ at six months to be −17 (−35 to −8) in the
case management group (random sample of N = 29) and −12
(−35 to −8) in the usual-care group (random sample N = 24).
Naylor 2004 reported MLHFQ scores at the end of 52 weeks, but
only with reference to quartiles, and for 75 out of 117 people in
the intervention group who completed a baseline assessment, and
74 out of 118 in the control group. At the end of follow-up, the
quartile scores were 2.8 ± 1.8 in the case management group and
2.6 ± 1.7 in the usual-care group. In this context, a score of two
indicates a firstQuartile Score (435) and a score of three the second
Quartile Score (418 to 35). Although Atienza 2004 reported that
220 out of 257 participants completed the MLHFQ at one year’s
follow-up, it was not clear how many participants there were in
each group, so we could not add these data to themeta-analysis. At
the end of follow-up, the mean score was 28.9 in the intervention
group and 35.5 in the control group (no SD given; P = 0.01).
Four studies, which also did not report theMLHFQ, useddifferent
tools. We have not added these to the meta-analysis since the
direction of effect is different and the magnitude of scores may
not be comparable. Whilst it is possible to correct for this in the
meta-analysis, the high degree of heterogeneity already observed
means that adding further, and perhaps less compatible, studies is
unlikely to be helpful, so these are summarised below.
Lopez 2006 reported very similar EuroQol (EQ-5D) scores for
intervention and control group participants. By 12 months there
was a small difference between the two groups, but with high SDs
(64.0 (15.4) versus. 60.6 (17.8)).
Tsuchihashi-Makaya 2013 used the SF-8 tool to measure quality
of life. 70 of the 79 intervention group participants and 68 of the
82 control group participants completed the questionnaire at 12
months. For the physical component score, the mean (SD) score
in the intervention group was 44 (8) compared with 42 (10.5) in
the control group (P = 0.36). For the SF-8 Mental component,
the scores were 48 (8) and 46 (7.5) for intervention and control
groups, respectively (P = 0.05).
Mehralian 2014 used the Iranian version of the SF-36, and re-
ported that the overall score was higher in the intervention group
than in the control group (P < 0.05), but did not give the scores
themselves. For the individual components, the role-physical do-
main was similar in both groups at baseline but higher in the in-
tervention group after six months (intervention: 55.74 ± 11.65
versus control: 51.32 ± 7.51; P < 0.05). The role-emotional do-
main was similar at baseline and remained so at six months (58.34
± 12.27 (intervention) versus 56.43 ± 8.67 (control); P > 0.05).
Clark 2015 used the Kansas City Cardiomyopathy Questionnaire
(KCCQ). On this scale, higher scores reflect better quality of life
and a five-point change in total score is a clinically important
difference. In this small study, the large SDs indicate a lack of
evidence for a difference between groups, either at baseline or
the end of nine months’ follow-up. At baseline, the intervention
group’s mean (SD) score was 55.38 (23.98), increasing to 62.21
(21.80) after nine months. For the control group, the mean (SD)
score was 63.08 (22.90) at baseline and 60.43 (24.12) at nine
months.
Jaarsma 2000, a largely educational casemanagement intervention
study, suffered severe attrition and we assessed it to be of lower
quality. This study assessed quality of life for three dimensions
(functional capabilities, symptoms, and psychosocial perceptions)
but did not appear to use a validated tool so we have not included
it here.
The funnel plot (Figure 7) is broadly symmetrical, so does not
suggest publication bias affects this outcome.
23Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 7. Funnel plot of comparison 1. Case management vs usual care, outcome: 1.13 Quality of life
(MLHFQ mean score at end of follow-up)
The very low-quality evidence indicated by GRADE assessment
means that we are uncertain about the effect of case management
on quality of life.
Cost-effectiveness
Four of the casemanagement programmeswere the subject of cost-
effectiveness analyses. Ruschel (2018), reports a cost-effectiveness
analysis of the de Souza 2014 study. The incremental cost-effec-
tiveness ratio (ICER) was BRL 585 per hospital readmission visit
prevented, which was favourable from the personal health services
perspective, and dominant when analysed from the perspective of
private healthcare. Reily (2015), reports a cost-effectiveness anal-
ysis of the Dunbar 2014 study, finding that the intervention low-
ered costs without sacrificing quality-adjusted life years (QALYs).
The effect difference for change in QALY using the change in EQ-
5D from baseline to six months was 0.04 (-0.04 to 0.11).
Two economic evaluations of the COACH study (Jaarsma 2008)
were carried out. Cao (2013), stratified participants into different
risk categories based onpredicted 18-monthmortality risk.Using a
threshold value of EUR10,000per life-year, they found itwas 83%
likely that the intensive support option would be optimal for the
low-risk participants, and 84% likely that the basic support option
would be best for the high-risk participants. Postmus (2011), also
performed an economic evaluation of the COACH study. Basic
support was more cost effective than care as usual, and the ICER
for intensive support was EUR 8915 per QALY. For participants
with severe heart failure, cost per QALY compared with usual care
was EUR 77,335 for basic support, and EUR 59,289 for intensive
support.
Moertl (2013), published a cost-utility analysis of the Berger 2010
study. The incremental cost-effectiveness ratio for the case man-
agement intervention compared with usual care was EUR 3746
per QALY gained.
Various case management studies reported the costs of their pro-
grammes, although the wide range in dates of studies and different
locations complicates interpretation. Lang 2018 estimated that the
average cost of the REACH-HF intervention was GBP 362.61.
Lopez 2006 reported that the total cost per participant was EUR
578 lower in the intervention group compared with control. The
intervention’s mean cost (USD 11,315) was higher than the con-
trol group’s (USD 8789) in the Kasper 2002 study. Kwok 2008
reported that public healthcare and personal care costs were sim-
ilar in both groups. Naylor 2004 reported mean cost savings of
USD 4845 per participant for the case management intervention.
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Tsuyuki 2004 calculated the cost of care for all-cause events, and
these were CAD 2463 lower in the patient support programme
compared with usual care. Salehitali 2009 reported lower costs in
the intervention group comparedwith the casemanagement group
(intervention: IRR 2,313,000 ± 151,490; control: IRR 2,736,800
± 167,360).
The GRADE rating for this outcome was low, and results indicate
that casemanagement interventionsmay reduce costs and improve
cost-effectiveness slightly, compared with usual care.
Clinic-based intervention versus usual care
We did not construct funnel plots to assess publication bias for
any of the outcomes, as there were too few studies.
Mortality due to heart failure
None of the seven clinic-based intervention studies reported mor-
tality due to heart failure as a specific outcome.
All-cause mortality
We included all seven of the clinic-based intervention studies in
the meta-analysis of the effect of the intervention on mortality
from any cause; the median follow-up was 12 months (RR 0.87,
95% CI 0.68 to 1.10; participants = 1686; studies = 7; I2 = 37%,
low-quality evidence; Analysis 2.1). Overall, the clinic-based in-
tervention model may result in little to no difference in all-cause
mortality. The NNTB is 29 (95% CI NNTH 37 to NNTB 12),
so you could expect one death from any cause to be averted for
every 29 people treated, but uncertainty associated with the wide
confidence interval means you may find one extra all-cause death
for every 37 people treated, or avoid one death for every 12 people
treated.
Heterogeneity may not be important for this outcome according
to statistical tests, but the forest plot suggests some small difference
in effect. However, subgrouping by length of follow-up (Analysis
2.2), or by person delivering the intervention (Analysis 2.3), did
not indicate any important differences between subgroups (P =
0.38 and P = 0.17, respectively).
Sensitivity analysis restricted to only those studies at low risk of
bias for randomisation and allocation concealment, and to low
or unclear risk of bias for attrition gave a different result to the
main analysis (RR 0.65, 95% CI 0.23 to 1.88; participants = 296;
studies = 2; I2 = 82%; Analysis 2.4). The wide confidence intervals
for this sensitivity analysis indicate a lack of evidence for effect, as
there are only two small studies included.
As one of the clinic-based intervention studies was a cluster-RCT
(Doughty 2002), we performed a sensitivity analysis excluding this
study (Analysis 2.5). There was no substantial difference between
this and the main result, although the confidence intervals and
heterogeneity both increased with removal of Doughty 2002.
Readmissions to secondary care due to heart failure
Only two clinic-based intervention studies (Jaarsma 2008;Mejhert
2004), reported heart failure readmissions in a format that could
be included in a meta-analysis, with a median follow-up of 18
months. Pooling the two studies indicated that there is probably
little or no difference in heart failure readmissions between clinic-
based interventions and usual care (RR 1.01, 95% CI 0.87 to
1.18; participants = 887; studies = 2; I2 = 0%, moderate-quality
evidence; Analysis 2.6). As the RR is over 1.0, we calculated the
NNTH, and its interpretation is more complex due to the inclu-
sion of the null. TheNNTH is 290 (95%CINNTH17 toNNTB
23), so you could potentially expect one additional heart failure
readmission for every 290 people treated; but the confidence in-
terval goes from one person avoiding readmission for every 17
treated to one person being readmitted for every 23 treated.
Only two studies reported data for this outcome, so we did not
carry out any subgroup analysis or sensitivity analysis. Doughty
2002 reported that there were 36 readmissions for heart failure in
the intervention arm and 65 in the control arm, but did not report
the number of participants with a readmission, so we could not
pool these data.
All-cause readmissions
We pooled four studies for this outcome (RR 0.90, 95% CI 0.72
to 1.12; participants = 1129; studies = 4; I2 = 65%, low-quality
evidence; Analysis 2.9), with a median follow-up of 15 months.
The low-quality evidence suggests that clinic-based interventions
may result in little or no difference in all-cause readmissions. The
NNTB is 19 (95% CI NNTH 16 to NNTB 7), so you could
expect one readmission from any cause to be averted for every 19
people treated, but the uncertainty due to the wide confidence
interval means that there could be an additional readmission for
every 16 people treated, or one admission avoided for every seven
people treated.
Heterogeneity was substantial for this outcome. Subgroup analysis
indicated that there may be a difference between studies with six
months’ follow-up, and those with longer follow-up (P = 0.03;
Analysis 2.10). The risk of readmission following six months of
a clinic-based intervention appears to be around half that of the
usual-care arm (RR 0.51, 95%CI 0.29 to 0.91). By contrast, there
is no evidence that a clinic-based intervention reduces the read-
mission rate in the longer studies. However, the test for subgroup
differences may well be underpowered given the paucity of stud-
ies and the small size of the only trial with six months’ follow-
up. Subgroup analysis by person delivering the intervention did
not indicate any important differences between groups (P = 0.27;
Analysis 2.11).
It was not possible to conduct the sensitivity analysis for this out-
come as only one study (Cline 1998), was at low risk of bias for
both randomisation method and allocation concealment.
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Two other clinic-based intervention studies reported readmission
rates in a different format. Doughty 2002 reported that the all-
cause readmission rate at 12 months was 1.37 readmissions per
participant per year in the intervention arm, compared with 1.84
in the usual-care group, rate difference = 0.47 per patient per year
(95% CI 0.16 to 0.78). Stromberg 2003 reported total number
of readmissions but not the number of participants with read-
missions. The total number of readmissions was similar between
groups (82 in the intervention arm and 92 in the control arm,
P = 0.31). However, the mortality rate was three times higher in
the control group, and once this was adjusted for in the analysis,
Stromberg 2003 reported that the intervention group tended to-
wards fewer readmissions.
Adverse effects
No clinic-based intervention model studies reported adverse ef-
fects.
Health-related quality of life
Four of the clinic-based intervention studies reported quality-of-
life assessments, but it was not possible to pool these due to differ-
ences in tools used, and the way the data were reported. The me-
dian follow-up was 12 months. Doughty 2002 reported that there
was no difference in MLHFQ total scores between intervention
and control participants at one year. Thompson 2005 reported that
the mean change in MLHFQ total score was −14.2 in the clinic-
based intervention group and −13.7 in the usual-care group, but
only 46 out of 106 trial participants completed a questionnaire.
Cline 1998 and Mejhert 2004 reported the Nottingham Health
Profile, with mean (SD) scores of 25.3 (22.2) versus 23.4 (22.2)
for clinic-based intervention and usual-care groups, respectively,
in the one-year Cline 1998 study. The longer study by Mejhert
2004 reported the total mean (SD) score at 18 months to be 134
(11*) in the intervention group and 130 (125) in the usual-care
group. The SD denoted by * is assumed to be a typographic error,
as the total (SD) score at 12 months is 136 (107). The quality of
evidence for this outcome was low, indicating that the clinic-based
interventions may result in little or no difference in quality of life.
Costs
Only two clinic-based studies reported data on costs. Bohmer 2011
reported a cost saving of EUR 193.57 (EUR 1382 per person over
six months).
Cline 1998 reported that the lower readmission rate in the inter-
vention group in their study contributed to a mean reduction in
overall annual costs of USD 1300 per participant (P = 0.07) over
12 months. The GRADE quality assessment was low for this out-
come, indicating that clinic-based interventions may reduce costs
slightly.
Multidisciplinary interventions versus usual care
We did not construct funnel plots to assess publication bias for
any of the outcomes, as there were too few studies.
Mortality due to heart failure
Only two of the nine multidisciplinary intervention trials reported
heart failure mortality in a way that could be included in themeta-
analysis (RR0.46, 95%CI0.23 to 0.95; participants = 277; studies
= 2; I2 = 0%, very low-quality evidence; Analysis 3.1). Themedian
follow-up was 12 months. The NNTB is 12 (95% CI NNTB 9 to
NNTB 126), so you could expect one death due to heart failure
to be averted for every 12 people treated.
There was no indication of heterogeneity. As there were only two
studies, we did not carry out any subgroup or sensitivity analysis
for this outcome. We are uncertain about the effect of multidisci-
plinary disease management programmes on heart failure mortal-
ity.
All-cause mortality
The pooled analysis for all-cause mortality (RR 0.67, 95% CI
0.54 to 0.83; participants = 1764; studies = 8; I2 = 0%, moderate-
quality evidence; Analysis 3.2), indicates that multidisciplinary
teams probably reduce all-cause mortality, with people receiving
this intervention having approximately 33% less risk of death from
any cause than people receiving usual care. TheNNTB is 17 (95%
CI NNTB 12 to NNTB 32), so you could expect one death from
any cause to be averted for every 17 people treated. One study
not in the meta-analysis (Chen 2018), only reported composite
outcomes of death or all-cause re-hospitalisations, and death or
heart failure readmissions.We contacted the study author but were
unable to get the data for the individual outcomes.
There was no indication of heterogeneity for this outcome and
subgroup analysis by length of follow-up did not indicate any
difference between groups (P = 0.37; Analysis 3.3).
Senstivity analysis restricted to only those two studies at low risk
of bias for randomisation and allocation concealment, and at low
or unclear risk of bias for attrition suggested a lack of evidence for
any difference between multidisciplinary interventions and usual
care (RR 0.65, 95% CI 0.34 to 1.25; participants = 342; studies
= 2; I2 = 0%; Analysis 3.4). However, this analysis was dominated
by the Ducharme 2005 study, which carried 93.4% of the weight.
Readmissions to secondary care due to heart failure
Five studies of multidisciplinary interventions provided data that
could be pooled (RR 0.68, 95% CI 0.50 to 0.92; participants
= 1108; studies = 5; I2 = 48%, low-quality evidence; Analysis
3.5).The median follow-up was 12 months. Multidisciplinary in-
terventions may reduce the risk of readmission to hospital due to
heart failure. The NNTB is 11 (95% CI NNTB 7 to NNTB 44),
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so you could expect one heart failure readmission to be averted for
every 11 people treated.
Heterogeneity was moderate for this outcome, although subgroup
analysis did not suggest any difference between six-month studies
and those with longer follow-up (P = 0.13). We did not carry out
the subgroup analysis by person delivering the intervention for
this category, as they were all by their nature multidisciplinary.
Only one study (Ducharme 2005), was at low risk of bias for
randomisation and allocation concealment, so sensitivity analysis
could not be carried out for this outcome.
In addition to the meta-analysis, Wierzchowiecki 2006 reported
that the total number of heart failure readmissions was lower in the
multidisciplinary group than in the usual-care group (13 versus
25, respectively).
All-cause readmissions to secondary care
Five multidisciplinary studies reported data on all-cause readmis-
sions that we could pool in meta-analysis (RR 0.85, 95% CI 0.71
to 1.01; participants = 1152; studies = 5; I2 = 40%, low-quality
evidence; Analysis 3.7). The median follow-up was 12 months.
Results indicate that multidisciplinary programmes may slightly
reduce all-cause readmissions. The NNTB is 15 (95% CI NNTH
223 to NNTB 8), so you could expect one readmission for any
cause to be averted for every 15 people treated. However, the un-
certainty associated with the inclusion of the null in the RR’s con-
fidence interval means that one extra readmission for every 223
people treated and one fewer readmission for every eight people
treated are also possible outcomes.
Statistical tests indicated that there may be some moderate hetero-
geneity, but none was detected on visual inspection of the forest
plot. There was no indication that results differed by length of fol-
low-up (P = 0.98). As with heart failure readmissions, we assessed
only Ducharme 2005 as being at low risk of bias, so we could not
carry out sensitivity analysis for this outcome.
Two other studies reported data in a format that could not be
pooled, presenting only the total number of readmissions and not
the number of people with at least one readmission. Bernocchi
2017 reported that there were 21 readmissions in the multidis-
ciplinary group and 37 in the usual-care group. Wierzchowiecki
2006 reported fewer all-cause readmissions in the intervention
group than in the control group (22 versus 35).
Adverse effects
Two multidisciplinary intervention trials mentioned adverse ef-
fects. Bekelman 2015 reported that there were no adverse effects in
either study arm during the 12-month follow-up, and Bernocchi
2017 noted that, “no major side effects were recorded” during
the six months of the study. We assessed the evidence as being
of moderate quality using GRADE, suggesting that there may be
little or no difference in adverse effects between multidisciplinary
interventions and usual care.
Health-related quality of life
Due to differences in reporting, only two multidisciplinary stud-
ies could be pooled for quality of life, although four others also
reported use of the MLHFQ (MD −12.21, 95% CI −16.43 to
−7.99; participants = 140; studies = 2; I2 = 0%, very low-quality
evidence; Analysis 3.9). The median follow-up was 12 months.
The very low GRADE rating leads to the conclusion that we are
uncertain whether these interventions affect quality of life. There
was no statistical evidence of heterogeneity and we could not carry
out any subgroup analysis as there were too few studies. We did
not carry out sensitivity analyses for this secondary outcome.
Although Wierzchowiecki 2006 also reported the MLHFQ, data
were unclear and we could not include them. Del Sindaco 2007
reported that quality of life measured by the MLHFQ total score
improved compared to baseline in the multidisciplinary group,
but did not report data for the usual-care arm. Gonzalez-Guerrero
2014 reported the MLHFQ, but only with reference to quartile
scores, where a score of two indicates a first quartile score (26 or
higher), and a score of three, a second quartile score (more than
15 to 25 or less). At end of follow-up, the mean (SD) value for the
intervention group was 2.7 ± 1.8, compared with 2 ± 1.8 in the
control group. The median (IQR) values were 3 (1 to 4) and 2 (0
to 3), respectively (P = 0.036). Ducharme 2005 reported a “sub-
stantial improvement” in both emotional and physical quality-of-
life scores of the MLHFQ for multidisciplinary care compared
with usual care (P < 0.001) but did not report the actual scores.
Bekelman 2015 reported quality of life using the KCCQ. The
mean (SD) change from baseline in the intervention group was
13.5 (16.7) compared with 13.5 (18.6) in the usual-care group.
Costs
Only one multidisciplinary intervention study reported costs or
cost-effectiveness. In Gonzalez-Guerrero 2014, the cost per addi-
tional QALY for the disease management programme compared
with usual care was EUR 38,274 from a healthcare perspective
and EUR 25,390 from a societal perspective. The GRADE rating
for this outcome was low, suggesting that multidisciplinary disease
management programmes may be cost-effective from a societal
perspective, but less so from a health-services perspective.
Other types of interventions
This section reports the results of the three studies (Agren 2012;
Capomolla 2002; Shively 2013), that did not fit into one of the
three categories used in this review. The 24-month data from the
study by Agren 2012 were reported by Liljeroos 2015.
Mortality due to heart failure
None of the studies reported mortality due to heart failure.
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All-cause mortality
The Agren 2012 long-term follow-up (Liljeroos 2015), reported
that all-cause mortality was lower in the intervention group (12/
71, 17%) than in the usual-care group (22/84, 26%).
Readmissions due to heart failure
After 24 months, 31 out of 71 participants (38%) of the Agren
2012 study’s intervention group were readmitted for heart failure,
compared with 33/84 (34%) in the control group; P = 0.64 (re-
ported by Liljeroos 2015).
All-cause readmissions
Capomolla 2002 noted a substantial reduction in hospital read-
missions in the intervention group (total number of hospital read-
missions at mean 12 (SD 3) months’ follow-up: 13 versus 78, P
< 0.00001), but the generalisability and quality of this study are
very unclear. It is also unclear if these are all-cause readmissions
or readmissions for haemodynamic instability. Capomolla 2002
also reported that eight day-hospital participants and 35 usual-
care participants had at least one rehospitalisation during follow-
up (P < 0.05).
The number of people with at least one all-cause readmission in
the long-term follow-up of the Agren 2012 study was reported by
Liljeroos 2015. In the intervention group, 51out of 71 participants
(72%) were readmitted, compared with 58 out of 84 participants
(68%) in the control group; P = 0.72.
Shively 2013 reported data on hospital readmissions and emer-
gency department visits at six months’ follow-up, with no statis-
tically significant differences reported between intervention and
control groups. At six months, the mean (SD) number of hospital
admissions per person was 0.21 (0.41) in the intervention group
and 0.32 (0.48) in the usual-care group.
Adverse effects
None of the ’other’ studies reported adverse effects.
Quality of life
Capomolla 2002 reported the time trade off method for assessing
quality of life. In the day-hospital group this was 0.72 (SD 0.17),
meaning that participants were willing to trade 10 years of their
present health for 7.2 years of excellent health. In the usual-care
group, themean (SD) was 0.63 (0.22), indicating that participants
were willing to trade 6.3 years of their present health.
Agren 2012 reported quality of life using the SF-36 tool. The
mental component score was very similar at end of follow-up in
both groups (intervention −4.55 (11.2); control −4.22 (11.9);
P = 0.88). The physical component score was also similar at 12
months (−1.9 (9.8) versus −0.5 (7.9) for intervention and con-
trol, respectively; P = 0.39).
Costs
Capomolla 2002 reported a higher QALY for the day-hospital
group than the usual-care group (79.4 versus 70.5, P = 0.01). The
cost/utility ratio was better for the day-hospital model, at USD
2244 compared with USD 2409 for the usual-care group. They
also reported a cost saving of USD 1068 per QALY gained.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Clinic-based intervention compared to usual care for heart failure
Patient or population: adults with heart failure
Setting: heart failure clinic (outpat ients, community)
Intervention: heart failure clinic
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care Risk with clinic-based
intervention
HF mortality - - - - - Not reported
All- cause mortality
Follow-up: median 12
months
Study populat ion RR 0.87
(0.68 to 1.10)
1686
(7 RCTs)
⊕⊕©©
Low1,2
Clinic may result in lit t le
to no dif ference in all-
cause mortality
NNTB 29 (95%CI NNTH
37 to NNTB 12)
273 per 1000 238 per 1000
(186 to 300)
HF readmissions
Follow-up: median 18
months
Study populat ion RR 1.01
(0.87 to 1.18)
887
(2 RCTs)
⊕⊕⊕©
Moderate3
Clinic probably results
in lit t le to no dif ference
in HF readmissions
NNTH 290 (95% CI
NNTH 17 to NNTB 23)
345 per 1000 348 per 1000
(300 to 407)
All- cause
readmissions
Follow-up: median 15
months
Study populat ion RR 0.90
(0.72 to 1.12)
1129
(4 RCTs)
⊕⊕©©
Low2,4
Clinic may result in lit t le
to no dif ference in all-
cause readmissions
NNTB 19 (95%CI NNTH
16 to NNTB 7)
549 per 1000 494 per 1000
(395 to 615)
Adverse effects - - - - Not reported
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Quality of life
Follow-up: median 12
months
1 study reported no dif ference in MLHFQbetween
groups at 1 year, and another reported sim ilar
changes f rom baseline for both intervent ion and
control groups. 2 studies used the Nott ingham
Health Prof ile (NHP) rather than the MLHFQ,
both report ing sim ilar scores in intervent ion and
control groups
- 641
(4 RCTs)
⊕⊕©©
Low5
A lower score indicates
better quality of lif e on
both the MLHFQ and
NHP
Clinic may result in lit -
t le to no dif ference in
quality of lif e
Costs and cost-effec-
tiveness
Follow-up: range 6
months to 12 months
1 study reported a cost saving of EUR 1382 per
person, the other a saving of USD 1300 per person
- 390
(2 RCTs)
⊕⊕©©
Low6,7
Clinic may reduce costs
slight ly.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HF: heart failure; MLHFQ: Minnesota Living with Heart Failure Quest ionnaire; NNTB/H: number needed to treat for an addit ional benef icial/ harmful
outcome; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Sensit ivity analysis included only 2 small studies at low risk of bias and showed more posit ive ef fect est imate but with much
wider conf idence interval. Downgraded by one level for risk of bias.
2Wide conf idence interval includes null but not an important harm. Downgraded by one level for imprecision.
3Both studies were at unclear risk of bias for concealment of allocat ion, and one was also at unclear risk for randomisat ion
method. Downgraded by one level for risk of bias.
4Only 1 small study was at low risk of bias for key domains. Downgraded by one level for risk of bias.
5Unblinded self -assessment of this subject ive outcome. One study only collected data f rom fewer than half of the part icipants
and the number of people providing data is unclear for another study. Downgraded by two levels for risk of bias.
6Costs reported but not cost-ef fect iveness. Age of one of the studies lim its the generalisability of this. Downgraded by one
level for indirectness of evidence.
7Small sample size. Downgraded by one level for imprecision.
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Multidisciplinary disease management programmes compared to usual care for heart failure
Patient or population: adults with heart failure
Setting: community
Intervention: mult idisciplinary disease management programmes
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care Risk with multidisci-
plinary disease man-
agement programmes
HF mortality
Follow-up: median 12
months
Study populat ion RR 0.46
(0.23 to 0.95)
277
(2 RCTs)
⊕©©©
Very low1,2,3
We are uncertain about
the ef fect of mult idis-
ciplinary disease man-
agement programmes
on HF mortality
NNTB 12 (95% CI 9 to
126)
159 per 1000 73 per 1000
(37 to 151)
All- cause mortality
f ollow-up: median 12
months
Study populat ion RR 0.67
(0.54 to 0.83)
1764
(8 RCTs)
⊕⊕⊕©
Moderate4
Mult idisciplinary dis-
ease management pro-
grammes probably re-
duce all-cause mortal-
ity
NNTB 17 (95% CI 12 to
32)
185 per 1000 124 per 1000
(100 to 154)
HF readmissions
Follow-up: median 12
months
Study populat ion RR 0.68
(0.50 to 0.92)
1108
(5 RCTs)
⊕⊕©©
Low5,6
Mult idisciplinary dis-
ease management pro-
grammes may reduce
HF readmissions. One
study reported data that
could not be included in
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the meta-analysis
NNTB 11 (95% CI 7 to
44)
290 per 1000 197 per 1000
(145 to 267)
All- cause
readmissions
Follow-up: median 12
months
Study populat ion RR 0.85
(0.71 to 1.01)
1152
(5 RCTs)
⊕⊕©©
Low7,8
Mult idisciplinary dis-
ease management pro-
grammes may slight ly
reduce all-cause read-
missions. 2 addit ional
studies reported data
that could not be in-
cluded in the meta-anal-
ysis
NNTB 15 (95%CI NNTH
223 to NNTB 8)
450 per 1000 383 per 1000
(320 to 455)
Adverse effects
Follow-up: range 6 to 12
months
2 mult idisciplinary intervent ion trials mentioned
that there were no adverse ef fects, or no major
side ef fects, in either study arm
- 496
(2 RCTs)
⊕⊕⊕©
Moderate9
Mult idisciplinary dis-
ease management pro-
grammes probably re-
sult in lit t le to no dif fer-
ence in adverse ef fects
Quality of life (MLHFQ)
Follow-up: median 12
months
1 study reported score
at end of follow-up (34.
3 in usual-care group)
1 study reported a de-
crease f rom baseline of
0.5 in usual-care group
MD 12.21 lower
(16.43 lower to 7.99
lower)
1 study reported score
at end of follow-up (19.
4 in intervent ion group)
1 study reported a de-
crease f rom baseline
of −11 in intervent ion
group
- 140
(2 RCTs)
⊕©©©
Very low10,11
A lower score indicates
better quality of lif e on
the MLHFQ.
4 other studies used the
MLHFQ but did not re-
port data in a form that
could be included in the
meta-analysis. 1 study
reported the KCCQ tool
but not the MLHFQ
Overall, we are uncer-
tain whether mult idis-
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ciplinary disease man-
agement programmes
af fect quality of lif eCosts and cost-effec-
tiveness Follow-up 12
months
Only 1 mult idisciplinary intervent ion study re-
ported costs or cost-ef fect iveness. In Gonzalez-
Guerrero 2014, the cost per addit ional QALY for
the disease management programme compared
with usual care was EUR 38,274 f rom a health-
care perspect ive and EUR 25,390 f rom a societal
perspect ive
- 117
(1 RCT)
⊕⊕©©
Low12,13
Mult idisciplinary dis-
ease management pro-
grammes may be cost-
ef fect ive f rom a so-
cietal perspect ive but
less so f rom a health-
care perspect ive
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HF: heart failure; KCCQ: Kansas City Cardiomyopathy Quest ionnaire; MLHFQ: Minnesota Living with Heart Failure Quest ionnaire; NNTB/H: number
needed to treat for an addit ional benef icial/ harmful outcome; QALY: quality-adjusted lif e year; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1The intervent ion for one of the studies (Gonzalez-Guerrero 2014), took place in a geriatric day care hospital. Whilst this
was characterised as mult idisciplinary due to the nature of care, it may not be fully characterist ic of the more usual
mult idisciplinary intervent ion. Downgraded by one level for indirectness.
2The largest of the two studies was at unclear risk of bias for randomisat ion and allocat ion concealment, and high risk
for attrit ion. the other was at low risk of bias for randomisat ion and allocat ion concealment, but unclear risk for attrit ion.
Downgraded by one level for risk of bias.
3Small sample size and low event rate. Downgraded once for imprecision.
4Sensit ivity analysis restricted to the only two studies at low risk of bias in key domains indicated a lack of evidence for an
ef fect, whereas the overall analysis of all eight studies showed a posit ive ef fect. Downgraded by one level for risk of bias.
5Only one of the f ive studies was at low risk of bias, so sensit ivity analysis was not possible. Downgraded by one level for risk
of bias.
6There was moderate heterogeneity (I2 = 48%); the second largest study showed a null result , whereas the largest and third
largest showed a benef icial ef fect. Subgroup analysis by length of follow-up did not explain this. Downgraded by one level for
inconsistency.
7Only one of the f ive studies was at low risk of bias, downgraded by one level for risk of bias.3
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8Conf idence interval includes a benef it but also the null. Doesn’t include potent ial harm. Downgraded by one level.
9Only two small studies reported this outcome. Downgraded once for imprecision.
10Both studies were at low risk of bias for randomisat ion and allocat ion concealment, but quality of lif e was self -reported,
and this was an unblinded study. Unbalanced percentage of responders in Bernocchi 2017 (80% intervent ion, 63% control).
Downgraded by two levels for risk of bias.
11Very small number of part icipants. Downgraded by one level for imprecision.
12Only reported by one small study. Downgraded by one level for imprecision.
13The only study report ing this outcome took place in a geriatric day hospital, which is not representat ive of the majority of
mult idisciplinary intervent ions. Downgraded once for indirectness.
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D I S C U S S I O N
Summary of main results
This updated review contains 47 RCTs of disease management
interventions. Of these, 28 RCTs were of case management in-
terventions, seven were clinic-based interventions, and nine had
a multidisciplinary approach. One of the clinic-based studies also
had a case management arm. Three RCTs had interventions that
we could classify into one of these groups. The 47 RCTs contained
a total of 10,869 participants.We have summarised results for each
main intervention category in Summary of findings for the main
comparison; Summary of findings 2; and Summary of findings 3.
Mortality due to heart failure was poorly reported, with many
studies only reporting cardiovascular-relatedmortality. There were
no data for this outcome for the case management interventions,
nor for clinic-based interventions. Two multidisciplinary inter-
ventions reported this outcome, but we assessed the evidence to
be of very low-quality, so we are uncertain about their effect on
heart failure mortality.
Mortality from any cause was reported for all three types of in-
terventions. After taking into consideration the GRADE quality
ratings, results indicated that case management interventions may
reduce all-cause mortality, clinic-based intervention models ap-
pear to have little to no effect, and multidisciplinary interventions
probably reduce all-cause mortality.
Heart failure readmissions to secondary care were not always dis-
tinguished from cardiovascular-related readmissions. Where stud-
ies reported this outcome separately, we found that case man-
agement interventions probably reduce heart failure readmissions.
The strongest evidence was when the intervention was led by a
specialist nurse. The clinic-based interventions probably made lit-
tle or no difference to the risk of readmission for heart failure, and
evidence suggested that the multidisciplinary programmes may
reduce the risk of being readmitted to hospital for heart failure.
Case management studies probably slightly reduce readmissions
to hospital for any cause. As for heart failure readmissions, evi-
dence was strongest for those interventions delivered by a specialist
nurse. Clinic-based intervention models appeared to have little to
no effect on the risk of readmission for any cause, whereas multi-
disciplinary programmes may slightly reduce the risk of all-cause
readmission.
Very few studies mentioned adverse effects. None of the case man-
agement or clinic-based intervention models reported this out-
come, and two multidisciplinary intervention studies mentioned
that no adverse effects were reported during the trials.
It was difficult to assess the quality-of-life outcome due to dif-
ferences in reporting methods and very high attrition rates. For
case management and multidisciplinary interventions, the quality
of evidence was very low, so we are uncertain of the evidence for
these. Evidence for clinic-based intervention models suggests that
these may result in little or no difference in quality of life.
Low-quality evidence suggested that case management models
may reduce costs and improve cost-effectiveness slightly, com-
pared with usual care. Clinic-based interventions may reduce costs
slightly, and multidisciplinary models may be slightly cost-effec-
tive.
Overall completeness and applicability of
evidence
The review question set out to explore the evidence for disease
management interventions for heart failure. We included 47 stud-
ies with a total of 10,869 participants. Just under half of the studies
took place in Europe and 13 were in North America; seven were
in upper-middle income countries as defined by the World Bank
2018. Mao 2015, whose study took place in Taiwan, emphasised
the importance of evaluating disease management programmes in
non-Western countries. The more extensive literature available for
this update has therefore somewhat broadened the applicability
of the evidence beyond that available at the last update (Takeda
2012).
The included studies randomised participants with a range of heart
failure severity and co-morbidities. Although participants in most
studies were aged on average between 67 and 80 years, 10 stud-
ies had younger participants on average, and one had very elderly
participants. Some studies excluded participants with serious co-
morbidities, those awaiting surgery or those who had heart fail-
ure associated with acute myocardial infarction. This may affect
generalisability as people with heart failure often have multiple
chronic conditions. However, the diversity of the 47 studies does
appear to be broadly representative of the population of interest.
The range of interventions and countries where the studies took
placemean that the comparator ’usual care’ differed between them.
Whilst this adds heterogeneity to the analysis of outcomes, it does
to some extent reflect the ’real world’ situation and widen the
applicability of findings.
Complex interventions of this kind differ widely in terms of con-
tent, delivery and setting. Intervention-specific factors can there-
fore contribute to the success of the programme, and heterogene-
ity in these can affect the overall results described in this review.
We explored the contribution of individual components of an in-
tervention, but it was difficult to clarify the exact structure of each
intervention due to limitations in reporting. The transferability of
complex interventions is also difficult, as the interaction between
components may be equally as important as the impact of each
individual aspect. Undocumented aspects, such as the relationship
between patients and their carers, the influence of a patient’s par-
ticular domestic circumstances, and the dynamic between mem-
bers of the multidisciplinary team, may also be influential.
The outcomes for this update were more narrowly focused than
those for the previous update (Takeda 2012), aiming to provide
more succinct patient-relevant outcomes specific to the disease
and intervention in question. However, it was notable that heart
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failure readmissions and mortality due to heart failure were re-
ported more rarely than general cardiac-related readmissions or
causes of death. This led to a less complete summary of evidence
for these outcomes. Reporting cause of death may not be partic-
ularly reliable in this frail, elderly, multimorbid population, and
heart failure may be contributing to another cause of death. The
beneficial effect of case management programmes in reducing all-
cause mortality is, therefore, a helpful indicator of their broader
impact.
Quality of the evidence
Evidence from case management interventions was moderate for
heart failure readmissions, all-cause readmissions and costs. We
downgraded quality for publication bias, imprecision and indi-
rectness, respectively. The evidence for all-cause mortality was low
due to high risk of bias and suspected publication bias. We as-
sessed quality-of-life data as being very low-quality, due to risks
of attrition and detection bias, inconsistency (heterogeneity), and
imprecision.
The GRADE quality assessments for outcomes of clinic-based in-
terventions were low for all outcomes except heart failure read-
missions, which we assessed as having moderate-quality evidence.
Low-quality assessments for all-cause mortality and all-cause read-
missions were due to high risk of bias, imprecision (CI includ-
ing the null). The moderate rating for heart failure readmissions
was due to the only downgrade being for risk of bias. We down-
graded the quality-of-life outcome by two levels due to risk of de-
tection bias (unblinded outcome), and high attrition. We down-
graded the cost outcome for indirectness, due to the age of the
cost data, and for imprecision associated with the small sample
size. We assessed all-cause mortality as moderate-quality evidence
(downgraded once for risk of bias). We downgraded both adverse
events and costs once for imprecision, so we assessed them as be-
ing of moderate quality. Our GRADE assessment for both heart
failure readmissions and all-cause readmissions was low-quality,
being downgraded once for risk of bias and once for inconsistency
due to heterogeneity (heart failure readmissions), or for impreci-
sion due to wide confidence intervals including the null (all-cause
readmissions). The evidence for mortality due to heart failure was
of very low quality, downgraded for indirectness, risk of bias and
imprecision due to the low event rate. Similarly, quality-of-life
evidence was very low quality, downgraded twice for risk of bias
(detection and attrition) and imprecision.
Potential biases in the review process
Although we searched key databases and trials registries, it is pos-
sible that we did not identify some relevant publications. For the
majority of outcomes there were too few studies for a funnel plot to
be constructed, so we were not able to assess the possibility of pub-
lication bias. There were also too few studies for robust subgroup
analyses for several of the outcomes. We had difficulty classifying
some of the studies, so studies where the intervention was poorly
described may not have been assigned to the most appropriate
group, had the most appropriate person recorded as delivering the
intervention, or had all the components of the intervention listed
accurately. One of the key inclusion criteria for this review was
the requirement for study participants to have been admitted to
secondary care at least once for heart failure. This was often un-
clear in the publications, and we contacted many study authors for
further information. The inclusion of such studies may therefore
be biased towards those where study authors were responsive and
able to provide the necessary information.
Agreements and disagreements with other
studies or reviews
The previous update of this review (Takeda 2012) concluded
that case management interventions led by specialist nurses re-
duce heart failure readmissions, all-cause readmissions and all-
cause mortality after 12 months’ follow-up. The authors of the
previous update found that multidisciplinary interventions may
be effective in reducing readmissions for heart failure or any cause,
but found little evidence for effectiveness of clinic-based interven-
tions. In addition to adding new studies to the review, we have
used the GRADE system to assess the quality of evidence and
this has affected the interpretation of results. This current update
agreed with the previous review in finding that case management
interventions probably reduce all-causemortality, readmissions for
heart failure, and probably slightly reduce readmissions for any
cause. Our subgroup analyses also indicated that interventions led
by a specialist nurse were more effective than others in reducing
readmissions for either heart failure or any cause. As with the pre-
vious review, we found evidence that multidisciplinary interven-
tions may slightly reduce the risk of readmission for heart failure
or any cause. Unlike the previous update, the larger body of evi-
dence reviewed now indicates that multidisciplinary interventions
probably reduce all-cause mortality. As previously, we found little
to no effect of clinic-based interventions for heart failure on any
of the clinical outcomes in the review. Evidence for the effect of
disease management programmes on quality of life remains very
uncertain.We reviewed costs and cost-effectiveness for this update
but not the previous one. We found that case management in-
terventions probably reduce costs and improve cost-effectiveness
slightly, that clinic-based interventions may reduce costs slightly,
and that multidisciplinary models are probably slightly cost-effec-
tive.
The most similar recent systematic review to our own is that by
Huntley 2016, who reviewed the impact of case management in-
terventions in the community for people with heart failure, in
terms of reduction in hospital admissions or readmissions. That
review included 17 RCTs and five non-RCTs, and was not re-
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stricted to people who had been admitted to hospital for heart fail-
ure. The authors found that hospital-initiated case management
interventions reduced readmissions, as was found in our review.
They did not find much difference in costs between case manage-
ment and usual care, whereas we found that such interventions
probably reduce costs and improve cost-effectiveness slightly.
Oyanguren 2016 conducted a meta-analysis of management pro-
grammes for people with heart failure, which included 66 RCTs.
It is important to note that these included a broader spectrum
of management interventions than just disease management pro-
grammes of the type described in our own review (for example
trials on use of beta-blockers), and there was also no restriction on
length of follow-up. The authors did not divide the studies into
case management, clinic-based intervention and multidisciplinary
programmes, but found overall that heart failure management in-
terventions reduce mortality and readmissions.
Other systematic reviews in this area include a meta-analysis and
cost-effectiveness study of six ’care in the home’ trials, broadly
comparable with case management interventions (Fergenbaum
2015). The authors reported that care in the home reduced the
number of hospitalisations (as did our review), but not all-cause
mortality (unlike our review). They also reported better quality of
life for people who had care in the home. However, the authors
also noted that the quality of evidence indicated uncertainty over
outcomes. As with our current review, they found care-in-the-
home interventions to be less costly and more cost-effective than
usual care.
A recent meta-analysis of 16 RCTs of multidisciplinary, heart fail-
ure clinic-based interventions (Gandhi 2017), reported lower odds
of heart failure hospitalisation (but not all-cause hospitalisation),
and lower odds of all-causemortality for people attending the heart
failure clinics. Differences between the conclusions of the Gandhi
2017 review and our own, less optimistic, findings, are likely due
to the different studies included - we excluded nine of their stud-
ies from our own review for various reasons, including having a
follow-up of under six months, having the wrong participants or
comparator, and because hospital admission was not an inclusion
criterion.
There is some overlap in included studies between our own re-
view and the network meta-analysis of transitional care services
published by Van Spall 2017, although that analysis included a
wider range of interventions, and studies with shorter follow-up
than our own. Interestingly, they found that home visits by nurses
were the most effective services in terms of decreasing all-cause
readmissions, followed by nurse case management. Both of these
would fall into the ’case management’ category in our review.
It is interesting to compare our findings with the recommenda-
tions of the 2016 ESCGuidelines (ESC2016), which recommend
the use of multidisciplinary management programmes to reduce
the risk of heart failure-related hospitalisation and mortality. Our
review supports the likely reduction in all-cause mortality for peo-
ple treated by multidisciplinary teams, with low-quality evidence
also indicating a possible reduction in heart failure readmissions.
In addition, our review found that a case management approach,
particularly when led by specialist nurses, can also be effective in
reducing all-cause mortality and HF readmissions.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found limited evidence for the effect of disease manage-
ment programmes on mortality due to heart failure, with no case
management or clinic-based interventions reporting this outcome
specifically; the evidence frommultidisciplinary studieswas of very
low quality. However, it is difficult to classify death due to heart
failure in this elderly, co-morbid population. The use of all-cause
mortality may therefore be a better indicator of the intervention’s
impact than mortality due to heart failure.
The available evidence suggests that either case management or
multidisciplinary models are likely to deliver reductions in overall
mortality and heart failure readmissions, and may reduce all-cause
readmissions. Themore limited evidence fromclinic-basedmodels
generally found little or no effect on mortality or readmissions
for heart failure or any cause. For case management models, the
evidence suggests that a specialty trained heart failure nurse is
important, a strong education component may be beneficial, but
that weight monitoring may be of limited value.
There was a lack of evidence for adverse events, but this is not
unexpected due to the nature of the interventions. It would be
difficult to identify and collect specific adverse effects of disease
management interventions - for example, widening gaps in access
to services for people unable to receive home visits or answer tele-
phone calls.
Despite many studies reporting quality-of-life assessments, the ev-
idence remains of very low-quality for case management and mul-
tidisciplinary interventions, so results are uncertain for this out-
come. The evidence for clinic-based interventions was of low qual-
ity, and the studies appear to make little or no difference to quality
of life.
Variations in study location and time of occurrence hamper at-
tempts to review costs and cost-effectiveness, but limited data sug-
gest that these models are cost-effective.
Implications for research
Despite the inclusion of 22 new studies since the last update of this
review, there remains a gap in the evidence for quality of life, as
this outcome is poorly reported and suffers high attrition. For the
mainly elderly, heart-failure populations in the studies included in
this review, the potential to improve quality of life is an important
37Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
consideration both for patients themselves, their carers and health
professionals. Improved reporting of this outcome in future trials
would be helpful in strengthening the evidence for this patient-
relevant outcome.
The assessment of complex interventions is an active area of re-
search, and new methods could be useful for improving interpre-
tation of studies. For example, Freeman 2018 describes methods
for undertaking a component network meta-analysis to assess the
effects of specific components of complex interventions. Any such
work would also require an improvement in the reporting of ran-
domised controlled trials (RCTs), as it is often difficult to identify
exactly what components have been included in an intervention
and to estimate the relative time spent on each.
It is also worth considering whether a traditional meta-analysis of
RCTs is the best approach for evaluating complex interventions.
Mixed methods may be more helpful in analysing the many in-
teracting components of disease management programmes, and
helping to understand the various impacts on their effectiveness.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agren 2012
Methods Multicentre RCT (2 hospitals)
Recruiting: January 2005-December 2008
Follow-up: 3 and 12 months (with 24 months’ long-term results in subsequent publica-
tion by Liljeroos 2015)
Intervention category: other
Person delivering the intervention: nurse
Participants Country: Sweden, setting described as hospital-based, but interventions took place in
participants’ homes or the HF clinic depending on participant preference
Participants: N = 155: 71 (46%) in intervention group, 84 (54%) in usual-care group
Mean ± SD age 69 ± 13 in intervention group, 73 ± 10 in usual-care group
Male sex: 49 (69.1%) in intervention group, 68/84 (80.9%) in control group
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA class, N (%)):
• intervention group, class I, N = 0; class II, N = 25 (35%); class III, N = 39 (55%);
class IV N = 7(10%);
• control group, class I N = 0; class II, N = 25 (30%); class III, N = 43 (51%); class
IV, N = 16 (19%)
Median EF%: NR
Inclusion criteria:
• a dyad consisting of a patient diagnosed with HF based on the ESC guidelines,
NYHA functional class II-IV, with a partner living in the same household, recently
discharged from hospital (i.e. 2-3 weeks) after a HF acute exacerbation
Exclusion criteria:
• dementia or other severe psychiatric illnesses
• drug abuse
• difficulties in understanding or reading the Swedish language
• undergoing cardiac surgery, including cardiac transplant
• participating in other studies
Interventions Median duration of intervention: 12 weeks
Intervention:
• psychosocial support to maintain and strengthen physical and mental functions,
knowledge, and perceived control to make participants feel involved and reduce their
stress and their partners’ burden.
• 3 nurse-led, face-to-face counselling sessions of at least 1 h each, including
education on HF with booklets and computer-based education using a CD-ROM
program, and other written teaching materials
• intervention focused on changing thoughts and behaviours and implementing
strategies for self-care
• dyads were also encouraged to talk about lifestyle changes, communication, and
prospects and learning to live with lifelong HF
Comparator:
• dyads in the control group received care as usual, including traditional care in
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Agren 2012 (Continued)
hospital and outpatient education and support. At present, this care is mainly focused
on the participant’s needs. The partner is not systematically involved in the follow-up
focusing on education and psychosocial support.
Outcomes Primary outcome: unclear
Outcomes: perceived control, self-care, HRQOL, depression, caregiver burden
SF-36 for self-rated health
BDI-II
CAS: 4 items, 2 about perceived control and 2 about helplessness
EHFscBS
Caregiver Burden Scale
Notes Funding: “Funding: Grants from Linkoping University, Swedish Research Council,
Swedish Institute for Health Sciences, Heart and Lung Foundation, Heart and Lung
Disease National Association, and Lions Research Foundation”
Disclosures: none
Data source: published data only
165 dyads accepted for study participation, 10 thenwithdrew before baseline assessment,
155 dyads randomised after baseline assessment, 71 (46%) randomised to experimental
group and received intervention, 84 (54%) randomised to control group
7 intervention participants and 9 intervention partners; 6 control participants and 9
control partners did not complete 3 months’ follow-up. At 12 months, 14 intervention
participants, 13 intervention partners, 21 control participants and 26 control partners
did not complete follow-up
Liljeroos 2015 reports long-term follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation code was developed us-
ing a random-number table
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
High risk No blinding possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “both data collectors, and re-
searchers entering the data were blinded to
group assignment”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Self-completed QoL questionnaires, no
blinding of participants
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Agren 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Agren 2013: 14/71 (19.7%) intervention
and 21/84 (25%) control participants did
not complete - not balanced
Liljeroos 2015 (long-term follow-up): low
for readmissions and mortality - all ran-
domised participants included in analysis;
high for QoL data: Although missing data
in the SF-36 were imputed by the means
of the subscale if only 1 item in the sub-
scale was missing, only 62% in both in-
tervention and control groups completed
questionnaires so 38% of dyads were not
included
Selective reporting (reporting bias) Unclear risk The study was registered at ClinicalTrials.
gov, identifier: NCT02398799, after par-
ticipant recruitment began
Quote: “The reason for this is that when
recruitment began, it was unusual to regis-
ter this type of intervention studies.”
However, reported outcomes are in line
with the study’s objectives
Other bias Unclear risk There was a higher proportion of men in
the intervention group than the control
group (80.9% vs 69.1%)
Aldamiz-Echevarria 2007
Methods Single-centre RCT
Recruitment dates: February 2001- June 2002
Follow-up: 12 months
Intervention category: case management
Person delivering the intervention: nurse
Participants Country: Spain
N randomised: 279
Intervention (N = 137) vs control (N = 142)
Mean (SD) age: 75.3 (11.1) vs 76.3 (9.4)
Percentage male: 38.7 vs 40.1
Ethnicity: NR
NYHA functional class intervention/control: NR
Mean (SD) EF: 50.9 (16.6), N = 130 vs 48.3 (17.6), N = 124
Inclusion criteria:
• all participants had been hospitalised for HF
• lived in area covered by the collaborating home care unit
• sufficient family support
Exclusion criteria:
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• severe cognitive deficits
• advanced psychiatric disease
• non-cardiological terminal disease
• COPD
Interventions Duration of intervention: 15 days
Intervention:
• home visits by physicians and nurses, for clinical examination, tests/analyses as
required, and adjustment of medication as required (N.B. this intervention was not
HF-specific, but was intended to reduce readmissions across a range of medical and
surgical conditions)
• additional nursing staff home visits 2, 5 and 10 days after discharge for education
for participants and relatives about HF (basic facts and management, i.e. symptoms,
life style, diet and therapy)
• participants received educational manual and a phone number for queries
Compatator:
• usual care (referral to primary care physician)
Outcomes Primary: cumulative unplanned readmission or death 6 and 12 months after discharge
Secondary:
• cumulative unplanned readmissions
• cumulative mortality
• duration of readmission
• use of emergency services during 1st 6 months after discharge
Notes Data source: published data only
Planned admissions were not considered events
Funding/CoI: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Closed envelopes prepared by the Instituto
deCiencias de la Salud. The randomisation
process was stratified with respect to the
services involved (internal medicine, cardi-
ology and short-stay)
Allocation concealment (selection bias) Low risk The sequence was concealed until interven-
tions were assigned
Blinding of participants and personnel
(performance bias)
High risk Quote: “By the very nature of the interven-
tion being tested, neither the patients tak-
ingpart in this study nor the home care unit
personnel were blind to their treatment.”
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Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “... staff attending them in other
services were unaware of whether patients
belonged to the programme or control
group. Events assignment was, therefore,
blinded.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk QoL NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “There were no dropouts from the
study.”
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Atienza 2004
Methods Multicentre RCT (3 centres)
Recruiting: January 1999- June 1999
Follow-up: median duration 509 days (IQR 365-649)
Intervention category: case management
Person delivering the intervention: cardiologist
Participants Country: Spain
Participants: 164 in intervention group, 174 in usual-care group
Median age (IQR) 69 (61-74) in intervention group, 67 (58-74) in usual-care group
Male sex (both groups) 203 (60%), (intervention group 101/164, 62%), (control group
102/174, 59%)
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA class, N):
• intervention group: class I, N = 11; class II, N = 39; class III, N = 40; class IV, N
=10
• control group: class I, N = 10; class II, N = 40; class III, N = 40; class IV, N = 10
Median EF% (IQR): intervention 36 (30-53); control 40 (30-55)
Inclusion criteria:
• all patients with congestive HF discharged from cardiology wards of 3 hospitals in
Spain
• HF diagnosis based on the presence of symptoms and signs of HF with objective
evidence of major cardiac dysfunction at rest
• All patients had been hospitalised for HF
Exclusion criteria:
• expected survival < 3 months
• discharge to a nursing home or long-term care facility
• living > 30 km from hospital
• impossible to contact by phone
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• dementia or psychiatric illness
• on a waiting list for invasive cardiology or heart surgery on discharge
Interventions Median duration of intervention: 509 days (IQR 365-649)
Intervention: discharge and outpatient management programme
• 1-to-1 single education session for participants and carers prior to discharge and
session with primary care physician post discharge to reinforce education
• teaching brochure to reinforce education, covering: diagnosis of HF, information
about the disease (pathogenesis etc), symptoms of HF, symptoms and signs of
worsening HF, what to do if condition worsens, lifestyle advice, medication education
for carers
• cardiologist outpatient clinic every 3 months, including medication review
• participant given specific/tailored self-management plan
• visit with primary care physician scheduled within 2 weeks of discharge
• telemonitoring component; a facilitated telephone monitor (SCT) providing a
24-h mobile phone contact number which participants were encouraged to contact as
necessary. Participants could also telephone the HF team for advice during office hours
Comparator:
• discharge planning according to the routine protocol of the study hospitals
Outcomes Primary outcome: event-free survival (survival without readmission to hospital) at 1 year
Secondary outcomes: total number of hospital admissions (all-cause and for HF) at 1
year
Other outcomes: readmission rate (all-cause and for HF); HRQoL (MLHFQ); costs;
rate of deaths per observation year; time to readmission (all-cause + HF); time to death
Notes Data source: published data only
Funding: “Dr. Atienza was funded by the Spanish Society of Cardiology, Madrid, Spain.
Prof. Martinez-Alzamora was funded by a Research Incentive Program from the Poly-
technic University of Valencia, Spain. Merck, Sharp & Dohme contributed financially
to the edition and printing of the brochure for HF patients used in the study”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An independent assistant allocated par-
ticipants using a computer-generated ran-
domisation list. Block stratified randomi-
sation performed according to age and sex
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information on whether objective out-
come assessment was blinded
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data analysed on ITT principles, “one pa-
tient in each arm transferred to a nursing
home during the study so their data were
included in analyses but censored at time
of transfer”
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified, beyond a slight base-
line imbalance: more control participants
had valvular heart disease (47/174 com-
pared with 31/164) and fewer were on a
beta blocker 20/174 compared with 31/
164)
Bekelman 2015
Methods Multicentre RCT (4 centres)
Recruiting: May 2009-June 2011
Duration of follow-up: 12 months
Intervention category: multidisciplinary
Person delivering intervention: “Each site had a collaborative care team consisting of
a nurse coordinator (registered nurse), a primary care physician, a cardiologist, and a
psychiatrist.”
Participants Country: USA
Participants: N = 392 randomised (193 intervention, 199 usual care)
Mean ± SD age: intervention: 67.3 (9.6); usual care: 67.9 (10.6)
Male sex N (%): intervention: 178 (95.2); usual care: 193 (98.0)
Ethnicity: N (%) intervention: 149 (79.7) white; control: 165 (83.8) white
Actual severity of HF in study participants at recruitment (LVEF (%)):
• intervention: data available for N = 171: normal 78 (45.6), mildly reduced 34
(19.9), moderately reduced 46 (26.9), severely reduced 13 (7.6)
• usual care: data available for N = 177: normal 84 (47.5), mildly reduced 34 (19.2)
, moderately reduced 32 (18.1), severely reduced 27 (15.3)
NYHA class (N (%)):
• Intervention: class I, N = 16 (8.9%); class II, N = 77 (42.8%); class III, N = 82
(45.6%); class IV, N = 5 (2.8%)
• Control: class I, N = 16 (8.5%); class II, N = 85 (45.0%); class III, N = 82 (43.
4%); class IV, N = 6 (3.2%)
Comorbidities
• hypertension: intervention: 158 (84.5); control:159 (80.7)
• diabetes: intervention: 99 (52.9); control: 93 (47.2)
67Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bekelman 2015 (Continued)
Inclusion criteria:
(1) a primary inpatient hospital discharge diagnosis of HF
(2) at least 2 secondary inpatient hospital discharge diagnoses of HF and a primary
inpatient hospital discharge diagnosis related to heart disease;
(3) at least 3 secondary inpatient hospital discharge diagnosis codes related to HF;
(4) at least 2 outpatient visit diagnoses of HF, excluding emergency department visits;
and
(5) at least 2 secondary inpatient hospital discharge diagnoses of HF and at least 1
outpatient HF diagnosis
Exclusion criteria:
(1) severe cognitive or psychiatric impairment;
(2) current residence in a nursing home;
(3) irreversible, noncardiac medical conditions likely to affect 6-month survival or ability
to execute the study protocol;
(4) prior heart transplantation; and
(5) alcohol abuse
Interventions Intervention: “The intervention included 3 components. These were multi-disciplinary
collaborative care HF disease management, screening for and treatment of depression,
and telemonitoring with patient self-care support.” “For each intervention patient, the
team reviewed the electronic health record and baseline depression scores from the Pa-
tientHealthQuestionnaire 9 (PHQ-9). The team recommended care changes for a given
patient in accord with the American College of Cardiology and American Heart Asso-
ciation Guidelines for the Diagnosis Research Original Investigation Patient-Centered
Disease Management for Heart Failure Trial and Management of Heart Failure in Adults
and the collaborative depression care intervention as described herein. In addition, the
teammet weekly to recommend care changes based on review of telemonitoring data and
the follow-up PHQ-9 score.” “Intervention patients who screened positive for depres-
sion (PHQ-9 score, ≥10) received the depression care component of the intervention,
adapted from a successful collaborative depression care intervention.” “Intervention pa-
tients received daily telemonitoring using home-based equipment that tracked signs and
symptoms ofHF and depression. The system collected daily measures of blood pressure,
pulse, weight, and self-reported symptoms (eg, shortness of breath and edema). Patients
with depression were asked questions about their mood and behavior. The telemonitor-
ing system assigned a risk to each response on the system. The nurse reviewed medium
risk indicators and decided whether an action needed to be taken (eg, for patients unable
to understand a low sodium diet, the nurse provided counseling). The nurse acted on all
of the high risk indicators by contacting the patient for assessment and then, if necessary,
contacted the care team for any changes in medications or tests to be written in the
electronic medical record.”
Comparator: “Patients randomized to the usual care arm continued to receive care from
their regular health care professionals and regular telehealth nurses (if enrolled in tele-
monitoring), with no involvement of the study collaborative care team. Care was fully at
the discretion of the patient’s regular health care professionals and may or may not have
included cardiology or mental health clinic care in addition to primary care. Usual care
patients were given information sheets at the enrollment visit that described self-care for
HF and were provided with a weighing scale if needed.”
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Outcomes All-cause mortality
All-cause readmissions
HRQoL (KCCQ)
Cost-effectiveness planned but NR
Notes Funding/support: ”The Patient-Centered Heart Failure Trial was funded by grant IIR
06-068 from the Department of Veterans Affairs Health Services Research and Devel-
opment. Dr Bekelman was supported by Career Development Award 08-022 from the
Department of Veterans Affairs Health Services Research and Development during this
study. Role of the Funder/Sponsor: The Department of Veterans Affairs had no role in
the design and conduct of the study; the collection, management, analysis, and inter-
pretation of the data; the preparation, review, or approval of the manuscript; and the
decision to submit the manuscript for publication.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The study database was used to
create the randomization sequence using
block randomization, with stratification by
study site and 1:1 randomization of pa-
tients to the intervention and to usual care”
Allocation concealment (selection bias) Unclear risk Quote: “The randomization sequence was
concealed from the study personnel. Ran-
domization occurred after baseline survey
information was entered into the database.
“
Blinding of participants and personnel
(performance bias)
High risk Quote: “unable to blind participants”
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Blinding unclear for nurse co-ordinator
who collected outcome data at 12 months
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk A research assistantwho collectedQoLdata
was blinded, but QoL was self-reported by
unblinded participants
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6 intervention and 2 control partici-
pants dropped out at randomisation, and
couldn’t be included in results. Trial reg-
istry indicates that data were otherwise re-
ported for all randomised people, includ-
ing those who later dropped out/couldn’t
be contacted, but published paper’s analysis
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appears to be of 165/193 intervention par-
ticipants and 172/199 control participants
Selective reporting (reporting bias) Unclear risk Protocol published after end of trial, but
registered prospectively on clinicaltrials.
gov. 2 secondary outcomes plannedbutNR
Other bias Low risk Nothing detected
Berger 2010
Methods Multicentre RCT (8 centres). 3 arms - only multidisciplinary care and usual-care groups
are discussed here, since the BM arm (N-Terminal Pro-B-Type Natriuretic Peptide-
Guided, Intensive Patient Management in Addition to Multidisciplinary Care) was not
relevant to this review
Recruiting: July 2003-September 2004
Duration of follow-up: 12 months
Intervention category: case management
Person delivering the intervention: multidisciplinary
Participants Country: Austria
Participants: N = 186: 96 in intervention group, 90 in usual-care group
Mean ± SD age: 73 ± 11 in intervention group, 71 ± 13 in usual-care group
Male sex: intervention 66/96 (68.8%); usual-care 59/90 (65.6%)
Ethnicity: NR
Actual severity of HF in study participants at recruitment: NYHA class NR
Inclusion criteria:
• hospitalised due to HF
• clinical signs and symptoms of cardiac decompensation during the present
hospitalisations
• NYHA functional class III or IV at admission
• cardiothoracic ratio > 0.5 or LVEF < 40% as documented by echocardiography
Exclusion criteria:
• NR
Interventions Intervention:
• multidisciplinary care by a specialised HF nurse, which included 4 home visits
and telephone contact, 2 pre-scheduled consultations from the HF specialist 10 days
and 2 months after discharge, and consultations on demand that were performed if any
deterioration in the participant’s status was noted by the HF nurse. Consultations
included physical examination and laboratory testing of blood chemistry and blood cell
count, and optimisation of medical therapy based on these.
• Nurse care consisted of 4 home visits at 1, 3, 6, and 12 months after discharge by
a nurse specialised in caring for people with HF. The nurse checked and recorded
weight, symptoms and signs of HF, heart rate and blood pressure, and reviewed blood
analyses on demand. In co-ordination with the HF specialist, the nurse checked for
and implemented guideline-based HF medication. Nurse provided individualised
patient and caregiver education and self-management advice.
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Comparator:
• usual care. Participant’s management plan sent to primary care physician, who
was responsible for patient evaluation and treatment, including assessing need for
readmission. In hospitals in which the usual patient management offered visits for
selected patients at the cardiac outpatient clinic, the discharging physician was allowed
to arrange such visits as usual. Contact with the HF specialists of the research team was
discouraged. Neither a structured follow-up nor specialised HF nurses were available
for participants in the usual-care group
Outcomes Pilot study so no primary outcome specified. End points included HF rehospitalisation,
duration of time it takes to reach the combined end point of death and HF rehospitali-
sation, the first HF rehospitalisation, and death
Cost utility analysis published by Moertl et al. 2013 (see Berger 2010)
Notes Funding: ”This study was funded by AstraZeneca, Novartis, Roche Diagnostics, Roche
Medical, Merck, Medtronic, and Guidant, who provided the financial support for a
clinical investigator, a specialised chronic HF nurse, and data collection.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to groups us-
ing computer-generated permuted block
randomisation (6 participants per block)
Allocation concealment (selection bias) Low risk At discharge, concealed allocation was per-
formed by sending the baseline character-
istics of each participant to an independent
medical project management institute
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Independent data collectors ob-
tained information from medical reports
and from interviews with relatives during
the follow-up at least every 3 months. Dur-
ing a consensus reading, 2 cardiologists,
who were blinded to the treatment groups,
classified the cause of rehospitalization as
being a result of cardiac decompensation
or not. If the cause of rehospitalization was
classified unclear by 1 cardiologist, the data
collector provided the appropriate hospital
charts for final classification.”
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk No subjective outcomes reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Selective reporting (reporting bias) Unclear risk NCT record registered after enrolment was
completed, no published protocol identi-
fied
Other bias High risk NCT record suggests trial terminated, but
no reason given for early stoppage. Gener-
ally similar at baseline, but 18/96 interven-
tion vs 31/90 usual-care participants had
mild-moderately reduced LVSF and 73/96
intervention vs 61/90 usual-care partici-
pants had severely reduced LVSF
Bernocchi 2017
Methods Multicentre RCT (3 rehabilitation hospitals)
Recruiting: July 2013-October 2014
Duration of follow-up: 6 months
Intervention category: multidisciplinary
Person delivering intervention: multidisciplinary (nurse and physiotherapist)
Participants Country: Italy
Participants: randomised N = 112 (N = 56 intervention, N = 56 control)
Mean ± SD age: intervention: 71 (9); control 70 (9.5)
Male sex N (%): intervention 50 (88%); control 42 (75%)
Ethnicity: NR
Participants in this trial had both HF and comorbid COPD
Actual severity of HF in study participants at recruitment (NYHA class, N (%)):
• intervention: class II, N = 25 (45%); class III, N = 22 (39%); class IV, N = 9
(16%)
• control: class II, N = 29 (52%); class III, N = 19 (34%); class IV, N = 8 (14%)
Inclusion criteria:
• aged > 18 years
• COPD GOLD classification, classes B, C, and D
• systolic and/or diastolic HF NYHA classes II, II, and IV
• ≥ 1 hospitalisation or visit due to HF or COPD exacerbation in the previous 12
months
• signed informed consent
The confirmed diagnosis of HF (NYHA class II-IV) and COPD (B, C and D GOLD
class) had to be documented by an echocardiogram (HF) and by a spirometry examina-
tion (COPD) performed within the previous 12 months. The majority of participants
had been hospitalised for HF as the first diagnosis. Of the 112 participants enrolled, 76
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of them had as first diagnosis HF
Exclusion criteria:
• physical activity limitations due to noncardiac and/or pulmonary conditions
• limited life expectancy
• severe cognitive impairments
Interventions Intervention:
• educational intervention from a nurse tutor and a physiotherapist tutor, who then
followed participants for 4-month telerehabilitation phase
• weekly structured phone call from nurse tutor to collect information about disease
status and symptoms, offering advice regarding diet, lifestyle and medications,
previously defined with the cardiologist and pulmonologist supervising the programme
• participants were provided with a pulse oximeter and a portable 1-lead
electrocardiograph) for real-time telemonitoring of vital signs
• participants could call in the case of urgent need or emergency 24 h/day 365
days/year
• physiotherapist tutor designed a personalised exercise programme for each
participant; who was provided with mini-ergometer, pedometer and diary.
• physiotherapist tutor instructed participants and their caregivers on how to
perform the exercises correctly, focusing on the rehabilitation goals. The number/
intensity of training sessions according to participants’ progress were adjusted during 4
months or in the case of problems
• there was a ‘basic level’ and ‘high level’ programme, physiotherapist tutor assessed
participant to decide which to use
• physiotherapist tutor phoned each participant weekly to verify the training level
of physical activity performed, plan the rehabilitation targets for the following week
and give extra reinforcement on the value of lifestyle changes and the importance of
exercise.
Comparator:
• participants received the standard care programme (including medications and
oxygen prescription, visits from GP, and in-hospital check-ups on demand). At
enrolment, participants received an educational session about healthy lifestyle and daily
physical activity. Study author confirmed that this should be considered as standard
care (26.6.18)
Outcomes All-cause mortality; CV-related readmissions (but not HF readmissions); all-cause read-
missions (total not number with readmission); QoL (MLHFQ)
Notes Funding: Ministero della Salute (ItalianMinistry of Health). The funding source did not
influence or comment on planned methods, protocol, data analysis or the draft report
Study author supplied unpublished data for change from baseline to 6 months, and
confirmed that the majority of participants had been hospitalised for HF as the primary
diagnosis
Published and unpublished data. Searches identified the published protocol, study author
sent the published paper (published after search date) and also sent the unpublished data
on change in quality of life from baseline to 6 months
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated tables to allo-
cate patients in fixed blocks of 4”
Allocation concealment (selection bias) Low risk Quote: “the allocation sequence was con-
cealed from the investigators enrolling and
assessing patients, in sequentially num-
bered, opaque, sealed envelopes.”
Blinding of participants and personnel
(performance bias)
High risk Quote: “Due to the nature of the trial, it was
not possible to blind patients and health-
care personnel to intervention.”
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “outcome assessors and data ana-
lysts were blinded to the allocation.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported by participants who
knew their allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low overall (majority of participants ac-
counted for for readmissions and mortal-
ity)
High for QoL, as 80% of intervention
group and63%of control group completed
this outcome - imbalance could lead to bias
Selective reporting (reporting bias) Low risk Outcomes stated in trial registry published
prior to study completion, match the out-
comes of interest in the publications. Study
author provided additional data for base-
line to 6months, as this had only been pub-
lished as 0-4 months and 4-6 months
Other bias Low risk Quote: “We tried to standardise as much
as possible the nursing and physiotherapy
approach in the three hospitals involved
in the enrolment of patients, conducting
joint training of staff, organisational meet-
ings and planning before commencing pa-
tient enrolment.”
74Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Blue 2001
Methods Single-centre RCT
Recruiting: March 1997-November 1998
Duration of follow-up: 12 months (mean follow-up)
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Scotland (UK)
Participants: 81 participants (41 men, 51%) in comparison group, 84 (54 men, 64%)
in intervention group
Actual age of study participants: intervention 74.4 years (SD 8.6); usual-care mean 75.
6 years (SD 7.9)
Male sex: 58%
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA class, N (%)):
• intervention group: class II, N = 19 (23%); class III, N = 28 (34%); class IV, N =
36 (43%)
• control group: class II, N = 16 (20%); class III, N = 33 (42%); class IV, N = 30
(35%)
LVEF: NR
Inclusion criteria:
• patients admitted as an emergency to the acute medical admissions unit at 1
hospital with HF due to LV systolic dysfunction.
• all patients had been hospitalised for HF
Exclusion criteria:
• unable to give informed consent or to comply with the intervention
• acute MI (unless they had a previous history of HF)
• co-morbidity (such as advanced malignancy) likely to lead to death or readmission
in the near future
• awaiting cardiac surgery
• planned discharge to long-term residential care
• residence outside the hospital catchment area
Interventions Duration of intervention: up to 12 months
Intervention: “Specialist nurse intervention”
During index hospitalisation:
• participants were seen by a HF nurse prior to discharge
After discharge:
• home visit by HF nurse and within 48 h of discharge
• subsequent visits by HF nurse at 1, 3, and 6 weeks and at 3, 6, 9 and 12 months.
• scheduled phone calls at 2 weeks and at 1, 2, 4, 5, 7, 8, 10 and 11 months after
discharge.
• participants and their families encouraged to contact nurses with problems or
questions by phone during office hours (answering machine where they could leave
messages after hours)
• additional unscheduled home visits and telephone contacts as required
Home visits covered:
• participant education about HF and its Rx, self-monitoring and management
(especially the early detection and treatment of decompensation)
• participants were given a booklet about HF which included a list of their drugs,
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contact details for HF nurses, blood test results and clinic appointment times
• trained HF nurses used written drug protocols and aimed to optimise participant
treatment (drugs, exercise and diet)
• HF nurses also provided psychological support to the participant
• HF nurses liaised with the cardiology team and other healthcare and social
workers as required
Comparator:
• usual care
• “Patients in the usual care group were managed as usual by the admitting
physician and, subsequently, general practitioner. They were not seen by the specialist
nurses after discharge.”
Outcomes Primary endpoints:
• unplanned readmissions within 90 days of discharge
• total number of days hospitalised during follow-up (12 months)
Also looked at:
• readmission rates in the moderate-risk subgroup compared to the high-risk sub
group
Notes Data source: published data only
Funding: “This study was supported by a grant from the Scottish Office, Department
of Health. Competing interests: None declared.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Study nurses phoned the Robert-
son Centre for Biostatistics and the patient
was allocated to one or other randomisa-
tion group from a randomisation list.”
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “We obtained data on admissions
and deaths from the hospital records de-
partment, the information and statistics di-
vision of the Scottish NHS (hospital ad-
missions) and the Registrar General’s Of-
fice, Scotland (deaths). All hospital admis-
sions were adjudicated blind to treatment
allocation.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk No subjective outcomes reported
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 person withdrew
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Bohmer 2011
Methods Single-centre RCT
Recruiting: November 2006-July 2008
Duration of follow-up: 6 months
Intervention category: clinic
Person delivering the intervention: multidisciplinary
Participants Country: Austria, setting outpatient department plus phone calls to participant’s home
Participants: 140 (70%) intervention group, 60 (30%) usual-care group
Mean age 68.3 years in intervention group, 73.4 in usual-care group
Male sex: intervention group 77%, usual-care group 62%
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA class, %):
• intervention group: class I, 21%; class II, 47%; class III, 30%; class IV, 2%
• control group: class I, 23%; class II, 57%; class III, 20%, class IV, 0%
LVEF %: intervention 32%, usual care 33%
Inclusion criteria:
• patients with chronic HF (LVEF < 40%)
Exclusion criteria:
• severe non-cardiac illness with a life expectancy < 1 year;
• severe disability that would make ambulatory care impossible;
• planned heart surgery
Interventions The ’Kremser Model’ involved education and training, testing, stepwise optimisation of
drug therapy with the aim of achieving recommended target doses, regular outpatient
visits to the hospital HF clinic (every 4 weeks) as required and regular phone calls by
a trained HF nurse to check if drugs were tolerated and taken as prescribed or if other
problems had arisen
The usual-care group were discharged from hospital with usual procedures of referral
to GP and internal medicine specialist, with recommendation to adjust medication
according to guidelines
Outcomes No specification of primary outcome
Outcomes:
• mortality
• adjustment of medication to target dose
• NYHA score
• well-being
• LVEF
• B-type natriuretic peptide
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Notes Funding: NR. CoI: study authors declare no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information in paper
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information given
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk No subjective outcomes included
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 8% of the intervention group and no
participants in the control group left the
study (but intervention group was twice
the size of control group). No information
on whether their data were included in the
analysis
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Unclear risk There were some imbalances at baseline in
this pilot study (age 68.3 (I) vs 73.4 (C);
23% female (I) vs 38% (C)
Brotons 2009
Methods Multicentre RCT (4 hospitals)
Recruiting: January 2004-September 2005
Duration of follow-up: 1 year
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Spain, participants recruited from 2 university hospitals and 2 community
hospitals for a home-based intervention
Participants: N = 283 randomised, 144 to intervention, 139 to control
Mean (SD) age: intervention: 76.6 (7.5) control: 76 (8.9)
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Male sex: intervention: 66 (45.8%), control: 61 (43.9%)
Ethnicity: NR
Actual severity of HF in study participants at recruitment (NYHA at hospital discharge
(class, N, %)):
• intervention: class I, N = 61 (42.2%); class II, N = 75 (52.1%); class III, N = 7 (4.
9%); class IV, N = 1 (0.7%)
• control: class I, N = 77 (55.4%); class II, N = 52 (37.4%); class III, N = 8 (5.8%);
class IV, N = 2 (1.4%)
Inclusion criteria:
• no age limits
• either sex
• hospitalised for suspected HF based on dyspnoea with signs of pulmonary or
systemic hypertension, consistent with the Framingham criteria (2 major criteria, or 1
major and 1 minor criterion were required)
• diagnosis at hospital discharge had to show HF in the first or second position
Exclusion criteria:
• concomitant diseases and an expected survival of < 1 year
• cognitive deficit
• possibility of being outside the geographic area during the following year
• participation in a clinical trial within the previous 3 months
Interventions Intervention:
• pre-discharge information about disease and treatments, with a participant
booklet on HF
• monthly home visits for 1 year (including education and recognition of warning
symptoms, assessment of adherence to prescribed medication and lifestyle habits, plus
checking of functional status and vital signs)
• telephone calls from nurse every 15 days to evaluate clinical status
• nurses contacted the participant’s family physician or cardiologist when they
deemed it was necessary to start a new treatment or modify the existing one
Control:
• participants randomised to the usual care were referred to their family physician
and/or referral cardiologist
Outcomes Primary: combination of all-cause death and hospital readmissions due to worsening of
HF
Secondary:
• CV death
• hospital readmissions due to CV disease (hospital emergencies not considered)
• QoL (MLHFQ, adapted for use in Spain)
• adherence to therapy
• satisfaction
Notes Funding: “This study was funded by a subsidy from the Agència d’Avaluació de Tecnolo-
gia i Recerca Mèdiques (084/03/02), a research grant from the Acadèmia de Ciències
Mèdiques i de la Salut de Catalunya i Balears (2005), and unrestricted funds from No-
vartis, Pfizer, Almirall-Prodesfarma, AstraZeneca, and Sanofi-Synthelabo. ”
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by com-
puter, stratified for each hospital
Allocation concealment (selection bias) Low risk At the end of each interview, the nurse tele-
phoned a central data management site to
request random assignment of participants
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “The endpoints were assessed by a
committee of clinical events, blinded to the
patient’s treatment group.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Potentially high risk forQoLas participant-
reported outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low for events: only 1 participant lost to
follow-up;
high for QoL (101/133 in intervention
group responded at 1 year, 97/129 in con-
trol group)
Selective reporting (reporting bias) Unclear risk Trial registration (ISRCTN35096435) was
after enrolment started
Other bias Low risk Nothing identified
Capomolla 2002
Methods Single-centre RCT
Recruitment: January 1999-January 2000
Duration of follow-up: mean follow-up of 12 months
Intervention category: other (day hospital)
Person delivering the intervention: multidisciplinary
Participants Country: Italy
Participants: N randomised = 234:122 participants (102 men, 84%) in comparison
group, 112 (94 men, 84%) in intervention group
Actual age of study participants: mean age 56 years (SD 10)
Male sex: 84%
Ethnicity: NR
Actual severity of HF in study participants at baseline:
• NYHA class I-II/III-IV: 158/81 (68% I-II)
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• LVEF: 29% (SD 7)
Inclusion criteria:
• patients with HF referred for admission to the HF Unit at 1 centre or the Heart
Transplantation Programme (unclear if at the same centre)
• a diagnosis of HF supported by clinical history, physical signs and symptoms, and
by LVEF < 40%
• all participants had been hospitalised for HF
Exclusion criteria:
• None given
Interventions Duration of intervention: not clear
Intervention:
• comprehensive HF outpatient management programme delivered by the day
hospital
During index hospitalisation:
• cardiac prognostic stratification and prescription of individual tailored therapy
following guidelines and evidence
After discharge:
• attendance at day hospital staffed by a multidisciplinary team (cardiologist, nurse,
physiotherapist, dietician, psychologist and social assistant). Participant access to the
day hospital, “modulated according to demands of care process”
• care plan developed for each participant
• tailored interventions covering: cardiovascular risk stratification; tailored therapy;
tailored physical training; counselling; checking clinical stability; correction of risk
factors for haemodynamic instability; and healthcare education
• participants who deteriorated re-entered the day hospital through an open-access
programme
• day hospital also offered intravenous therapy, laboratory examinations and
therapeutic changes as required
• education given covered: knowledge about HF and drug treatments; and self-
management, including daily weights, fluid restriction and nutrition
Comparison Group:
• usual care
During admission:
• cardiac prognostic stratification and prescription of individual tailored therapy
following guidelines and evidence
After discharge:
• “The patient returned to the community and was followed up by a primary care
physician with the support of a cardiologist”
Outcomes Primary outcomes (evaluated at a mean of 12 months):
• readmissions because of haemodynamic instability
• deaths from cardiac causes
• cardiac mortality and urgent heart transplant
Secondary outcomes (evaluated at a mean of 12 months):
• “Tailored therapy management”
• QOL
• NYHA functional class
Also looked at:
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• cost utility of the 2 strategies
Not clear if analysis done on ITT basis
Notes Data source: published data only
Funding/CoI: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients referred to our HFU had
a prognostic evaluation, their therapy was
optimised, and they were then randomised
to one of two management strategies.”
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk After 12 months all participants were re-
evaluated in the HF Unit and the day hos-
pital is part of this unit
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias High risk Not all the 112 participants in the in-
tervention received all the components of
the intervention: 76% received education
and physical training; 47% received car-
diovascular risk stratification; 45%received
tailored therapy; 19% received multidisci-
plinary intervention.
There were 49 “open access interventions”
in the intervention group, which included
interventions that would have required ad-
mission in the control group
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Cavusoglu 2017
Methods Multicentre RCT (10 centres)
Recruiting: March 2010-April 2013
Duration of follow-up: 6 months
Intervention category: multidisciplinary
Person delivering intervention: multidisciplinary
Participants Country: Turkey
Participants: randomised N = 248 (125 intervention; 123 control)
Mean ± SD age intervention: 60.6 ± 14.3; control: 61.1 ± 13.2
Male sex (%): intervention 76%; control 70%
Ethnicity: NR
Actual severity of HF in study participants at recruitment
LVEF (%) mean (SD): intervention 27.4 ± 7.1; control: 26.2 ± 7.1
NYHA class III-IV (%): intervention 60%; control 61%
Diabetes: intervention35%; control 37%
Inclusion criteria:
• > 18 years
• discharged from hospital with a diagnosis of HF within 6 months of
randomisation
• current symptoms of HF despite optimal medical therapy consistent with recent
guidelines (ACEI or angiotensin receptor blocker, beta blocker, mineralocorticoid
receptor antagonist, and diuretics)
• NYHA functional class II-IV
• LVEF < 40% as measured by transthoracic echocardiography
Exclusion criteria:
• severe renal failure requiring dialysis
• serum creatinine > 2.5 mg/dL
• severe COPD
• chronic or intermittent inotropic support
• acute coronary syndromes defined by progressive angina or chest pain at rest or
new ECG changes and/or serial increase in cardiac troponin levels
• recent percutaneous coronary interventions (PCI), cardiogenic shock,
hypertrophic cardiomyopathy, acute myocarditis, severe primary valvular heart disease,
dysfunction of a prosthetic heart valve, pericardial disease
• pregnancy
• uncontrolled thyroid disease
• currently enrolled in another HF study
• life expectancy < 6 months
Interventions Intervention:
• a cardiologist and nurse provided education on HF management during discharge
and gave participants an education booklet and digital home scales
• a printed HF education booklet was prepared in to unify the education content
between centres
• 1 session of HF education was implemented by a cardiologist together with a
nurse at randomisation, in which the primary educator was the cardiologist
• participant education took almost 1 h (30 min by the cardiologist and 30 min by
the nurse), or more if needed
• phone calls from cardiologist or nurse at months 1, 3
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• phone call or hospital visit at 6 months to collect clinical data and go over HF
education material
• also assessed adoption of life style changes and adherence to medications, and
reminded participants about salt and fluid intake, weight monitoring, daily routine
activities, and exercise training
• correction of doses or regimen of medication were made by a cardiologist or a
nurse under the supervision of a cardiologist.
• participants were invited to come to the hospital if needed
Baseline education included:
• description, causes, symptoms, prognosis and treatment of HF
• lifestyle changes: salt intake, fluid and alcohol intake, the importance of weight
monitoring, managing weight gain, daily measurement of blood pressure, adherence to
medications, participation in daily routine activities, exercise training, recognition of
worsening HF symptoms, and when to contact the cardiologist.
Comparator: usual care
• participants were discharged from hospital without receiving any education or
follow-up instructions
• prescriptions were given along with the suggestion of a follow-up office visit
Outcomes • CV mortality (not specifically HF mortality)
• all-cause mortality
• all-cause readmissions
• HF readmissions
Notes Funding: “This study had been designed, supported and conducted by the Working
Group on Heart Failure of the Turkish Society of Cardiology.”
Published data only. Study author (Cavusoglu) confirmed by email 27 June 2018 that
data for HF-mortality are not available, only data for CV-mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
High risk Quote: “because of the design of this study,
both patients and investigators could not
be blinded to treatment groups”
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Study nurses collected data at phone fol-
low-up
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Not applicable - QoL NR
84Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cavusoglu 2017 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No informationon losses to follow-up, ITT
analysis conducted
Selective reporting (reporting bias) Unclear risk No protocol or clinical trials registry entry
found
Other bias Low risk Nothing identified
Chen 2018
Methods Single-centre RCT
Recruiting: December 2013-June 2015
Duration of follow-up: 6 months
Intervention category: multidisciplinary
Person delivering intervention: multidisciplinary
Participants Country: China
Participants: N = 62 randomised, intervention N = 31; control N = 31
Mean ± SD age: intervention 61.1 (14.2); control 62.4 (14.9)
Male sex N (%): intervention 22 (71.0); control 15 (48.4)
Ethnicity: NR
Actual severity of HF in study participants at recruitment:
LVEF (mean (SD)%): intervention 39.9 (13.4); control 47.1 (13.4)
NYHA class N (%):
• intervention: class II, N = 1 (3.2%); class III, N = 15 (48.4%); class IV, N = 15
(48.4%)
• control: class II, N = 1 (3.2%); class III, N = 16 (51.6%); class IV, N = 14 (45.2)
Diabetes: intervention 6 (19.4) ; control 8 (25.8)
Inclusion criteria:
• HF diagnosis with NYHA class II to IV
• > 18 years old
Exclusion criteria:
• cognitive impairment (people with scores < 24 on the MMSE questionnaire
• inconvenience of home visit
• inaccessible by telephone
• concurrent inclusion in another study
• diagnosis of COPD
• diagnosis of other diseases whose life expectancy is < 1 year
• diagnosis of other conditions that would restrict participant’s activity
Interventions Intervention: follow-upbyHF team (3 cardiologists, 1 coach nurse, 10nurses, 1 dietician,
1 psychiatrist)
• individualised discharge education with cardiologist (HF info, weight
monitoring, when to contact for help, self-care, medication adherence, dietary advice
• psychiatrist and dietician involved where necessary
• physical exercise training, individually tailored
• home visit by coach nurse 2 weeks after discharge to check changes in signs and
symptoms
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• phone contact every 2 weeks by cardiologist to monitor physical exercise, check
medication adherence, reinforce education
• intensified education by coach nurse at 90 and 180 days, tailored to participant’s
understanding of HF and self-care
• during outpatient clinic visits, the coach nurse delivered specialised education and
physical exercise training based on the participant’s QoL, physical performance, and
self-care behaviours
Comparator: usual care
• a telephone call within 2 weeks after discharge by a nurse
• 2 follow-up visits for adjustment of medications by a cardiologist at outpatient
clinic at 90 days and 180 days after discharge.
• contacts with the cardiologists and nurses on HF team were discouraged
Outcomes • HF readmission
• all-cause readmissions
• HRQoL (MLHFQ - Chinese version)
Outcomes only reported for combined endpoint (death or hospitalisation)
AT emailed study author 11 July 2018 for individual outcomes, no response
Notes Funding: Chia Family Health Fellowship granted by the Yale-China Association; Funda-
mental Research Funds for the Central Universities of Central South University granted
by the Central South University. No CoI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated randomisation list
was created by a statistician for patient ran-
domisation
Allocation concealment (selection bias) Low risk Randomisation list was generated by the
statistician not the study team
Blinding of participants and personnel
(performance bias)
High risk Blinding not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Nurses who recruited patients,
collected patients’ data, and administered
questionnaires were blind to the patient
randomization.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Participants themselves were aware of al-
location, so self-reported MLHFQ not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data appear to be reported for all partici-
pants, but mortality and readmissions only
reported as composite outcome
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Selective reporting (reporting bias) Unclear risk No protocol or trial registration found
Other bias Unclear risk The proportion of eligible patients was low
(of 264 people diagnosed with HF, 202
were excluded before randomisation (90
declined to participate, 56 did not meet
inclusion criteria, 51 lived too far away, 5
died). May limit generalisability
Clark 2015
Methods Single-centre RCT
Recruiting: NR
Duration of follow-up: 9 months
Intervention category: case management
Person delivering intervention: specialist nurse
Participants Country: USA
Participants: randomised N = 50; intervention N = 25; control N = 25
Mean ± SD age: intervention 61.7 (10.3); control 63.0 (11.7)
Male sex N (%): intervention 9/25 (36%); control 15/25 (60%)
Ethnicity: intervention 20/25 (80%) white; control 20/25 (80%) white
Actual severity of HF in study participants at recruitment:
NYHA class N (%):
• intervention: class I, N = 3 (12%); class II N = 10 (40%); class III, N = 12 (48%)
• control: class I, N = 4 (16%); class II, N = 11 (44%); class III, N = 10 (40%)
Diabetes: 48% of all participants
Inclusion criteria:
• diagnosed with NYHA class I-III 28 systolic or diastolic HF
• aged ≥ 45 years
• willing to participate in a randomised 9-month study
• living at home independently
• able to speak, read, and write in English
• a score of at least 23 on the MMSE
Exclusion criteria:
• major CVD (e.g. stroke
• NYHA class IV HF
Interventions Intervention: “this study was underpinned by the health promotion model and self-
efficacy theory, and the APRN’s support in building participants’ self-efficacy was a key
part of the intervention.”
• 100-page booklet containing 8 modules formed the main educational material:
HF information, signs and symptoms, diet, lifestyle, medications; when to seek help;
memory enhancement techniques; diet; exercise; stress; depression; self-management;
goal setting.
• participants also received a book on improving memory
First 3 months:
• education-support intervention delivered by APRNs with expertise in HF
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• meeting every 10-14 days for 1-1.5 h to present the educational content
Next 3 months:
• phone and/or email support by APRN but no visits (average contact was 5-15
min every 3-4 weeks
• Final 3 months without contact with the research team
• All participants received a USD 25 cash appreciation gift
Comparator:
“The control group received a loose-leaf notebook of selected pages containing infor-
mation on health promotion for adults/older adults information obtained from the Na-
tional Institute of Aging website; Centers for Disease Control and Prevention, American
Cancer Society, and the American Geriatric Society. Sample topics were: fall preven-
tion; crime and older adults; arthritis; and bladder control. No content about HF was
included. Meetings were scheduled during the first 3 months depending on the needs
and interest of the participant. No phone or email teaching was done. Instruments were
completed at the same 4 time periods (baseline, 3 months, 6 months, and 9 months) and
retention gifts were provided ($25 each testing period). Usual medical care was received.
All participants were offered the chance to receive the intervention at the end of the
study; the majority received it.”
Outcomes • KCCQ; total score data extract higher scores reflect better QoL. A 5-point change
in total score is a clinically important difference.
Notes Funding: NIH/NINR
Study author checked all participants’ data and confirmed that the majority had been
admitted to hospital for HF at least once
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomized’ with no further details.
2 participants who dropped out were re-
placed, NR whether allocation of these was
randomised or not
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Nurse delivered intervention and collected
outcomes
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL was self-reported by participants who
knew group allocation
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Two participants lost to follow-up
were replaced (one moved out of state; the
other moved and could not be located) and
their data were eliminated from the analy-
sis” - not clear which group they were from,
or whether the replacement participants’
data were included in the analysis
Selective reporting (reporting bias) Unclear risk No protocol or trial registration identified
Other bias Low risk Nothing noted
Cline 1998
Methods Single-centre RCT
Recruitment: December 1991-October 1993
Duration of follow-up: 12 months
Intervention category: clinic
Person delivering the intervention: specialist nurse
Participants Country: Sweden
Participants: 190 participants; intervention: 80 (44 men, 55%); control 110 (57 men,
52%)
Actual age of study participants: mean 75.6 years (SD 5.3)
Male sex: 53%
Ethnicity: NR
Actual severity of HF in study participants at baseline:
NYHA class, mean:
• intervention 2.6 (SD 0.7)
• control 2.6 (SD 0.7)
LVEF: 75% LVEF < 40%
• intervention mean 31.6% (SD 8.4)
• control mean 35.7% (SD 12.3)
Inclusion criteria:
• patients hospitalised primarily because of HF
• HF diagnosed on symptoms and signs with “at least one objective sign present on
admission such as pulmonary rales, peripheral oedema, congestion on chest
radiograph, or a third heart sound”
• aged 65-84 years
Exclusion criteria:
• the presence of other serious disease that either prevented participation or was
expected to significantly influence QoL, morbidity or mortality in the following year
• foreseeable follow-up problems, including residence outside the hospital
catchment area
• serious alcohol or drug abuse
• psychiatric disease
• inability to understand or answer study questionnaire
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• participation in another clinical trial
• discretion of treating physician
Interventions Duration of intervention: 12 months
Intervention: “Management programme for heart failure”
During index hospitalisation:
• Patients received an education programme from HF nurse consisting of two 30
minute visits.
After discharge:
• 2 weeks after discharge participants and their families were invited to a 1-h group
education session led by the HF nurse. which included an oral presentation by the
nurse, and educational video and a question and answer session
• participants were also offered a 7-day medication dispenser if deemed appropriate
• participants were followed up at a nurse directed outpatient clinic and there was a
single prescheduled visit by the nurse at 8 months after discharge
• HF nurse was available for phone contact during office hours
• participants encouraged to contact the study nurse at their discretion, if unsure, if
diuretic adjustments did not ameliorate symptoms in 2-3 days, or if there were
“profound changes in self management variables”
• participants were offered cardiology outpatient visits 1 and 4 months after
discharge
The inpatient and outpatient education programme covered:
• HF pathophysiology, pharmacological and non-pharmacological treatment
• participants were also given guidelines for self-management of diuretics in the
event of fluid overload or fluid depletion
• participants were given a “heart failure diary” containing information on HF, list
of HF medications, names and contact phone numbers for the HF clinic and in which
to regularly record bodyweight, ankle circumference and HF symptoms
Comparator: usual care
• participants “followed up at the outpatient clinic in the department of cardiology
by either cardiologists in private practice or by primary care physicians as considered
appropriate by the discharging consultant.”
Outcomes Primary endpoint: unclear, abstract states that main outcome measures were:
• time to readmission
• days in hospital
• healthcare costs during 1 year
Other endpoints:
• QoL (at 1 year) using The Quality of Life in Heart Failure Questionnaire,
Nottingham Health Profile and patients’ global self assessment (all self-administered)
Also looked at:
• Deaths at 90 days - not included in this review as < 6 months
• Event-free (i.e. death or readmission) survival at 90 days - not included in this
review as < 6 months
Notes Data source: published data only
Funding: “The study was supported by grants from the Swedish Heart and Lung Foun-
dation, the research foundation administered by Malmö University Hospital, and the
Council for Health Care Research, Lund University.”
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated random allo-
cation”
Allocation concealment (selection bias) Low risk Quote: “Patients were invited to partici-
pate and informed consent was given on
the basis of information relevant to the allo-
cated study group. This procedure avoided
bias arising from control patients being in-
formed of the intervention strategy.”
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk No objective outcomes at 6 months
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-assessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants were accounted for and
deaths were verified by hospital records or
death certificates, but QoL is the only in-
cluded outcome here, and it is not clear
howmany people completed this at follow-
up
Selective reporting (reporting bias) Unclear risk No protocol identified
Other bias Unclear risk Slightly lower LVEF in intervention group
at baseline: mean (SD) LVEF (%) interven-
tion: 31.6 (8.4) < 0.05; control: 35.7 (12.
3)
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Methods Multicentre RCT (2 centres)
Recruiting: August 2009-April 2012
Duration of follow-up: 6 months
Intervention category: case management
Person delivering intervention: nurse
Participants Country: Brazil
Participants: randomised N = 252; intervention N = 123; control N = 129
Mean ± SD age: intervention 62 ± 14; control: 63 ± 12
Male sex N (%): intervention 75 (61.0%); control 83 (64.3%)
Ethnicity: intervention 83 (67.5% white); control 81 (62.8% white)
Actual severity of HF in study participants at recruitment:
EF mean SD %: intervention 29.2 ± 8.2; control 30.1 ± 9.5
NYHA class N (%)
• intervention: class I, N = 6 (4.8%); class II, N = 48 (39.0%); class III, N = 52 (42.
2%); class IV, N = 14 (11.3%)
• control: class I, N = 10 (7.7%); class II, N = 47 (36.4%); class III, N = 64 (49.
6%); class IV, N = 11 (8.5%)
Inclusion criteria:
• Adult patients (≥ 18 years old)
• LV systolic dysfunction (LVEF ≤ 45%)
• admitted because of acute decompensated HF
• diagnosis of acute HF was confirmed by the attending physician, and all enrolled
participants had to be on i/v diuretic therapy and to present the expected HF signs and
symptoms.
Exclusion criteria:
• an acute HF episode secondary to sepsis, myocarditis or MI
• major communication barriers
• residence > 20 km from the hospital
• lack of the possibility of telephone contact
Interventions Intervention:
• 4 home visits, about 1 h each, 1st within 10 days of discharge, approx. days 30, 60
and 120 days after discharge
• included physical examination, knowledge/self-care assessment and adherence to
recommendations, medications, weight control, hydro-saline restriction, physical
activity, vaccination, weight monitoring, signs and symptoms to watch for and
therapeutic strategies.
• consultant would adjust drugs where necessary
• 4 reinforcement phone calls, about 10 min each both led by trained nurses, to
reinforce the info given at the home visit, check use of medications, and clarify any
issues
• Outpatient clinic visit at 180 days follow-up to finalise assessment
Comparator: usual care
• medical outpatient visits in which they received instructions regarding
pharmacological and non-pharmacological therapeutic strategies.
• no specific management plan was applied and each hospital decided the approach
for each participant.
• Typically, participants were followed-up by a GP after hospital discharge.
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• No home visits or telephone contact
Outcomes • All-cause mortality
• HF readmissions
• All-cause readmissions
• Cost-effectiveness
Notes Funding: Fundo de Incentivo à Pesquisa e Eventos doHospital deClínicas de PortoAlegre
(FIPE); Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS);
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). No CoI
Study author confirmed that this study (HELENII) has the outcomes from the previously
identified ongoing HELEN I study (a related paper by Mussi 2013 was previously
excluded as no relevant outcomes reported)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple sequence randomisation was used,
generated electronically on the website
www.randomization.com
Allocation concealment (selection bias) Low risk Quote: “A healthcare professional who was
not a member of the research group was
responsible for the patient allocation list.
The intervention nurses were blinded to
the patients’ allocation group until all in-
struments had been completed
in the baseline period.”
Blinding of participants and personnel
(performance bias)
High risk Not possible to blind
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk A nurse who was blinded to group allo-
cation was responsible for the final evalu-
ations and for assessment of clinical out-
comes
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Not applicable: QoL NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study flow chart indicates all randomised
participants included in follow-up (per-
haps just for Kaplan Meir survival analysis?
) Outcome table indicates 117/123 inter-
vention participants and 126/129 control
participants included in clinical outcomes
at 6 months
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Selective reporting (reporting bias) High risk Trial registered after it had started. NCT
trial register states original primary out-
come (2010) was to be absolute number
readmissions and visits to ED for decom-
pensation of HF. Changed in 2014 to a
composite endpoint of a first visit to ED,
or a first hospital readmission, or all-cause
death
Other bias Low risk Nothing identified
DeBusk 2004
Methods Multicentre RCT (5 centres)
Recruitment: May 1998-October 2000
Duration of follow-up: 12 months
Intervention category: case management
Person delivering the intervention: nurse
Participants Country: USA
Number randomised: 462 (intervention N = 228, control N = 234)
NYHA class, N (%)
• intervention group: class I-II, N = 103 (50%); class III-IV, N = 103 (50%)
• control group: class I-II, N = 112 (50%); class III-IV, N = 113 (50%)
Median EF%: NR
Mean age: all: 72 years (SD 11);
• intervention: < 60 years: 35 (15%); 60-70 years: 52 (22%); 70-80 years: 92
(40%); > 80 years: 49 (21%)
• control: < 60 years: 32 (14%); 60-70 years: 55 (24%); 70-80 years: 86 (37%); >
80 years: 49 61 (26%)
Ethnicity, N (%):
• intervention: white 195 (86); black 13 (5); American Indian 9 (4); Hispanic 7 (3);
Asian 4 (2)
• control: white 191 (82); black 14 (6); American Indian 18 (8); Hispanic 7 (3);
Asian 4 (2)
Inclusion criteria:
• hospitalised with a provisional diagnosis of HF in study hospitals as indicated by
new onset or worsening HF on the basis of shortness of breath (dyspnoea at rest,
orthopnoea or paroxysmal nocturnal dyspnoea)
Exclusion criteria:
• scheduled for coronary artery bypass surgery or valvular surgery
• undergone cardiac surgery in preceding 8 weeks
• serum creatinine value ≥ 5 mg/dL
• receiving dialysis
• awaiting renal Tx
• history severe pulmonary disease on home O2
• ≥ 1 additional diagnoses expected to result in death within the year
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• cognitive mental deficits
• substance abuse
• severe psychiatric disorders
• expected to move from area within 1 year
Interventions Duration of intervention: 12 months
Intervention: “specialist nurse intervention”
• I-h educational session with a nurse in the participant’s medical centre
• participant received printed educational materials including methods for self-
monitoring symptoms, body weight and medications; a dietary management
workbook; food frequency questionnaires
• participants viewed a video portraying the treatment process
• participants received instructions on how to access emergency care in case
symptoms abruptly worsened
• 45-min baseline telephone counselling session within 1 week of randomisation by
experienced nurse care manager
• subsequent nurse contacts tailored to meet needs of the participant
• nurse initiated follow-up phone calls to participant weekly for 6 weeks, biweekly
for 8 weeks, monthly for 3 months, bimonthly for 6 months
• nurse care managers obtained permission from physicians to initiate and regulate
pharmacologic therapy for HF according to study protocol
• nurses communicated with physicians about participant’s medical status
• nurses co-ordinated treatment plan with participants and physicians
Comparator: usual care (no details given)
Outcomes Outcomes (1 year)
Primary outcome:
• time to first hospitalisation HF and all-cause
Secondary outcomes:
• time to composite outcome of death,
• readmission or ED visit for cardiac cause or for any cause
• rate of outpatient and ED visits
Notes Data source: published data only
Funding: “The National Heart, Lung and Blood Insitute reviewed and financially sup-
ported the project but did not participate in the design, conduct, or reporting of the
study or in the decision to submit the manuscript for publication.”
“Potential financial conflict of interest: none disclosed.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Research staff whowere not associatedwith
delivering the intervention randomly as-
signed participants to treatment conditions
by using sealed assignments. Equal num-
bers of participants were allocated to the
2 groups in each medical centre using the
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Efron procedure
Allocation concealment (selection bias) Low risk Research staff whowere not associatedwith
delivering the intervention randomly as-
signed participants to treatment conditions
by using sealed assignments
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Research staff who were not asso-
ciated with, and were blinded to, the in-
tervention conditionsmeasuredhealth out-
comes at 12months. Two cardiologistswho
were not associated with implementing the
intervention reviewed medical records on
deaths, rehospitalizations, and emergency
department visits to determine whether
these events were primarily due to heart
failure or due to other causes. They did
not use discharge diagnoses recorded in the
medical record to make these judgments.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk No subjective outcomes reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Slightly unbalanced drop out rate (15/234
6% in usual care, 8/228 3.5% in interven-
tion group) but ITT analysis used
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing noted
Del Sindaco 2007
Methods Open RCT
Recruitment: January 2001-December 2002
Duration of follow-up: 24 months
Intervention category: multidisciplinary
Person delivering the intervention: multidisciplinary
Participants Country: Italy
Number randomised: 184 (control N = 87, intervention N = 86)
NYHA:
• intervention: class I, N = 0 (0%); class II, N = 32 (37.2%); class III, N = 44 (51.
2%); class IV, N = 10 (11.6%)
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• control: class I, N = 0 (0%); class II, N = 34 (39.1%); class III, N = 49 (56.3%);
class IV, N = 4 (4.6%)
LVEF: intervention: 33.5 (SD 11); control: 32.5 (SD 10)
Age: intervention: 77.4 (SD 5.9); control: 77.5 (SD 5.7)
Percentage male: intervention: 51.2; control: 52.8
Ethnicity: NR
Inclusion criteria:
• ≥ 70 years
• discharged home after hospitalisation due to HF
• NYHA III-IV for ≥ 24 h requiring i/v therapy on admission
• diagnosis determined according to ECS guidelines
Exclusion criteria:
• valvular heart disease requiring planned surgical correction
• active substance abuse
• severe gait impairment
• confined to bed
• severe dementia
• psychiatric disease likely to limit compliance
• co-existent non-cardiac disease likely to reduce life expectancy
• need for long-term i/v inotropic therapy
• unwillingness to provide informed consent
• living in a nursing home
• Living outside the area served by the clinical sites
Interventions Duration of intervention: 24 months
Intervention: DMP combining hospital clinic-based and home-based care
• teams included a cardiologist experienced in geriatrics, 2-4 specialised nurses and
the participant’s primary care physician
• components of the programme were; discharge planning, continuing education,
therapy optimisation, improved communication with healthcare providers, early
attention to signs and symptoms and flexible diuretic regimes
• participants given a written list of recommendations, a weight chart, a contact
number available 6 h/day, and an education booklet
• follow-up via hospital clinic visits, periodical nurse’s phone calls
• participants attended HF clinics within 7-14 days of discharge and at 1, 3 and 6
months thereafter for optimisation of treatment and education
• primary care physicians assessed adherence to treatment, evaluated adverse effects
and co-morbidities, and monitored diet
Control: usual care
• optimised treatment and standard education
• all treatments and services ordered by primary care physician and/or cardiologist
• baseline clinical evaluation and therapeutic plan documented
Outcomes Primary:
• composite of all-cause death and hospital admissions from HF at 24 months
Secondary (24 months):
• all-cause and HF hospitalisations
• cumulative number of hospitalisations
• all cause and HF related mortality
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• QoL
• perceived health status
• functional status and indexes of quality of care (such as % of participants taking
beta-blockers) - not recorded here
Notes Data source: published data only
Funding/CoI: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given, just states “randomised”
Allocation concealment (selection bias) High risk Eligible patients were randomised and in-
formed consent was given on the basis of
information relevant to the allocated study
group
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Outcomes were evaluated in a
blindedmanner by a central endpoint com-
mittee composed of three cardiologists,
who had no knowledge of the treatment as-
signment.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in ta-
ble of outcomes at 2 years
Quote: “A relatively high rate of patients
abandoned the hospital component of the
programme and continued care with their
primary care physicians and/or personal
cardiologists. The participation of these pa-
tients until the end of the follow-up would
have further improved the effects of in-
tervention because, on intention-to-treat
analysis, this high drop-out rate was not as-
sociated with a significant decline in the ef-
ficacy of the model.”
Selective reporting (reporting bias) Unclear risk No protocol found
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Other bias Low risk Nothing identified
Doughty 2002
Methods Single-centre, cluster-RCT, GP as the unit of randomisation (but see note)
Recruitment: during 1997 and 1998
Duration of follow-up: 12 months
Intervention category: clinic
Person delivering the intervention: multidisciplinary
Participants Country: New Zealand
Participants: 97 participants; intervention 100 (64 men, 64%); control (54 men, 56%)
Actual age of study participants: mean 73 years (SD 10.8, range 34-92 years)
Male sex: 60%
Ethnicity: ’NZ European’ 79%
Severity of HF in study participants at index admission: NYHA class, N (%)
• intervention: class II, N = 24 (24%), class III, N = 76 (76%)
• control: class II, N = 24 (25%), class III, N = 73 (75%)
Severity of HF in study participants at baseline: LVEF
• intervention group 30.6% (SD 12.7)
• control group mean 33.8% (SD 12.7)
Inclusion criteria:
• Patients admitted to general medical wards with a primary diagnosis of HF
Exclusion criteria:
• surgically remediable cause for HF
• consideration for heart transplantation
• terminal cancer
• participation in another trial
• inability to provide informed consent
Interventions Duration of intervention: 12 months
Intervention: integrated heart failure management programme
After discharge:
• outpatient review at HF clinic within 2/52 of discharge from hospital: clinical
status reviewed, pharmacological treatment based on evidence based guidelines, 1-to-1
education with study nurse, education booklet provided
• participant diary for daily weights, Rx record and clinical notes provided
• detailed letter faxed to GP and follow-up phone call to GP
• GPs encouraged to discuss management with clinic team
• Follow-up plan aiming at 6 weekly visits alternating between GP and HF clinic
• Group education sessions for participants run by cardiologist and study nurse: 2
sessions offered within 6 weeks of discharge and 1 at 6 months post-discharge
• telephone access to study team for GPs or participants during office hours
Group education sessions covered:
• education about disease
• monitoring daily body weight and action plans for weight changes
• medication
• exercise
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• diet
Comparison: usual care
Outcomes Primary endpoints (12 months):
• time to first event i.e. death or hospital readmission
• HRQL measured using MLHFQ at baseline and 12 months
Other endpoints (12 months):
• all-cause hospital readmissions
• HF hospital readmissions
• all-cause hospital bed-days
Also looked at:
• medications at 12 months
Notes Data source: published data only
Funding: “The study was funded by a project grant from the National Heart of New
Zealand and an unrestricted educational grant from Merck Sharp Dohme (NZ) Ltd.
RND was the recipient of the New Zealand Heart Foundation BNZ Senior Fellowship.
”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “General practitioners were ran-
domly allocated using computer generated
random numbers…after consent was ob-
tained the patient was informed of their
group allocation based on the randomisa-
tion of their current general practitioner.”
Allocation concealment (selection bias) Unclear risk NR. GPs were randomised before partic-
ipant recruitment - possibility that team
were aware of assignment of GP before re-
cruitment of patient into study
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one participant lost to follow-up
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Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Unclear risk This was a cluster-RCT, but outcomes were
reported for individual participants. Paper
states that,
Quote: “Data were analysed using two ap-
proaches. Firstly the unit of randomization
was assumed to be the individual, as if sim-
ple randomization had been performed. ..
. In other analyses the unit of randomiza-
tion was the GP, consistent with the ac-
tual method of cluster randomization. ...
Since the median number of participants
per general practitioner was small (1·5 in
each arm) the influence of clustering was
small and only results from the first ap-
proach are presented. In no case did sta-
tistical significance differ depending upon
the approach adopted.”
Ducharme 2005
Methods Single-centre RCT
Recruitment: January 1998- January 2000
Duration of follow-up: 6 months
Intervention category: multidisciplinary
Person delivering the intervention: multidisciplinary
Participants Country: Canada
Participants: intervention N = 115/control N = 115
Mean (SD) age: 68 (10)/10 (10)
% male: 83 (73)/82 (71)
Ethnicity: NR
EF% (SD): 34 (14)/35 (15)
NYHA class, N (%)
intervention: class II, N = 8 (7%); class III, N = 68 (59%); class IV, N = 39 (34%)
control: class II, N = 14 (12%); class III, N = 63 (55%); class IV, N = 38 (33%)
Inclusion criteria
• seen at the ED of or admitted to the Montreal Heart Institute with a primary
diagnosis of congestive HF
• radiologic confirmation of congestive HF or known impaired LVEF (< 45%)
Exclusion criteria:
• a primary diagnosis of acute MI
• discharge to a chronic care facility, scheduled cardiac surgery
• unwillingness to sign informed consent or to attend the outpatient clinic
• participation in another research trial
• residence in an outlying area
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Interventions Duration of intervention: 6 months
Intervention: multi-disciplinary HF clinic with phone follow-up from nurses
• evaluation at clinic within 2 weeks of hospital discharge
• HF clinic provided rapid access to cardiologists, clinician nurses, dieticians and
pharmacists, with access to social workers and other medical specialists as required
• clinic allowed observation for up to 5 h and i/v diuretics if required
• follow-up phone call from nurse within 72 h of hospital discharge and then
monthly, unless a problem necessitated more frequent contact
• After baseline evaluation, clinic cardiologists individualised treatment plan
(including pharmacologic treatment) for participants
• 1-on-1 education of the participant and family with the study nurse initiated at
1st clinic visit. Individualised advice on the disease process, symptoms and signs of HF
(changes in symptoms indicative of worsening HF), fluid and sodium intake
restrictions, the importance of daily monitoring of body weight and action plans to
remedy changes in weight, effects of medications and the importance of compliance,
and recommendations regarding exercise and diet
• participant diary for daily weight measurement,medication record, clinical notes
and appointments, physical activity recommendations, an education booklet and a
telephone number for clinic during business hours
• individualised dietary assessments by registered dietician at baseline, instructions
reinforced by nurse at subsequent visits
• pharmacist evaluated medications for each participant and assessed participant’s
knowledge
• individualised follow-up plan included monthly visits with both a cardiologist
and nurse at the clinic
• study team available for ad hoc consultation during normal working hours.
Participants advised to call clinic nurse if symptoms worsened. During calls nurse
evaluated signs of clinical deterioration and adverse effects and participants were
referred to clinic cardiologist as required
Comparator: usual care
Outcomes Primary endpoints:
• all-cause hospital readmissions
• total number of associated hospital days at 6 months
Secondary outcomes (at 6 months):
• number of ED visits
• QoL
• mortality
Notes Data source: published data only
Funding: “competing interests: none declared” but “James Brophy and Michel White
receive support from les Fonds de la recherche en santé du Québec”. “unrestricted edu-
cational grants from Merck Frosst and GlaxoSmithKline”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “Eligible patients who agreed to
participate were randomly assigned to the
control group or intervention group using
consecutively numbered opaque envelopes
that contained a random number generat-
ing group assignment.”
Allocation concealment (selection bias) Low risk Consecutively numbered opaque envelopes
used
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “It is also possible that incomplete
blinding of the data extractors may have
introduced another bias. To minimize the
potential impact of such a bias, we selected
outcomes (repeat hospital admission and
duration of hospital stay) that are not typi-
cally affected by subjective interpretations.
The unblinding of the study physicians is
also unlikely to have influencedhospital ad-
mission patterns since the physicians rep-
resent fewer than 10% of the cardiologists
with admission privileges at the institution.
”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported by participants who
knew allocation (although questionnaire
administered by blinded personnel)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses were ITT
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Dunbar 2014
Methods Multicentre RCT (4 centres)
Recruiting: 2010-2013
Duration of follow-up: 6 months
Intervention category: case management
Person delivering intervention: research nurse
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Participants Country: USA
Participants: N = 134 randomised (intervention N = 70; control N = 64)
Age mean ± SD, range: intervention 57.7 (10.5), 31-81; control 57.0 (10.8), 29-76
Male sex N (%): intervention 47 (67.1%); control 41 (64.1%)
Ethnicity N (%): intervention African American, 52 (74.3%); control African American,
41 64.1%)
Actual severity of HF in study participants at recruitment:
• LVEF (mean (SD) %): intervention 32.3 (16.6); control 35.7 (18.6)
NYHA class:
• intervention: class I, N = 1 (1.4%); class II, N = 28 (40.0%); class III, N = 36 (51.
4%); class IV, N = 5 (7.1%)
• control: class I, N = 0 (0.0%); class II, N = 28 (43.8%); class III, N = 31 (48.4%);
class IV, N = 5 (7.8%)
Diabetes: all participants had both diabetes and HF, as this was a specific inclusion
criterion
Inclusion criteria:
• current or recent hospitalisation for HF within the past 3 months
• age 21-80 years
• NYHA functional class II-IV symptoms
• type II DM
• planned discharge to home and not to an assisted living or skilled nursing facility
• English language fluency
• baseline guideline-derived medical therapy unless there was documented
contraindication, ambulatory and eligible for a walking physical activity programme,
• eligible for a low-sodium and low-carbohydrate diet
Exclusion criteria:
• newly diagnosed or 1st HF admission
• positive screenings for depressive symptoms and cognitive difficulty, which would
interfere with ability to participate in the intervention or perform adequate self-care
• uncorrected hearing or vision problem
• undergoing cardiac transplantation or mechanical circulatory assist device
implantation or evaluation at the time of enrolment
• renal failure requiring renal replacement treatment
• lack of telephone access
• severe COPD and earlier stroke if they impeded ability to ambulate
Interventions Intervention:
• individualised educational and counselling session by trained research nurse
including: overview of HF and DM, self-care diet, medications, symptom monitoring;
weight monitoring; physical activity
• HF-DM tool kit provided for home use
• home visit by research nurse 48-72 h later to review self-monitoring, reinforce
information and assess diet and medication congruent with discharge instructions
• scripted phone call at 7-10 days to review self-monitoring and check diet and
medication, physical activity mentioned
• 2 weeks - clinic visit that incorporated physical activity counselling
• scripted phone calls at 1, 2 and 4 months to review and promote self-monitoring,
diet, physical activity and medication-taking
Comparator: usual car
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• after randomisation given publicly available informational brochures. Standard
hospital discharge teaching from staff in the enrolling institutions and follow-up clinic
appointments
• control group participants received “attention control” telephone calls on the same
schedule as the intervention participants with information about the trial, number of
participants enrolled to date, and a reminder of their next set of study activities.
Outcomes • All-cause mortality
• All-cause readmissions
• HRQoL (MLHFQ)
• Cost-effectiveness
Notes Funding: NIH, NINR; National Center for Advancing Translational Sciences of the
National Institutes of Health; Atlanta Veterans Administration Medical Center. No CoI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A table of random numbers was
used to create group assignments that were
placed in sealed envelopes until baseline
data were collected.”
Allocation concealment (selection bias) Unclear risk Sealed envelopes used, but doesn’t spec-
ify that these are opaque and sequentially
numbered
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-assessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear: imbalance in loss to follow-up,
bias could affect completion of QoL as-
sessments. Paper indicates that mutlilevel
mixed models were run to adjust for attri-
tion over time
Selective reporting (reporting bias) Low risk Outcomes listed on trial registration site
(after study initiation but before study
completion) include MLHFQ
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Other bias Low risk Nothing identified
Gonzalez-Guerrero 2014
Methods Single-centre RCT
Recruiting: March 2007-November 2009
Duration of follow-up: 12 months
Intervention category: multidisciplinary team in geriatric day care hospital (categorised
as multidisciplinary for this review)
Person delivering intervention: multidisciplinary
Participants Country: Spain
Participants: randomised N = 120 (intervention N = 60; control N = 60; 1 interven-
tion and 2 control discontinued post-randomisation but before intervention so have no
baseline assessment)
Mean ± SD age: intervention 85 (6.4); control 85 (6.3)
Male sex N (%): intervention 17/59 (28.8%); control 15/58 (25.8%)
Ethnicity: NR
Actual severity of HF in study participants at recruitment: previous NYHA class, mean
(SD):
• intervention 2.5 (0.7)
• control 2.3 (0.8)
Diabetes N (%): intervention 26 (44.1); control 19 (32.8)
Inclusion criteria:
• Consecutive patients diagnosed with acute HF and discharged from the Geriatric
Service of the Cáceres Hospital Complex (Spain)
• diagnosis according to ESC criteria
• hospital stay of > 1 days
Additional information from trial registry:
• participants aged > 65;
• discharged home or to a nursing home without medical staff
• hospitalisation due to HF of≥ 48 h (determined according to the ESC guidelines)
Exclusion criteria:
• terminal disease (expected survival < 6 months)
• bedridden
• severe dementia or other serious psychiatric disease
• impossible to follow-up
• in retirement homes with own medical service
Interventions Intervention:
• DMP multidisciplinary team (geriatrician (case manager), nurse, social worker)
evaluated participants and their caregivers prior to the hospital discharge.
• participants were given an information manual about the disease, diet, weight
control, exercise, lifestyle, and medication, as well as how to recognize cardiac
decompensation symptoms.
• phone call from nurse 48 h after hospital discharge, to record any problems
• After 10 days, the team examined the participants in the geriatric day-care
hospital, using educational reinforcements and evaluating for possible cardiac
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decompensation
• Follow-up at the geriatric day-care hospital 1 and 6 months after discharge. Team
assessed treatment compliance, reinforced health education, and assessed participants’
ability to fulfil recommendations; prescriptions and doses were adjusted according to
clinical guidelines. Re-evaluation of global therapeutic regime and comorbidities
considering possible changes in functional, cognitive, affective, and social capacities.
• phone call from geriatrician during month 3. Geriatrician was also available by
phone during 09:00-14:00, and all participants could receive attention in the hospital
or via phone for unscheduled evaluation of clinical decline due to a medical problem
• all follow-up involved health-educational reinforcement and evaluation of
possible cardiac decompensation
Comparator:
• before the hospital discharge, each participant and the caregiver received an
information manual explaining the HF education.
• following hospital discharge, treatment and follow-up were provided by the
primary care physician
• visits were scheduled, and treatment was prescribed depending on the case
• outpatient appointments at the Geriatric Service or other medical facilities were
provided by non-members of the research study
Outcomes • HF-mortality
• All-cause mortality
• HF readmissions
• All-cause readmissions
• HRQoL (MLHFQ)
• Cost-effectiveness
Notes Funding: Research Group Grant, co-financed by Regional Government of Extremadura
(Spain) and European Union (FEDER). “The funder did not influence the design,
methods, subject recruitment, data collections, analysis, or preparation of paper.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were separated ran-
domly using a computer-generated list.”
Allocation concealment (selection bias) Unclear risk Quote: “Upon hospital discharge, the pa-
tients and the researchers ignored the group
assigned to each patient.”
Blinding of participants and personnel
(performance bias)
High risk Blinding not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “The results were obtained from
the patients and their relatives, the hospital
records, and theNational Death Index.The
result variables were adjudicated by a re-
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searcher of theDepartment of PatientMan-
agement, who was unaware of the group to
which the patients belonged.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL participant-reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses includes all randomised partici-
pants who received the intervention (ex-
cluding 1 intervention and 2 control par-
ticipants who moved out of the area before
receiving intervention).
ForMLHFQ, themissing values from cen-
sored cases were included. 3 participants
were censored during the follow-up as they
were hospitalised and referred to other
medical services (2 from the intervention
group and one from the control group)
Selective reporting (reporting bias) High risk Study registered retrospec-
tively (ISRCTN10823032)with a different
title, emphasising cost-effectiveness analy-
sis as a co-primary outcome with event-free
survival. No cost-effectiveness results pub-
lished on trials registry or in literature to
date
Other bias Low risk Nothing identified
Holland 2007
Methods Multicentre RCT (3 centres)
Recruitment: December 2003-March 2005
Duration of follow-up: 6 months
Intervention category: case management
Person delivering the intervention: community pharmacist
Participants Country: UK
Number randomised: 339
169 allocated to intervention, 170 to control
20 intervention and26 control participants excludedpost-randomisation. Study involved
149 intervention participants and 144 control group participants
NYHA:
• intervention: class I, N = 6 (4.0%); class II, N = 43 (28.9%); class III, N = 52 (34.
9%); class IV, N = 48 (32.2%)
• control: class I, N = 11 (7.6%); Class II, N = 37 (25.7%); class III, N = 47 (32.
6%); class IV, N = 49 (34.0%)
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LVEF: NR
Age: intervention: 76.4 (9.5); control: 77.6 (9.0)
Percentage male: intervention: 63.2; control: 63.8
Ethnicity: NR
Inclusion criteria:
• adults (aged ≥ 18 years), admitted as an emergency in which HF was an
important ongoing clinical condition, i.e. all participants had been hospitalised for HF
• prescribed ≥ 2 drugs (from any drug class) on discharge
Exclusion criteria:
• living in a residential or nursing home
• awaiting surgery for ischaemic or valvular heart disease
• awaiting heart transplantation
• terminal malignancy
Interventions Duration of intervention: 6-8 weeks
Intervention: community pharmacist home visits within 2 weeks of discharge, where
• pharmacist provided education to participant and carer on HF, drugs, exercise,
diet and smoking cessation, in line with British Heart Foundation’s ’Living with Heart
Failure’ booklet *which was left with participants
• participants encouraged to complete simple sign and symptom monitoring diary
card (including weight)
• pharmacist fed back recommendations to GP and any need for drug adherence
aid to local pharmacist
• An additional follow-up visit was made 6-8 weeks after discharge to review
progress and reinforce original advice
Control group: usual care
Outcomes Primary:
• total emergency admissions to hospital in 6 months
Secondary:
• deaths at 6 months
• QoL (EQ-5D) and MLWHF at 6 months
Notes Data source: published data only
Funding: “Research costs were funded by a project grant from the British Heart Foun-
dation. Excess treatment costs were funded by Great Yarmouth and Southern Norfolk
Primary Care Trusts. This trial received support for the educational training events from
Pfizer UK.”
CoI: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Weused third party telephone ran-
domisation based on a computer generated
random allocation sequence.”
Allocation concealment (selection bias) Unclear risk No information in paper
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Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Emergency admission data came
from Hospital Episode Statistics. The Of-
fice for National Statistics provided mor-
tality data”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “We analysed patient data accord-
ing to randomisation group, irrespective of
whether or not they received the interven-
tion as planned (the intention to treat prin-
ciple).” but flow chart indicates only 148/
169 (87.6%) intervention group and 143/
170 (84%) control group analysed
Selective reporting (reporting bias) Unclear risk Trial retrospectively registered:
ISRCTN59427925
Other bias Low risk Nothing identified
Jaarsma 2000
Methods RCT
Recruitment: May 1994-March 1997
Duration of follow-up: 9 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: the Netherlands
Participants (patients enrolled and surviving to discharge): 84participants in intervention
group* 95 participants in comparison group
Actual age of study participants: NR for original group, those who remained at 9months
were mean age 72 years (SD 9) at baseline
Male sex: of those who remained at 9 months, 60%
Ethnicity: NR
Actual severity of HF in study participants at recruitment: NR
Inclusion criteria:
• participants admitted to the cardiology unit of 1 hospital with HF symptoms and
diagnosis verified with Boston score
• NYHA III or IV
• HF diagnosis for > 3 months
• Aged ≥ 50 years
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• Dutch literate
Study exclusion criteria:
• coexisting, severe, chronic debilitating disease
• discharge to a nursing home
• psychiatric diagnosis
• CABG, angioplasty or valve replacement in past 6 months or expected to have
such treatment in next 3 months
Interventions Duration of intervention: up to 10 days after discharge from index admission, on average
one week*
Intervention: “Supportive educational intervention”
During index admission:
• intensive education by study nurse using standard nursing care plan
After discharge:
• study nurse phoned participant within 1 week of discharge to assess potential
problems and made appointment for home visit
• Home visit on average 1 week after discharge*. At home visit education continued.
• If required, study nurse wrote to participant’s home care nurse about participant’s
specific needs
• Between discharge and home visit participant could contact study nurse if they
encountered problems
• After home visit participant encouraged to contact their cardiologist, GP or
emergency heart centre with any problems
Educational component covered:
• symptoms of worsening failure
• sodium restriction
• fluid balance
• compliance and individuals’ problems,
• included education and support to participant’s family
Comparison: usual care
• “A nurse or physician, depending on his or her individual insight into the patients’
questions, provided these patients with education about medication and lifestyle”
• Usual care participants did not receive structured education
Outcomes Primary endpoints: NR
Measures of QOL:
• Heart Failure Functional Status Inventory (to assess functional capabilities at
baseline, 3 and 9 months)
• symptom occurrence (at baseline, 1, 3 and 9 months), severity and distress
questionnaire, designed for this study (at 3 and 9 months)
• Psychosocial Adjustment to Illness Scale (at baseline, 3 and 9 months)
• Cantril’s Ladder of Life (to measure overall well-being at baseline, 1, 3 and 9
months)
Measures of self-agency and self-care behaviour:
• participants’ ability to care for themselves using the Appraisal of Self-care Agency
Scale (ASE) (at baseline, 3 and 9 months)
• participants’ self-care behaviour using a Heart Failure Self-care Behaviour Scale,
designed for this study (at baseline, 1, 3 and 9 months)
Healthcare resource use:
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• participants’ report of number and reason for contact with GP, cardiologist,
medical specialists, physical therapists, social care providers and alternative health
specialists
• hospital readmissions and outpatient visits from hospital database
• reasons for readmission form patient charts
Also reported:
• deaths at 9 months
Notes Data source: published data and author contacted for clarification (indicated by *)
Funding: “Supported by the Netherlands Heart Foundation, grant 43.033,and Zilveren
Kruis, part of Achmea”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “By drawing from an envelope pa-
tients were randomly assigned to receive ei-
ther care-as-usual or the supportive-educa-
tion intervention”
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “The 2 study nurses were involved
in data collection as researcher and research
assistant. However, the person who col-
lected the data was never the same nurse
who visited the patient for the interven-
tion. Health care personnel (cardiologists
or staff ) involved in the care for the patients
did not know if the patient was in the in-
tervention or control group.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Participants themselves knew their assign-
ment, which could have affected self-re-
ported QoL outcome. The 2 study nurses
who delivered the intervention were also
involved in the study as data collectors and
were aware of the allocation status of the
participants
Incomplete outcome data (attrition bias)
All outcomes
High risk 186 participants enrolled in to the study
and 132 (71%) remained at 9 months.
58/84 (69%) remained in the intervention
group whilst 74/95 (78%) remained in the
control group. Analyses on self-care abili-
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ties and behaviour were adjusted in an at-
tempt to compensate for the influence of at-
trition - this adjustment assumed that those
who dropped out did not improve their
self-care and self-agency from baseline this
assumption may not have adequately ad-
justed for attrition
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Jaarsma 2008
Methods RCT (17 centres)
Recruitment: October 2002-February 2005
Duration of follow-up: 18 months
Basic intervention
Intervention category: clinic
Person delivering the intervention: specialist nurse
Intensive intervention
Intervention category: case management
Person delivering the intervention: multidisciplinary
Participants Country: Netherlands
Total number randomised = 1049 (basic intervention N = 348, intensive intervention
N = 353, control N = 348) 26 died before discharge, leaving 1023 in the total group
Actual severity of HF in study participants at recruitment: NYHA class, N (%):
• basic intervention: class I, N = 0 (0%); class II, N = 171 (51%); class III, N = 159
(47%); class IV, N = 8 (3%)
• intensive intervention: class I, N = 0 (0%); class II, N = 165 (48%); class III, N =
163 (48%); class IV, N = 13 (4%);
• control: class I, N = 0 (0%); class II, N = 177 (54%); class III, N = 139 (42%);
class IV, N = 13 (4%)
LVEF: basic: 34 (SD 14); intensive: 33 (SD 15); control: 34 (SD 14)
Age: basic: 71 (SD 11); intensive: 70 (SD 12); control: 72 (SD 11)
Percentage male: basic: 66; intensive: 61; control: 60
Ethnicity: NR
Inclusion criteria:
• admitted to hospital with HF NYHA functional class II-IV
• aged ≥ 18 years
• evidence of structural underlying heart disease as shown at CV imaging
• systolic and diastolic dysfunction (preserved LVEF)
• stable on standard HF medication before discharge
Exclusion criteria:
• concurrent inclusion in another study or HF clinic
• inability to complete the questionnaires
• invasive procedure or cardiac surgery intervention performed within the last 6
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months
• such procedure or intervention planned to be performed within the next 3 months
• ongoing evaluation for heart transplantation
• inability or unwillingness to give informed consent
Interventions Duration of intervention: 18 months
Intervention: NR
Basic intervention:
• during index hospital stay: participant (and family) education by HF nurse
according to protocol and guidelines, behavioural strategies used to improve adherence
• within 2/52 of discharge telephone call to participant from HF nurse
• during regular visits to cardiologist at the outpatient clinic (at 2, 6, 12 and 18
months after discharge) additional visits to HF nurse
• additional visits just to the HF nurse at the outpatient clinic at one, 3, 9, and 15
months after discharge
• telephone access to HF nurse Monday-Friday, office hours, participants (and
families) encouraged to contact their nurse if any change in their condition or any
questions
Intensive intervention:
• as for the basic intervention plus:
• home visit by HF nurse within 10 days of discharge to assess coping, HF health
status general health, and medical, health care and social support. Second home visit
11 months after discharge
• weekly telephone calls by the HF nurse in the 1st month after discharge then
monthly calls
• Out-of-hours back-up to provide 24-h telephone coverage
• HF nurse to consult multidisciplinary team at least once during both index
admission and once during follow-up to optimise her advice for each participant
Control: standard management by cardiologist and, subsequently, GP
Outcomes Primary (18 months):
• time to death (all-cause) or hospitalisation because of HF (composite outcome)
• number of days lost to death or hospitalisation
• number of readmissions per participant
Secondary (18 months):
• death from any cause
• hospitalisation because of HF
• QoL
• costs (cost-effectiveness results published by Cao (2013) and Postums (2011))
Notes Data source: published data only
“Financial Disclosure: None reported. Funding/support: This study was supported by
grant 2000Z003 from the NetherlandsHeart Foundation and by additional unrestricted
grants from Biosite France SAS, Jouy-en-Josas, France (brain natriuretic peptide), Roche
Diagnostics Nederland BV, Venlo, the Netherlands (N-terminal prohormone brain na-
triuretic peptide), and Novartis Pharma BV, Arnhem, the Netherlands.”
Some differences in number of contacts with the cardiologist in all groups:
• 40% more cardiologist visits and phone calls in basic group
114Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jaarsma 2008 (Continued)
• 10% more cardiologist visits and phone calls in intensive group
• 33% more cardiologist visits in control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The computer-generated ran-
domisation schemeused randompermuted
blocks of 6 patients stratified per centre to
ensure balanced assignment of patients to
each of the 3 groups in each of the 17 par-
ticipating centres.”
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “blinded endpoint evaluation”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Zero loss to follow-up after intervention
started (8 basic group, 9 intensive group,
and 9 control participants died before hos-
pital discharge and didn’t receive interven-
tion)
Selective reporting (reporting bias) Unclear risk Trial retro-
spectively registered (NCT 98675639) af-
ter enrolment complete but before follow-
up completed. Costs and QoL mentioned
as secondary outcomes, but NR in Jaarsma
2008. Cost evaluation in Cao 2013 and
Postums 2011
Other bias Low risk Nothing identified
115Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kasper 2002
Methods RCT (2 centres)
Recruitment: December 1996-December 1998
Duration of follow-up: 6 months from recruitment (plus additional 3 months)
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: USA
Participants: 102 participants (66 men, 65%) in intervention group, 98 (55 men, 56%)
in comparison group
Actual age of study participants at recruitment: median 63.5 years (range 25-88 years)
Male sex: 61%
Ethnicity: “white” 64%
Actual severity of HF in study participants at baseline NYHA class, N (%):
• intervention group: class II, N = 38 (37%); class III, N = 57 (56%)
• control: class II, N = 33 (34%); class III, N = 60 (61%)
LVEF:
• intervention group 27.1% (SD 13.8, range 10-70)
• control group mean 27.5% (SD 13.9, range 5-60)
Inclusion criteria:
• admitted to 1 of 2 hospitals with a primary diagnosis of NYHA class III/IV HF
• English speaking.
• Permission from participant’s “primary physician”
• judged to be at high risk of HF readmission, i.e. ≥ 1 of the following criteria:
◦ aged > 70 years
◦ LVEF < 35%
◦ ≥ 1 other hospital admission for HF in previous year
◦ ischaemic cardiomyopathy
◦ peripheral oedema at hospital discharge
◦ < 3 kg weight loss while in the hospital
◦ PVD
• or any 1 of the following during the index admission:
◦ pulmonary capillary wedge pressure > 25 mmHg
◦ cardiac index < 2.0 L/min/m2
◦ SBP > 180 mmHg
◦ DBP > 100 mmHg
Exclusion criteria:
• valvular heart disease requiring surgery
• active substance abuse
• cardiomyopathy (peripartum, hypertrophic with LV outflow tract obstruction or
restrictive). Constrictive pericarditis
• psychiatric disease
• dementia likely to limit compliance
• non-cardiac illness likely to cause repeat hospital admission
• heart Tx likely to occur within 6 months
• uncorrected thyroid disease
• serum creatinine ≥ 3.0 mg/dL
• long-term home i/v inotropic therapy
• cardiac surgery or MI during the index admission
• active participation in another research trial
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• residence in a nursing home, rehabilitation facility or outside the area served by
the 2 hospitals
Interventions Duration of intervention: 6 months
Intervention: “multidisciplinary program”
During index hospitalisation:
• HF cardiologist designed an individualised treatment plan for each participant
before randomisation, which included medication, diet and exercise management
After discharge:
• “Telephone nurse co-coordinator” phoned participants within 72 h of discharge
and then weekly for 1st month, bi-weekly in 2nd month and then monthly. (Content
of phone calls: set script with problems pursued as clinically indicated . No medication
adjustments over phone.)
• Monthly follow-up with HF nurses (usually in HF clinic)
• “Primary care physicians” (66% internal medicine physicians, 29% cardiologists)
received regular updates from HF nurses and were notified of abnormal lab results.
• All intervention participants received: pill sorter, list correct medications, list of
dietary and exercise recommendations, 24-h telephone contact number and participant
educational material
• If required and financial resources limited, participants also received: 3 g sodium
’Meals on Wheels’ diet, weigh scale, medications, transport to the clinic and a phone
• HF cardiologist saw participants at 6 months
Content of HF nurse follow-up:
• aimed to implement the treatment plan designed by HF cardiologist by using a
pre-specified 55-page algorithm (also designed by the HF cardiologists), which
included initiation and titration of drugs, a low sodium diet and exercise
recommendations
Comparison group: usual care
• this was care by the participants’ primary physicians (73% internal medicine
physicians, 26% cardiologists).
• HF cardiologist designed treatment plan for each participant “documented in
patient’s chart without further intervention”
Outcomes Primary endpoint (6 months):
• total number of HF hospital admissions
• all-cause deaths (i.e. composite endpoint)
Secondary outcomes (6 months):
• death
• HF hospital admissions
• all-cause hospital admissions
• change in HRQOL (MLHFQ)
• change in activity status (Duke Activity Status Index)
• process indicators including: proportion of participants with systolic dysfunction
receiving ACEI according to published guidelines or appropriate alternative treatment
if intolerant of ACEI; percentage participants euvolaemic according to defined goal
weight; compliance with dietary guidelines using locally developed sodium score and
cost data
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Notes Data source: published data and information supplied by study author for ’Rsk of bias’
assessments (indicated by*)
Funding: “Partial funding was provided by CardioContinuum, Inc., Rockville, Mary-
land. Under a licensing agreement between The Johns Hopkins University and Cardio-
Continuum, the University and, in particular, its Division of Cardiology, are entitled to
royalty on the use of the HF management program described in this study. The Uni-
versity also owns CardioContinuum stock, which is subject to certain restrictions under
University policy. The University, in accordance with its conflict of interest policies, is
managing the terms of this arrangement. None of the investigators, with the exception of
Ms. Van Anden (once an employee of CardioContinuum), have personal stock, royalty
interests or consulting arrangements with CardioContinuum.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The coordinating centre made
treatment assignments by using an auto-
mated telephone response system”
Allocation concealment (selection bias) Low risk Quote: “Random number schedules were
prepared before initiation of patient re-
cruitment and were unknown to the clini-
cal investigators”
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “An independent central telephone
data collector, who had no knowledge of
the patients’ treatment assignment, col-
lected data monthly from all patients dur-
ing the nine months after enrollment.
Medical document coordinators blinded to
treatment assignment searched the on-line
medical records.... The coordinating cen-
ter deleted from all documents and records
information that revealed personal iden-
tity or treatment assignment.... A commit-
tee composed of three cardiologists, who
had no knowledge of the treatment assign-
ment, categorized each hospital admission
anddeath usingdocuments prepared by the
coordinating center.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
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Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT principle for main outcomes. QoL
data available for 94/102 (92%) interven-
tion and 85/98 (87%) control group at 6
months
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Kimmelstiel 2004
Methods Multicentre RCT (6 centres)
Recruitment period: 22 months, dates NR
Duration of follow-up: 12 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: USA
Number randomised: 200 (control N = 97, intervention N = 103)
Actual severity of HF in study participants at baseline NYHA class, %:
• intervention: class I, 0%; class II 50.5%; class III 49.5%; class IV 0%
• control: class I 1.9%; class II 58.3%; class III 35.9%; class IV 3.9%
LVEF: intervention: 30 (SD 14); control: 31 (SD 12)
Age: intervention 70.3 (SD 12.2); control: 73.9 (SD 10.7)
Percentage male: intervention: 57.7; control: 58.3
Ethnicity: NR
Inclusion criteria:
• participants were enrolled during an index HF hospitalisation or within 2 weeks
of discharge
• participants with HF resulting from ischaemic heart disease, dilated
cardiomyopathy, valvular heart disease (either surgically treated or deemed inoperable),
or hypertensive heart disease
Exclusion criteria:
• noncardiac debilitating illness such as active malignancy
• severe liver disease
• severe renal insufficiency (creatinine 3.0 mg/dL)
• dementia
• obstructive lung disease requiring hospitalisation
• angina at rest or as the principal cause of activity limitation
• MI or revascularisation procedure during the index hospitalisation or within the
preceding 30 days
• planned revascularisation or valvular surgery
• restrictive myopathy
• pericardial constriction
• hypertrophic cardiomyopathy
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Interventions Duration of intervention: 90 days, followed by passive surveillance (nurse-manager avail-
able for incoming calls but didn’t make scheduled calls) for clinically stable participants
or continuation for participants with overt clinical instability (class A)
Intervention: Specialized Primary and Networked Care in HF (SPAN-CHF)
• home visit from nurse-manager within 3 days of discharge, focusing on dietary
and medical compliance, daily weights, self-monitoring,and early reporting of changes
in weight or clinical status
• teaching tool ’Patient and Family Handbook’ given to participants during home
visit, including sections on HF (definition), medications, low-salt diet, importance of
daily weight, and clinical signs and symptoms that should prompt a call to the SPAN-
CHF nurse or primary care physician (plus contact phone numbers)
• during home visit, nurse performed cardiovascular examination and symptom
assessment
• Weekly or biweekly phone calls from nurse-manager to participants focused on
identifying changes in clinical condition and education reinforcement
• participants had 24-h/7-day telephone access to nurse managers, and were
instructed to report changes in clinical status and relevant weight change
• Frequent communication between nurse-managers, primary care physicians and
HF specialist
Comparator: usual care
Outcomes Primary:
• hospitalisations for HF during the first 90 days after enrolment
Secondary (90 days):
• cardiac hospitalisations and all-cause hospitalisations
• number of days hospitalised per patient-year of follow-up for HF, cardiac and all-
cause hospitalisations at 1 year
• costs presented by Gregory 2006, but only for 90-day data not full length of
follow-up
Notes Data source: published data only
Funding: “This study was funded in part by grants from the Fannie E. Rippel Foundation
and the Hewlett-Packard Corporation.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization lists were gener-
ated independently for each hospital (in
blocks of 4 patients), stratifying patients
first by level of care needed.”
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
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Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Non-nurse study coordinators,
blinded to treatment assignment, per-
formed telephone follow-up in all patients
at 3 and 12 months after enrolment to as-
certain clinical events. Events were adjudi-
cated by an investigator blinded to treat-
ment group.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Subjective outcomes NR
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers included in analysis NR
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Krumholz 2002
Methods Single-centre RCT
Recruitment period: October 1997-September 1998
Duration of follow-up: 1 year
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: USA
Participants: 44 participants (21 men, 48%) in intervention group; 44 participants (29
men, 66%) in comparison group
Actual age of study participants:median age 74 years, intervention 75.9 (SD8.7); control
mean age 71.6 (SD 10.3)
Male: 57%
Ethnicity: “74% Caucasians”
Actual severity of HF in study participants at recruitment:
Mean EF: intervention group 38% (SD 17); control group 37% (SD 16)
NYHA: NR
Inclusion criteria:
• aged ≥ 50 years
• needed to have either admission diagnosis of HF or radiological signs of HF on
admission chest X-ray. All participants had been hospitalised for HF
• reviewed within 3 days to verify additional set of criteria derived from NHANES-
1
Study exclusion criteria:
• participants transferred from other hospitals or nursing homes
• participants with HF secondary to high output states or non-cardiac disease
• participants with another terminal illness (e.g. expected survival < 6/12)
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Interventions Duration of intervention: 1 year
Intervention: “Education and Support”
After discharge:
• initial hour-long face-to-face consultation with experienced cardiac nurse within 2
weeks of discharge using a teaching booklet (45% of these consultations took place in
participant’s home, remainder in hospital clinic)
• following this weekly telephone contact for 4 weeks, bi-weekly for 8 weeks then
monthly until 1 year
• initial consultation covered 5 sequential care domains for chronic illness
including: patient knowledge of illness; the relation between medication and illness;
the relation between health behaviours and illness; knowledge of early signs and
symptoms of decompensation, and where and when to obtain assistance. Follow-up
phone calls reinforced the 5 care domains but did not modify current regimens or
provide recommendations about treatment. However the nurse could recommend that
the participant consulted his/her physician when their condition deteriorated sharply
or when they had problems, in order to help participants to understand when and how
to seek and access care
Comparison: usual care
• All usual care treatments and services ordered by their physicians
Outcomes Primary endpoint:
• readmission or death at 12 months’ follow-up
Secondary endpoints (12 months’ follow-up):
• all-cause admissions
• HF or other CVD-related readmissions
• cumulative number of days in hospital
• cost of readmission
Notes Data source: published data and information from author*
Funding: “This study was funded in part by grants from the Fannie E. Rippel Foundation
and the Hewlett-Packard Corporation.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer generated”*
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk “One-year outcomes included deaths, as-
certained through next-of-kin, hospital
records, active monitoring of obituaries
and information about readmissions ob-
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tained from patients, their families, dis-
charge summaries and hospital records to
confirm the event and classify the cause,
based on the assessment of a clinician
blinded to the patients’ intervention allo-
cation.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk QoL NR
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk States ITT analysis used, but numbers in-
cluded in analysis NR
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Unclear risk Intervention group significantly older with
lower incidence of prior CABG and fewer
prescribed calcium channel blockers
Kwok 2008
Methods RCT (2 centres)
Recruitment: September 1999-February 2001
Duration of follow-up: 6 months
Intervention category: case management
Person delivering the intervention: community nurse
Participants Country: China (Hong Kong)
Number randomised: 105 (intervention N = 49, control N = 56)
NYHA: NR
LVEF < 40% : 15 (30%) 9 (18%) (intervention, N = 43); (control, N = 50)
Age (years): intervention: 79.5 (SD 6.6); control: 76.8 (SD 7.0)
Percentage male: intervention: 45; control: 45
Ethnicity: NR
Inclusion criteria:
• hospitalised with a principal diagnosis of HF
• age > 60 years
• residing within the region and had ≥ 1 hospital admission for HF in the 12
months prior to the index admission.
Exclusion criteria:
• communication problems but without caregivers
• residing in a nursing home
• terminal disease with a life expectancy of < six months
Interventions Duration of intervention: 6 months
Intervention: community nurse-supported hospital discharge programme
• community nurse (CN) visited participants prior to discharge, to provide health
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counselling, information on drug compliance, dietary advice
• home visit by CN within 7 days of discharge, then weekly for 4 weeks, then
monthly, to check vital signs and signs of poorly controlled HF (ankle swelling,
dyspnoea and basal crepitation on auscultation). Medications checked and dietary/
exercise advice given
• home care and day care services arranged if social support insufficient
• participants encouraged to contact CN via a telephone hotline during office hours
when they developed symptoms
• following liaison with geriatrician or cardiologist, CN able to alter medication,
arrange appointments and clinical admission as appropriate
• CN monitored participants refusing further home visits by telephone
Control: usual medical and social care, but with follow-up in the hospital outpatient
clinics by the same group of designated geriatricians or cardiologists
Outcomes Primary:
• percentage of participants who ever had unplanned hospital readmissions within
6 calendar months of discharge
Secondary (6 months):
• number of unplanned hospital readmissions
• changes in 6-minute walking test
• London Handicap Scale (LHS) domain scores
Notes Data source: published data only
Funding: “The research was funded by the Health Services Research Committee/Health
Care & Promotion Fund (HSRC/HCPF) of Hong Kong”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The ward nurses then phoned a
second research assistant who assigned trial
grouping according to a random number
table.”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “The research nurse was not aware
of the randomisation grouping of the sub-
jects.”
Quote: “All hospital admissions, including
attendance to the A&E, throughout Hong
Kong were traced by an electronic database
maintained by the Hospital Authority”
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk QoL NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 intervention and 2 control group
participants dropped out. Cost analysis
based on ITT
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Lang 2018
Methods Single-centre pilot RCT
Recruiting: April 2015-June 2016
Duration of follow-up: 6 months
Intervention category: case management
person delivering intervention: specialist nurse
Participants Country: Scotland, UK
Participants: randomised N = 50 (intervention N = 25; control N = 25)
Mean ± SD age: intervention 71.8 (9.9); control 76.0 (6.6)
Male sex N (%): intervention 9 (36%); control 14 (56%)
Ethnicity: intervention and control both 100% white
Actual severity of HF in study participants at recruitment NYHA class:
intervention: class I, N = 1 (4%); class II, N = 15 (60%); class III, N = 9 (36%); class
IV, N = 0 (0%)
Control: class I, N = 1 (4%); class II, N = 16 (64%); class III, N = 8 (32%); class IV, N
= 0 (0%)
Inclusion criteria:
• aged ≥ 18 years
• a confirmed diagnosis of HF by EF on echocardiography, radionuclide
ventriculography or angiography (i.e., LVEF ≥ 45% within the last 6 months prior to
randomisation)
Exclusion criteria:
• cardiac rehab undertaken within 6 months prior to enrolment
• any contraindication to exercise testing or exercise training (with consideration of
adapted ESC guidelines for HF)
Interventions Intervention:
Participants were provided with:
• REACH-HF manual, relaxation CD, chair-based exercise DVD, a ‘Progress
Tracker’ tool for patients and a ‘Family and Friends Resource’ for caregivers
• participants and caregivers worked through the REACH-HF manual over 12-
weeks, facilitated by 2 trained cardiac nurses (at least 1 face-to-face and 2 phone
contacts)
• REACH-HF manual includes:
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◦ progressive exercise training programme, tailored to participant’s ability and
choice of a walking programme or a chair-based exercise DVD, or a combination
◦ managing stress/breathlessness/anxiety.
◦ HF symptom monitoring
◦ taking medication
◦ understanding HF (and why self-management helps).
The core priorities for caregiver elements of the intervention were:
• to facilitate improvement in patient HRQoL by helping them to achieve the core
priorities for change
• to improve HRQoL for caregivers by acting to maintain their own health and
well-being
Comparator: usual medical management for HF according to current guidelines
Outcomes • All-cause mortality
• HF readmissions
• All-cause readmissions
• Serious adverse events
• HRQoL (MLHFQ) (EQ-5D and others also reported but not data-extracted as
MLHFQ)
Notes Funding: “National Institute for Health Research (NIHR) under its Programme Grants
for Applied Research Programme (Grant Reference Number RP-PG-1210-12004). NB,
CA, CJG and RST are also supported by the National Institute for Health Research
(NIHR) Collaboration for Leadership in AppliedHealth Research and Care (CLAHRC)
South West Peninsula at the Royal Devon and Exeter NHS Foundation Trust; KJ by
CLAHRC West Midlands and SS by CLAHRC East-Midlands”
Study author confirmed majority of participants hospitalised for HF
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from protocol: “Randomisation
numbers will be computer generated and
assigned in strict sequence. At the point
of randomisation, participants will be as-
signed the next randomisation number in
the sequence. To maintain concealment
andminimise selectionbias, randomisation
will be performed after the baseline visit
by a member of Peninsula Clinical Trials
Unit (CTU), independent from investiga-
tor teams, using a secure, web-based ran-
domisation system.”
Allocation concealment (selection bias) Low risk Quote from protocol: “To maintain con-
cealment and minimise selection bias, ran-
domisation will be performed after the
baseline visit by a member of Peninsula
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Clinical Trials Unit (CTU), independent
from investigator teams, using a secure,
web-based randomisation system.”
Blinding of participants and personnel
(performance bias)
High risk Quote: “Given the nature of the REACH-
HF intervention, it was not possible to
blind participants or those involved in the
provision of care.”
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “The statistician undertaking the
data analysis was blinded to treatment al-
location and we also blinded researchers
undertaking collection of outcome data to
minimise potential bias. We assessed the fi-
delity of blinding by asking outcome asses-
sors at each follow-up visit to guess patient
group allocation. Unblinding of groups did
not take place until after data analysis and
the blinded results had been presented to
the Trial Management Group and interpre-
tation of results was agreed. ”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL outcomes self-reported by partici-
pants not blind to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were small and similar
between arms (3/25 (12%) in intervention
group, 2/25 (8%) in control group, no rea-
sons given)
Selective reporting (reporting bias) Low risk Reported outcomes reflect published pro-
tocol, although this was published after en-
rolment began
Other bias Low risk Nothing noted
Leventhal 2011
Methods Single-centre RCT
Recruitment: July 2003-February 2005
Duration of follow-up: 1 year
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Switzerland
N randomised = 42, 20 to intervention, 22 to control
Age, mean (SD): intervention: 76.7 (7.1); control: 77.6 (6.0)
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Percentage male: intervention: 59.1 (13%); control: 65.0 (13%)
Ethnicity: NR
NYHA at discharge: NR
Inclusion criteria:
• adult patients hospitalised with decompensated HF (NYHA II-IV), irrespective of
LVEF
• brain natriuretic peptide (BNP) ≥ 100 pg/mL
• history of dyspnoea
• increased fatigue or weakness
• ability to speak German and to comprehend a telephone conversation
• discharge to a home setting
Exclusion criteria:
• acute MI within 8 weeks prior to inclusion
• severe myocardial or valvular obstructive disease
• uncontrolled angina pectoris
• co-morbid conditions compromising prognosis (life expectancy of < 12 months)
• planned (except heart Tx) or previous cardiac surgery within 3 months
• on dialysis
• unstable psychiatric disorders or substance abuse
• cognitive impairment (MMSE score < 24)
• enrolled in another study
• refused to sign an informed consent
Interventions Intervention:
• participant education (HF-educational booklet and kit (Swiss Heart Foundation))
• support with self-care including recognition of warning signs of deterioration
• advice on diet, fluids and sodium management
• importance of daily weighing
• identifying actions to take in case of increasing symptoms, individualised care
plans, communication with primary care physician
• Intensity and complexity: intervention duration 12 months, beginning with
home visit from specialist HF nurse, followed by 17 structured telephone calls (weekly
x 4, bi-monthly x 4, monthly x 6) plus additional calls when needed; 1 call with
primary care physician following home visit, additional calls when needed;
• nurse consultation with study internist, study cardiologist or dietician when
needed.
• home visit consisted of a physical, psychosocial and environmental assessment,
the provision of educational, behavioural, and supportive care to build self-care
abilities, and individualised participant goal-setting to increase self-efficacy.
• follow-up telephone calls included discussions of questions or problems the
participants had due to their HF identification of signs and symptoms signifying
possible decompensation of HF, review of current medications, reinforcement of self-
care activities and setting new goals
Comparator:
• all participants received similar care during hospitalisation. This consisted of the
normal medical and nursing care provided by hospital staff
• all study participants were examined by the study HF-cardiologist who
recommended lifestyle modifications and made suggestions for optimal medical
management to the participant’s primary care physician
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• all participants were given a HF education booklet published by the Swiss Heart
Foundation
• these efforts were made to standardise usual care, to remove unnecessary
variability in care provided to the control participants
• following hospitalisation, medical care was provided by the primary care physician
(usual-care group protocol)
Outcomes Primary:
• mortality (all causes)
• readmission (HF related and all causes)
Secondary:
• QoL (EuroQol- 5D (EQ-5D) and MLHFQ)
• length of stay
Notes Funding: “Funding for this study was provided by the Swiss National Foundation #
3200-068000 (www.snf.ch) and the Swiss Heart Foundation. There are no potential
competing interests.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Following discharge, the participant was
randomised by an independent centre,
according to a computer-generated list
(blocked, variable block size)
Allocation concealment (selection bias) Low risk The study nurse called the randomisation
centre, stated the chronological study re-
cruitment number and was given the group
assignment. Participants were notified of
their group assignment by telephone
Blinding of participants and personnel
(performance bias)
High risk Quote: “Patients, care-givers, primary care
physicians and the interventionnurseswere
not blinded to group assignment.”
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Mortality data were obtained
from the Department of Birth and Death
Records and re-admission data were ob-
tained fromhospital records, examined and
adjudicated by a senior researcher blinded
to group assignment, and entered into the
database by the study coordinator.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Quote: “Patients were sent the follow-up
study questionnaires with a pre-addressed,
stamped reply envelope and an appoint-
ment for a follow-up telephone interview
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with a special data collector blinded to
group assignments. Questionnaires were
entered into the database by research as-
sistants, blinded to group assignment, and
checked by random sample by the data an-
alyst.”
However, participants themselves knew
their group assignment, so QoL assessment
open to detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial planned to recruit 300 partici-
pants, but the trial was stopped early due to
recruitment problems, and only 42 partici-
pants were recruited. KaplanMeier survival
analysis was planned to compare time to
mortality and time to re-admission. How-
ever, since fewer participants were included
than was initially planned, preventing cal-
culation of reliable estimates, only a graph-
ical representation of the survival curves
were given, without formal testing
Selective reporting (reporting bias) Unclear risk QoL data only reported as a random inter-
cept regression analysis
No protocol found
Other bias Low risk Nothing identified
Lopez 2006
Methods RCT (2 centres)
Recruitment: September 2000-August 2002
Duration of follow-up: 1 year
Intervention category: case management
Person delivering the intervention: pharmacist
Participants Country: Spain
Number randomised: 134 (intervention N = 70; control N = 64)
Age: intervention: 75.3 (SD 8.4); control: 76.1 (SD 9.4)
Percentage male: intervention: 41.4; control: 46.9
Ethnicity: NR
Actual severity of HF in study participants at recruitment
NYHA class, N (%):
• intervention: class I-II, N = 58 (84.1%); class III-IV, N = 11 (15.9%)
• control: class I-II, N = 54 (87.1%); class III-IV, N = 8 (12.9%)
LVEF: intervention: 54.5 (SD 14.4); control: 47.4 (SD 17.3)
Inclusion criteria:
• patients admitted to the General Hospital of Vic and the Municipal Hospital of
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Badalona for HF who met 2 major or 1 major and 2 minor Framingham criteria
Exclusion criteria:
• regularly living out of the area of influence of the hospital
• regularly living in an old people’s home
• moved to a social-health centre or to other centres for acute patients
• suffering any type of dementia or disabling psychiatric disease
• refusing to participate in the study
Interventions Duration of intervention: 12 months
Intervention: Active Information Program, carried out by a pharmacist with 2 key com-
ponents:
• information -personal interview on day of discharge, covering information about
the disease, diet education, information on drug therapy and the need for compliance
• telephone support - participants given pharmacist’s name and phone number, and
encouraged to contact about any doubts arising during treatment, or questions about
the disease. Monthly during the 1st 6 months and every 2 months thereafter,
participants received home phone calls (not clear from whom) to reinforce the
intervention and solve any problems or questions arising
Comparison: no details given
• Follow-up visits at 2, 6 and 12 months to check compliance, QoL and participant
satisfaction
Outcomes Primary (2, 6 and 12 months):
• time to the first readmission for HF or for another cause
• percentage of participants with readmission
• total number of readmissions
• total of hospital stay days during the study period
Secondary (2, 6 and 12 months):
• treatment compliance (NR here)
• QoL (EuroQol)
• participant satisfaction with the care received and death during the follow-up (NR
here)
Notes Data source: published data only
Funding: “This study (PI00/0665) was co-financed with a grant from the Health Re-
search Fund (Fondo de Investigación Sanitaria, FIS) and the European Regional Devel-
opment Fund (ERDF).” CoI of study authors not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were randomised to
one of the two groups through a randomi-
sation software. Lists were generated in
blocks of 4 to assure a consistent patient
distribution in both groups.”
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Allocation concealment (selection bias) Low risk Quote: “Neither the physician nor the
nurse responsible for the patient knew the
allocation until the educational interven-
tion, the day of discharge”
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Self-reported QoL outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear if readmissions reported on an
ITT basis. Cost analysis stated to be ITT,
but 3 participants were excluded due to
missing data on outpatient appointments
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified, although intervention
group had slightly higher baseline EF than
controls
Mao 2015
Methods Single-centre RCT
Recruiting: June 2010-May 2012
Duration of follow-up: 24 months
Intervention category: multidisciplinary
Person delivering intervention: multidisciplinary
Participants Country: Taiwan
Participants: randomised N = 349 (intervention N = 174; control N = 175)
Mean ± SD age: intervention 59.2 (13.6); control 61.5 (12.6)
Male sex, N (%): intervention 127 (73.0); control 117 (66.9)
Ethnicity: NR
Diabetes, N (%): intervention 66 (37.9); control 82 (46.9)
Actual severity of HF in study participants at recruitment:
LVEF, mean (SD) %: intervention 36.9 (15.8); control 35.1 (14.3)
NYHA class N (%):
• intervention: class II, N = 34 (19.5); class III, N = 134 (77.0); class IV, N = 6 (3.4)
• control: class II, N = 34 (19.4); class III, N = 130 (74.3); class IV, N = 11 (6.3)
Inclusion criteria:
• typical signs and symptoms of HF and NYHA functional classification II-IV
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• hospitalised because of acute cardiogenic pulmonary congestion based on chest X-
rays after noncardiogenic causes were excluded
• structural abnormalities documented by echocardiograms
• aged 20-85 years
• both patients with impaired LVEF and those with preserved LVEF were enrolled
Exclusion criteria:
• having a disorder other than HF that might compromise survival within the next
6 months
• bedridden for > 3 months
• serum creatinine of ≥ 3 mg/dL
• dialysis within previous 2 weeks
• severe coronary artery disease without complete revascularisation therapy
• being pregnant
Interventions Intervention:
• participants were cared for by a HF team consisting of 2 cardiologists specialising
in HF care, one psychologist, one dietary assistant, one pharmacist, and 2 case
managers (nursing practitioners). Team provided individualised HF education and
information on self-monitoring, optimised guideline-based HF medication and
complete cardiac and laboratory assessments
• 1:1 education sessions with the case manager in hospital; participant diary for
daily weight, medication and intake/output; educational booklet (symptoms;
importance of monitoring body weight, intake/output; action plans; drug effects and
the importance of compliance; diet and exercise
• during follow-up: prescheduled outpatient visits to the combined clinic of a
cardiologist and case manager 7 days after discharge, then at least monthly or on
demand for 6 months (included adjustment of diuretic dose, nutritional consultation,
education, drug titration, weighing)
• After 6 months, if stabilised, participants visited clinic every 2-3 months, or on
demand, with phone contact every month; and 24/7 phone access to case manager
Comparator:
• primary care cardiologist was responsible for participant evaluation, treatment,
and clinic visits (usual care for Taiwan).
• neither scheduled follow-up nor specialised HF nurses were provided.
• contact with the HF specialists of the research team was discouraged.
• participants were advised to contact their primary care cardiologist if they had
questions about HF management
Outcomes • All-cause mortality
• HF readmissions
Notes Funding: National Science Council of Taiwan and Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier: NCT01416285. No CoI
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “computer-generated permuted
block randomization”
Allocation concealment (selection bias) Unclear risk Paper doesn’t specify whether block size is
concealed or random, so possible to guess
assignment of last participant in block
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “A committee of three cardiolo-
gists adjudicated all hospitalisations with-
out knowledge of the patients’ clinical data
to determine whether events were related
to worsening heart failure.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Not applicable - QoL NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5% of intervention group and 0% of con-
trol group lost to follow-up
Selective reporting (reporting bias) Unclear risk Trials registry states mortality (cardiac and
non-cardiac) as an outcome, whereas only
all-cause mortality is presented here
Other bias High risk Intervention included using guideline-
basedmedications. Post-hoc analysis found
that, after adjusting for this, theHRmoved
closer to the null and there was no evidence
for the disease management intervention
lowering all-cause death rates
Mehralian 2014
Methods Single-centre, single-blind RCT
Recruiting: September 2011-June 2012
Duration of follow-up: 6 months
Intervention category: case management
person delivering intervention: nurse
Participants Country: Iran
Participants: randomised N = 110 (intervention N = 55; control N = 55)
Mean ± SD age: intervention 61.28 ± 13; control 62.7 ± 10
Male sex: intervention 54%; control 62.2%
Ethnicity: NR
Actual severity of HF in study participants at recruitment, NYHA class:
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• intervention - class III most prevalent (67.3%)
• control: class III most prevalent (82%)
Inclusion criteria:
• having HF diagnosed by cardiologist
• aged > 18 years
• NYHA class II-IV
• EF < 45%
• ability to read and write
Exclusion criteria:
• history of other diseases requiring surgery during study period
• psychological disorder
Interventions Intervention: HF education
• nurses visited participants in their homes, using a checklist:
◦ information about their disease
◦ usual signs and symptoms and potential complications of their illness
◦ prescribed medications
◦ potential change in their lifestyle
◦ special signs and symptoms which they have to know in order to go to the
hospital on time
◦ any other information about the illness which participants may request to be
answered.
• participants also received a simplified booklet about HF
• Home-visits were scheduled twice a month in 1, 3 and 6 months after
participants’ discharge from hospital
• participants and their families were encouraged to make contact in the event of
problems
Comparator: usual education
• provided by nurses 1 h before hospital discharge
• nurses visited participants in their room and answered any questions
Outcomes • All-cause mortality
• HRQoL (SF-36 - Iranian version)
Notes Funding: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned” with no fur-
ther information
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
High risk Not possible
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Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Study described as “single blind” but not
clear who this applies to - participants were
aware of their group assignment due to the
nature of the intervention.
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported by participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Unclear risk More people in the control armhadNYHA
class III disease (82% vs 67.3% in interven-
tion group). Not clear whether there were
more or fewer people with class IV disease,
so possible that disease severity was worse
in the control arm.
Mejhert 2004
Methods Single-centre RCT
Recruitment: January 1996-December 1999
Mean (SD) follow-up: 1122 (405) days
Intervention category: clinic
Person delivering the intervention: nurse
Participants Country: Sweden
Number randomised: 208 (control N = 105, intervention N = 103)
NYHA:
• intervention: class II, N = 60 (58%); class III, N = 43 (42%); class IV, N = 0 (0%)
• control: class II, N = 69 (66%); class III, N = 34 (32%); class IV, N = 2 (2%)
LVEF (%): intervention: 34 (SD 12); control: 35 (SD 11),
Age: intervention: 75.9 (SD 7.7); control: 75.7 (SD 6.6)
Percentage male: intervention: 56; control: 59
Ethnicity: NR
Inclusion criteria:
• All participants ≥ 60 years of age
• hospitalised with HF according to NYHA class II-IV and LV systolic dysfunction
by echocardiography
Exclusion criteria:
• acute MI or unstable angina pectoris within the previous 3 months
• valvar stenosis
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• dementia
• severe concomitant disease
• refusal to participate
Interventions Duration of intervention: ≥ 18 months, mean follow-up was 1122 (405 ) days
Intervention: “nurse based outpatient management programme”
• regular visits to the outpatient clinic and participant encouraged to keep contact
with nurse (not clear how regular)
• nurse checking symptoms and signs of HF, blood pressure, heart rate, and weight
at each visit
• nurses can institute and change medication doses according to standard protocol
• participant instructed to check weight regularly and monitor early signs of
deterioration
• participants with good compliance instructed to change dosing of diuretics on
their own
• dietary advice recommends restricted sodium, fluid, and alcohol intake
• information repeated in booklets and computerised educational programmes
Comparator:
• treated by GPs according to local health care plan for HF.
• all participants had clinical examinations and detailed control of medication at 6,
12, and 18 months at the Cardiovascular Research Laboratory
Outcomes Primary:
• QoL (6, 12 and 18 months)
Secondary:
• cardiac function (NR?)
• medication (6, 12 and 18 months)
• hospitalisation (18 months)
• mortality (18 months)
Notes Data source: published data only
Funding: “This study was supported by the Vårdal Foundation, the Swedish Heart and
Lung Foundation, the Swedish Society of Medicine, and Karolinska Institutet. ” CoI for
study authors not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were enrolled and under-
went random assignment” but gives no fur-
ther details on method
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
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Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported by participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appears to report for all participants
Selective reporting (reporting bias) Unclear risk Cardiac function stated as a secondary out-
come, but doesn’t appear to be reported
No protocol found
Other bias Low risk No other apparent sources of bias
Naylor 2004
Methods Multicentre RCT (6 centres)
Recruitment: February 1997-January 2001
Follow-up: 1 year
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: USA
Participants: number randomised = 239 (control N = 121, intervention N = 118)
NYHA:
• NR
Documented EF, N (%) intervention 88 (72)/control 98 (80)
< 20% 12 (14) / 17 (17) P = 0.755
20 to < 25% 10 (11) / 9 (9) P = 0.760
25 to < 35% 28 (32) / 30 (30) P = 0.914
35 to < 45% 26 (30) / 28 (28) P = 0.942
45% or more: 12 (14) / 14 (14) P = 1.00
Age: intervention: 76.4 (SD 6.9); control: 75.6 (SD 6.5)
Percentage male: intervention: 40; control: 44
Ethnicity: intervention: 66% white; control: 62% white; remainder of participants,
African American
Inclusion criteria:
• all patients aged ≥ 65 admitted to study hospitals from their homes February
1997-January 2001 with a diagnosis of HF (diagnosis-related group 127 validated at
discharge) were screened for participation
• speak English
• be alert and oriented
• be reachable by telephone after discharge
• reside within a 60-mile radius service area of the admitting hospital
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Exclusion criteria:
• end-stage renal disease
Interventions Duration of intervention: 3 months
Intervention: transitional care delivered by 3 APNs, who received standardised training
before the study commenced
• Quality-Cost Model of APN Transitional Care management strategies, including:
◦ identification of participants’ and caregivers’ goals
◦ individualised plans of care developed and implemented by APNs in
collaboration with participants’ physicians
◦ educational and behavioral strategies to address participants’ and caregivers
learning needs
◦ continuity of care and care co-ordination across settings
• evidence-based protocol, guided by national HF guidelines, included:
◦ APN discharge planning
◦ initial APN visit within 24 h of index hospital admission, and at least daily
during the index hospitalisation for comprehensive assessment of participants and
carers
◦ ≥ 8 APN home visits (1 within 24 h of discharge), weekly during the first
month then bimonthly during 2nd and 3rd months to check clinical status
◦ additional APN visits based on participants’ needs
◦ APN telephone availability 7 days/week (8 am-8 pm, weekdays; 8 am-noon,
weekends)
◦ if readmission to hospital required during 1st 3 months, APN resumed
home visits
◦ APNs had email/phone access to multidisciplinary team for consultation of
cases as required
◦ APNs collaborated with each participants physician regarding adjustments
in medications and other therapies or worked under specific guidance from physician
◦ self-management of symptoms was promoted by APNs teaching participants
and caregivers about early symptom recognition and effective treatment, such as the
use of as-needed diuretics
◦ taped teaching material was left with participants
Comparators:
• routine care (including site-specific discharge planning and clinical paths)
• standard home agency care if referred, consisting of comprehensive skilled home
health services 7 days/week.
• On-call registered nurse available 24 h/day.
• 58% of control participants received skilled nursing or physical therapy after
index discharge
Outcomes Primary:
• time to first readmission or death during 52 weeks
Secondary (52 weeks’ follow-up):
• time to first readmission
• total rehospitalisations
• QoL
• functional status
• participant satisfaction
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• medical costs
• cumulative days of rehospitalisation
• mean readmission length of stay
• number of unscheduled acute care visits after discharge
• other treatments and healthcare utilisation
• cost of post-index hospitalisation readmission
Notes Data source: published data only
Funding: “The National Institute for Nursing Research, National Institutes of Health
funded this study”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “research assistants (RAs) blinded
to study aims and groups obtained base-
line sociodemographic and health status
data and notified the project manager, who
assigned patients to study groups using
a computer-generated, institution-specific
block 1:1 randomisation algorithm.”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “RAs blinded to study aims and
groups conducted standardized patient
telephone interviews at 2, 6, 12, 26, and 52
weeks after index hospital discharge to ob-
tain information about rehospitalizations
and unscheduled acute care visits to physi-
cians, clinics, and emergency departments;
quality of life ...Two cardiologists specializ-
ing in the treatment of HF blinded to study
group validated reasons for rehospitaliza-
tions and categorized them as index related,
comorbid (diagnoses abstracted frommed-
ical record during index hospitalization), or
new health problem.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported by participants
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Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT principle used, missing QoL data ac-
counted for in analysis (statistical methods
described in paper)
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Nucifora 2006
Methods Single-centre RCT
Recruitment: March 1999-January 2001
Duration of follow-up: 6 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Coutry: Italy
Number randomised: 200 (control N = 101, intervention N = 99)
NYHA:
• intervention: class I, N = 0 (0%); class II, N = 33 (33%); class III, N = 63 (64%);
class IV, N = 3 (3%)
• control: class I, N = 2 (2%); class II, N = 37 (37%); class III, N = 61 (61%); class
IV, N = 1 (1%)
LVEF: intervention: 43 (SD 16); control: 43 (SD 19)
Age: intervention: 73 (SD 9); control: 73 (SD 8)
Percentage male: intervention: 62; control: 62
Ethnicity: NR
Inclusion criteria:
• Aged ≤ 85 years
• admitted to internal medicine department with a diagnosis of HF during
recruitment period
• HF diagnosed by 2 major or 1 major and 2 minor Framingham criteria
Exclusion criteria:
• chronic cor pulmonale
• terminal illness in addition to HF
• severe dementia or other psychiatric illness
• indication for surgical therapy in the next 6 months
• refusal to participate
Interventions Duration of intervention: 6 months
intervention: “HF management programme”
• pre-discharge intensive education by an experienced CV research nurse using a
teaching booklet, covering causes of HF, recognition of symptoms of worsening HF,
the role of sodium restriction and pharmacological therapy, the importance of fluid and
weight control, physical activity and complete abstinence from alcohol and smoking
• phone call from nurse 3-5 days post discharge to assess any problems, promote
self-management and check compliance, weight and lifestyle issues
• participants had telephone access from 8.00 am to 9.00 am, Monday to Friday,
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and out of hours answering machine
• outpatient visits to doctor at 15 days, 1 and 6 months after discharge, to evaluate
test results, physical condition and medicine adherence and make any required changes
to drug therapy
Control:
• pre-existing routine of post-discharge care; i.e. usual care by primary care
physician
• outpatient visit to doctor at 6 months after discharge
Outcomes Primary:
• all-cause readmissions at 6 months
• all-cause deaths at 6 months
Secondary (6 months):
• event-free survival
• days of unplanned readmissions
• number of unplanned outpatient visits
• participants’ clinical status
• compliance
• adherence to treatment plan
• QoL
Notes Data source: published data only
Funding/CoI: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
to receive either the study intervention or
the usual care” but gives no details on
method of randomisation
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “No patient withdrew from the
study. Follow-up data were collected on ev-
ery patient.”
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However,QoL data at 6months only avail-
able from 74/98 in intervention group and
75/98 in control group
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk More participants in the intervention
group were in sinus rhythm compared to
control group (73% vs 52%, P = 0.06)
. More participants in control group had
previous CABG compared to intervention
group (13% vs 5%, P = 0.059)
Ong 2016
Methods Multicentre RCT (6 centres)
Recruiting: October 2011-September 2013
Duration of follow-up: 6 months
Intervention category: case management
Person delivering intervention: nurse
Participants Country: USA
Participants: randomised N = 1437 (intervention N = 715; control N = 722)
Median (IQR) age: intervention 73 (62-84); control 74 (63-82)
Male sex: intervention 53.4%; control 52.9%
Ethnicity:
• intervention: African American 21.5 (18.5-24.5); Hispanic/Latino 12.0; white
54.7; Asian/Pacific Islander or other 11.8
• control: African American 22.7; Hispanic/Latino 10.9; white 54.3; Asian/Pacific
Islander or other 12.1
Actual severity of HF in study participants at recruitment:
LVEF (%) intervention 42.7; control 43
NYHA class (mean (95% CI) %):
• intervention: class I, 0.2 (0.0-0.5); class II, 23.4 (20.0-26.9); class III, 65.6 (61.8-
69.4); class IV, 10.8 (8.3-13.3);
• control: class I, 0.7 (0.0-1.4); class II, 25.8 (22.2-29.4); class III, 63.9 (59.9-67.
8); class IV, 9.6 (7.2-12.0)
diabetes: intervention 44.8%; control 47.6%
Inclusion criteria:
• Individuals admitted as hospital inpatients or on observation status;
• ≥ 50 years
• receiving active treatment for decompensated HF
• expected to be discharged to their home
• capable of providing written informed consent in English, Spanish, Farsi, or
Russian
”Enrollment criteria were expanded in January 2012 to include all patients being actively
treated for HF instead of just those having a principal diagnosis of HF. This change
was made because patients deemed prospectively as not having a principal diagnosis of
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HF were being coded as patients with HF after their discharge because of patients with
multiple active problems.“
Exclusion criteria:
• transplant recipient/being evaluated/on a waiting list for a transplant
• enrolled or enrolling in hospice
• expected to expire shortly after discharge
• dementia
• being admitted from or expected to be discharged to a skilled nursing facility
(SNF)
• lack of phone line/reliable cell service
• chronic dialysis
• inability to identify a usual source of care (free clinic acceptable) and who will not
be assigned a provider upon discharge.
• Also ”patients with the following cardiovascular conditions: patients with valvular
disorders requiring surgical intervention (except for those with incidental valvular
disease, who will be included), acute myocardial infarction (except for those with
demand ischemia, who will be included); patients who are unable to use the
intervention equipment (e.g., unable to stand on the weight scale), or who are
otherwise unable to comply with the intervention
Interventions intervention: 3 components conducted by registered nurses:
• predischarge HF education by a study nurse, not part of usual care team. Used a
booklet and the ‘teach-back’ method to ensure understanding. Also included
demonstration of telemonitoring equipment and the important of monitoring
physiological variables
• regularly scheduled telephone coaching - 9 calls scheduled over 6 months, usually
the same call centre nurse. 1st contact within 2-3 days of discharge to reinforce pre-
discharge education, then weekly for the first month. After first month, calls were made
monthly until the end of the 6-month study period. Calls were designed to reinforce
predischarge education materials
• home telemonitoring of weight, blood pressure, heart rate, and symptoms. Results
monitored by call centre nurses.
Comparator: usual care
• “Usual care at the sites included robust pre-discharge education and often a post-
discharge follow-up telephone call. No additional surveillance was provided to control
patients beyond whatever may have been requested as part of routine clinical practice,
and the intervention did not substitute for usual care surveillance. Patients were not
precluded from exposure to other readmission reduction or chronic NRs implemented
by hospitals, physician groups, or health plans, such as education about HF, pharmacist
consultation, and post discharge telephone calls.”
Outcomes • All-cause mortality
• All-cause readmissions
• HRQoL (MLHFQ)
Notes Funding: “This study was supported by the Agency forHealthcare Research andQuality;
the National Heart, Lung, and Blood Institute (NHLBI); the National Center for Ad-
vancing Translational Science, Clinical and Translational Science Institute; the Robert
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Wood Johnson Foundation; the Sierra Health Foundation; the University of California
Center for Health Quality and Innovation; and by the participating institutions. The
funders had no role in the design and conduct of the study; collection,management, anal-
ysis, and interpretation of the data; preparation, review, or approval of the manuscript;
and decision to submit the manuscript for publication.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Block randomization was con-
ducted within each site using random
blocks of 4 to 8 individuals via aweb-based,
computerized, random number generator.
”
Allocation concealment (selection bias) Low risk Web-based implies centralised, and block
size was random 4-8
Blinding of participants and personnel
(performance bias)
High risk Not possible due to nature of intervention
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk States that survey interviews were con-
ducted “by staff at the coordinating center
who were unaware of the treatment ran-
domizations”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Self-reported QoL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was an unbalanced dropout rate
(15% and 26% for intervention and con-
trol, respectively, although all randomised
participants were included in primary anal-
ysis. Hazard models censored data on date
of withdrawal for people who had fully
withdrawn consent. QoL data only re-
ported for those participants who com-
pleted follow-up questionnaire (53.6% and
57.2% for intervention and control, respec-
tively).
Selective reporting (reporting bias) Low risk Outcomes match those on clinical trials.
gov, posted before trial started
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Other bias Low risk Outcomes match those on clinical trials.
gov, posted before trial started
Rainville 1999
Methods Single-centre RCT
Recruitment: July 1996-June 1997
Duration of follow-up: 12 months
Intervention category: case management
Person delivering the intervention: pharmacist
Participants Country: USA
Participants: intervention, N = 17 (8 men (47%)); control, N = 17 (9 men (53%))
Actual age of study participants: intervention mean 66.9 (SD 8.7); control mean 72.8
years (SD 10.7)
Male sex: 50%
Ethnicity: NR
Actual severity of HF in study participants at recruitment:
NYHA class, N (%):
• intervention group class II, N = 1 (6%), class III, N = 12 (71%), class IV, N = 4
(24%)
• control group class II, N = 4 (24%), class III, N = 11 (65%), class IV, N = 2 (10%)
LVEF: NR
Inclusion criteria:
• all patients with HF in their admission diagnoses and with a history of HF
• age ≥ 50 years
Exclusion criteria:
• a more significant concomitant disease (e.g. unstable angina, cardiac arrhythmia,
COPD)
• living in long-term care facility
• significant psychiatric illness
• long-term renal dialysis
• life expectancy < 3 months
• no home phone
• had a language barrier
Interventions Duration of intervention: 90 days
Intervention: ’pharmacist intervention’
During index hospitalisation:
• “Routine care plus pharmacist and clinical nurse specialist identified patient issues
which posed risk for rehospitalisation and determined corrective action.”
• before discharge the pharmacist reviewed pathology and treatment of HF, weight
monitoring and risk modifications with the participant or caregiver
• participant given information brochure, video, weight log and medication
organiser
• pharmacist also recommended medication changes to physicians
After discharge:
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• pharmacist phoned within 3 days of discharge, and at 7, 30, and 90 days and 12
months to enquire about any readmissions, respond to questions, reinforce information
given before discharge
• Pharmacist’s phone number provided to participants for further support
Comparator: usual care
• Routine care and preparation for discharge including: written prescription,
physician discharge instructions, nurse review of diet, treatment plans and medications;
participants provided with computer-generated drug information sheets
• At 30, and 90 days and 12 months pharmacist contacted participants to ask about
readmissions
Outcomes Primary endpoint:
• hospital readmission for HF or death (composite endpoint) at 1 year
Notes Data source: published data and information from author*
Funding/CoI: no information in paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated*
Allocation concealment (selection bias) Unclear risk Quote: “Information on patient randomi-
sation was concealed from the patient and
all care givers except for the pharmacists in-
volved in the study”. It is not clear who was
responsible for allocation
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information in paper
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk QoL NR
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 38 participants randomised, 2 intervention
and 1 control participant subsequently ex-
cluded as tests during initial hospitalisa-
tion showed normal LV function, long-
term dialysis was initiated, or participant
planned to move out of state after dis-
charge. 1 control participant was lost to fol-
low-up and excluded from analysis
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Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
Salehitali 2009
Methods Single-centre RCT
Recruiting: March 1997-March 1998
Duration of follow-up: 6 months
Intervention category: case management
Person delivering intervention: nurse
Participants Country: Iran
Participants: randomised N = 110 (intervention N = 55, control N = 55) analysed N =
99 (intervention N = 49; control N = 50)
Mean ± SD age: NR
Male sex (%): intervention 61.2, control 54
Ethnicity: NR
Actual severity of HF in study participants at recruitment:
NYHA class (%):
• intervention: class II, 10.2%; class III, 73.5%; class IV, 16.3%
• control: class II, 4%; class III, 82%; class IV, 14%
Inclusion criteria:
• people with congestive HF
Exclusion criteria:
• people receiving any surgical intervention
• or having any other chronic disease
Interventions Intervention: an education component and a care component:
• educational intervention:
◦ education about drugs, type and amount of activity, diet, adverse events
(complications) of disease, signs of HF, how to change behaviour and lifestyle
◦ educational needs based on checklist homecare of HF participants,
symptoms of return (relapse) of the disease, and immediately referring to the doctor in
case of signs and symptoms such as dyspnea, severe swelling, and angina pectoris
• care intervention:
◦ checking vital signs, weight check, assessing the peripheral swelling
◦ accurate assessment of the amount and timing of drugs
• mode of delivery:
◦ face-to-face education using booklet and CD
• time of delivery:
◦ interventions delivered when the participants were inpatient in hospital
◦ the interventions continued for 3 more sessions when the participants were
at home
◦ to fill the gap between the sessions, there was a phone call following up the
interventions
• timing of interventions:
◦ home care and education interventions were delivered exactly 1 month post-
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discharge, 2 months after first follow-up, and 3 months after second follow-up
Comparator: usual care
Outcomes • All-cause readmissions (average per person)
• Costs
Notes Funding: Shahrekord University of Medical Sciences
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised” with no further details
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk NR
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6/55 intervention group and 5/55 control
group dropped out, unclear why
Selective reporting (reporting bias) Unclear risk No protocol identified
Other bias Low risk Nothing identified
Shively 2013
Methods RCT, repeated measures
Recruiting: September 2006-January 2009
Follow-up: 6 months
Intervention category: other
Person delivering the intervention: nurse
Participants Country: USA, community setting
Participants: N = 43 in intervention group, N = 41 in usual-care group
Mean (SD) age: intervention: 63.4 (9.10), usual care: 68.9 (11.73); P = 0.02
Male sex N (%):intervention: 43 (100); usual care: 40 (97.6)
Ethnicity: intervention: 33 (76.6%) white; usual care: 32 (78.0%) white
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Actual severity of HF in study participants at recruitment:
NYHA class, N (%):
• intervention class I, N = 1 (2.3%), class II, N = 21 (44.2%), class III, N = 23 (53.
5%), class IV, N = 0(0%)
• control class I, N = 2 (4.9%), class II, N = 18 (48.6%), class III, N = 21 (51.2%),
class IV, N = 0 (0%)
Median EF%: NR
Inclusion criteria:
• documented clinical HF stage C
• hospitalisation or ED visit for HF treatment within previous 12 months
• aged ≥ 18 years
• resident in San Diego county
• read and speak English
• has telephone access
• has a primary care provider for routine medical care
Exclusion criteria:
• inability to provide written consent
• acute medical problems within the previous month
• considered by the investigators to be medically unstable
• enrolled in specialty HF care via the HF Program or telehealth
• long-term follow-up by cardiology after a hospital admission as well as severe
medical problems
• a life expectancy of < 1 year
• acute substance abuse or psychiatric problems
• homelessness
Interventions Median duration of intervention: 6 months
Intervention: Heart PACT program
• the intervention, given by 1 of 2 APNs, used activation theory and was tailored to
each participant’s activation level, focusing on individualised self-selected goals and
moving the participant to a higher level of activation
• goals included the importance of self management, improving confidence and
knowledge, skills and behaviour goals and plans for these under different situations
• each participant met with the intervention nurses for 6 sessions, by telephone or
in person. During these meetings, participants’ individualised health behaviour goals
were discussed, progress toward goals was reinforced, barriers were addressed, and
questions were answered
• the intervention group received a self-management toolkit (blood pressure cuff,
weight scale, pedometer, HF self-management DVD, and educational booklet) at the
first intervention visit
Comparator:
• routine medical care in primary care and specialty clinics (other than the HF
Specialty Clinic) at the study site.
• the usual-care group received the self-management toolkit after the final 6-month
assessment
Outcomes Primary outcomes were stated to be:
• activation using the Patient Activation Measure (PAM) total score
• self-management using the 3 scale scores (maintenance, management, and self-
confidence) from the Self-Care of Heart Failure Index (SCHFI) and the Medical
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Outcomes Study (MOS) Specific Adherence Scale
• hospitalizations and ED visits as reported by participants
Notes Data source: published data only
Funding/CoI: NR
Generalisability: 263 screened for eligibility, 103 (39%) were eligible, of whom 19 (18%)
declined and 84 (82%) enrolled and were randomised to Heart PACT program (N =
43) or usual care (N = 41). 77 assessed at 3 months’ follow-up, 68 at 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A stratified blocked randomisation ap-
proach based on the baseline Patient Acti-
vationMeasure (PAM) level (low, medium,
high) was used to ensure that participants
were equally distributed between groups by
activation level
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Outcome assessors were not blinded to in-
tervention allocation, hospitalisation data
reported by participants
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk No QoL data included in review
Incomplete outcome data (attrition bias)
All outcomes
Low risk Statistical analyses assessed missing data
as missing at random. Additional analyses
used a missing value analyses module using
an iterative expectation and maximisation
procedure. The additional hypothesis test-
ing analyses using imputed values for miss-
ing data are also reported in the paper. 68/
84 participants (81%) assessed at follow-
up (n NR by group)
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Unclear risk Participants in the intervention group were
younger at baseline (63 vs 69)
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Methods Single-centre RCT
Recruiting: March 1997-May 1998
Duration of follow-up: 6 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Australia
Participants: intervention, 100 participants (65men); control, 100 participants (59men)
Actual age of study participants: intervention mean 75.2 years (SD 7.1) years; control
mean 76.1 years (SD 9.3)
Male sex: 62%
Ethnicity: NR
Actual severity of HF in study participants at recruitment NYHA class, N:
• intervention group class II, N = 42, class III, N = 46, class IV, N = 12
• control group class II, N = 48, class III, N = 43, class IV, N = 9
LVEF: intervention group 37% (SD10); control group mean 37% (SD 11)
Inclusion criteria:
• Admitted to tertiary care hospital under cardiologist and at least 1previous
admission for acute HF (pulmonary congestion or oedema evident on chest X-ray with
acute dyspnoea at rest)
• NYHA class II-IV
• LVEF ≤ 55%
• age ≥ 55 years
• to be discharged home
• lives within hospital catchment area
Study exclusion criteria:
• terminal disease
• valvular disease suitable for surgery
• intended heart transplantation
• HF precipitated by extensive, reversible ischaemia
• home address outside hospital catchment area
Interventions Duration of intervention: mainly within 2 weeks of discharge but some phone contact
throughout study
Intervention: usual care plus ’Multidisciplinary, home-based intervention’
After discharge:
• comprehensive assessment at home by a cardiac nurse 7-14 days after discharge
• after home visit nurse sent report to primary care physician and cardiologist
• cardiac nurse arranged a flexible diuretic regimen for participant’s weight and
symptoms if required
• phone call by cardiac nurse to participant contact at 3 and 6 months
• participants encouraged to contact the nurse if any problems arose
• home visits repeated if a participant had ≥ 2 unplanned readmissions within 6
months of index admission
Home visit included:
• assessment of clinical status, physical activity, adherence to medication,
understanding of disease, psychosocial support and use of community resources
• followed by (as appropriate):
◦ ”remedial counselling“ to participants and their families
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◦ strategies to improve adherence
◦ simple exercise regimen
◦ incremental monitoring by family/carers
◦ urgent referral to 10 care physicians
• median duration of visit 2 h (range 1-3.5 h)
Comparison Group: usual care
• all study participants could be referred to cardiac rehab nurse, dietician, social
worker, pharmacist and community nurse as appropriate
• all participants had appointment with their primary care physician and/or
cardiology outpatient service within 2 weeks of discharge.
• regular outpatient review by the cardiologist was undertaken throughout the
follow-up period
Outcomes Primary endpoint (during 6 months follow-up):
• frequency of unplanned readmissions
• all-cause out-of-hospital deaths (i.e. composite endpoint)
Other endpoints (6 months):
• time to first primary endpoint (event-free survival)
• frequency of unplanned readmissions
• days of unplanned readmissions
• all-cause deaths
• out-of-hospital deaths
• cost of hospital and community-based health care (sample of participants only).
• Random sample of participants only: MLHFQ and Australian version of SF-36 at
baseline, 3 and 6 months
Notes Data source: published data only
Funding: NR. CoI: Simon Stewart is a recipient of a National Heart Foundation of
Australia Postgraduate Medical Research Scholarship
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Telephone call to an investigator
who was unaware of the patient’s demo-
graphic and clinical profile, who then allo-
cated the individual [to group] via a com-
puter generated protocol.“
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”all data collection and analysis was
done with masking maintained.“
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Analyses stated to be ITT, but for QoL,
quote: ”Equal numbers of patients from
the intervention and usual-care groups
were randomly selected for assessment of
changes in health-related quality of life“
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Unclear risk Quote: ”The twogroupswerewellmatched
for all but number of admissions for acute
heart failure and creatinine concentration
at hospital discharge.”
Stromberg 2003
Methods Multicentre RCT (3 centres)
Recruitment: June 1997-December 1999
Follow-up: 12 months
Intervention category: clinic
Person delivering the intervention: specialist nurse
Participants Country: Sweden
Number randomised: 106 ( intervention N = 52; control N = 54)
NYHA:
• intervention: class I, N = 0 (0%); class II, N = 7 (13%); class III, N = 39 (75%);
class IV, N = 6 (12%)
• control: class I, N = 0 (0%); class II, N = 12 (22%); class III, N = 36 (67%); class
IV, N = 6 (11%)
LVEF: NR
Age: intervention: 77 (SD 7); control: 78 (SD 6)
Percentage male: intervention: 33/52 (63%); control: 32/54 (59%)
Ethnicity: NR
Inclusion criteria:
• diagnosed HF, either by echocardiography, radiographic evidence of pulmonary
congestion or typical symptoms and signs of HF
• all participants had been hospitalised for HF
Exclusion criteria:
• severe chronic pulmonary disease
• dementia or other psychiatric illness
• short anticipated survival
• discharge to a geriatric clinic or home care
• already receiving follow-up at the nurse-led HF clinic
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Interventions Duration of intervention: not clear
Intervention: nurse-led HF clinic
• 1st visit 2-3 weeks after discharge, nurses evaluated status, assessed treatment and
provided education about HF and social support
• individualised education included both written and verbal information, and was
based on guidelines. It included information on HF, treatment, dietary advice,
individually adjusted energy intake advice, lifestyle advice (including exercise), and
promoted self-management
• nurses contactable by phone during office hours, Monday-Friday, and nurses
called participants to provide psychosocial support and evaluate drug changes required
• HF nurses called participants in order to provide psychosocial support, evaluate
drug changes or other actions
• extra appointments to attend HF clinic scheduled for participants unstable with
symptoms of worsening HF or if further education was needed
• participants referred back to primary health care once they were stable and well
informed
Comparator:
• conventional follow-up in primary health care.
• some participants got a scheduled visit after discharge, but most were encouraged
to phone primary health care if they had problems due to HF
Outcomes Primary:
• all-cause mortality or all-cause hospital admission after 12 months
Secondary (12 months):
• mortality due to CV disease or other
• number of readmissions for any reason
• number of days in hospital
• self-care behaviour
Notes Data source: published data only
Funding: Health Research Council in the South-East of Sweden, The Swedish Founda-
tion for Healthcare Science and Allergy Research, The Swedish Heart and Lung Foun-
dation and the Research Foundation of the University Hospital of Linkoping, Sweden
No CoI information given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was blinded with the
use of a computer-generated list of random
numbers and sealed envelopes
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
High risk Not possible
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Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “The assessment andoutcomemea-
sures were blinded. The nurse doing the as-
sessment and collecting of data was blinded
to the intervention and not involved in the
care of the patients.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk QoL NR
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants appear to be accounted for,
but study authors note that, quote: “The
number of readmissions was significantly
lower in the intervention group after 3, but
not after 12 months. The almost 3 times
higher mortality in the control group may
have influenced this and we therefore recal-
culated morbidity data to admissions dur-
ing time of survival.”
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Unclear risk Quote: “There were significantly more pa-
tients with hypertension in the interven-
tion group, 26 vs 16 (p<0.05). There were
more patients with diabetes in the control
group, 17 vs eight (p=0.05).”
Thompson 2005
Methods Multicentre, cluster-RCT (2 centres)
Recruitment: 20 months, dates NR
Follow-up: 6 months
Intervention category: clinic
Person delivering the intervention: specialist nurse
Participants Country: UK
Number randomised: 106 (intervention N = 58; control N = 48)
NYHA:
• intervention: class I-II, N = 14 (24%); class III-IV, N = 44 (76%)
• control: class I-II, N = 13 (27%); class III-IV; N = 35 (73%)
LVEF: intervention: 31 (SD 8); control: 29 (SD 11)
Age: intervention: 73 (SD 14); control: 72 (SD 12)
Percentage male: intervention: 72; control: 73
Ethnicity: NR
Inclusion criteria:
• acute admission to hospital with a diagnosis of HF
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• objective evidence (e.g. echocardiography or coronary angiography) of impaired
LVSF as evidenced by a LVEF of at least 45% immediately prior to study recruitment
• discharged to home
Exclusion criteria:
• awaiting an elective cardiac procedure with the intent to reverse the cause of
underlying HF (e.g. coronary artery bypass surgery for coronary artery stenosis)
• terminal illness other than HF
Interventions Duration of intervention: 6 months
Intervention: ”clinic plus home-based intervention“
• appointment with specialist nurse prior to discharge, to receive information on
HF and medications
• office-hours contact number for nurse specialist
• home visit with 10 days of hospital discharge, for education on symptom
management and lifestyle, and clinical examination
• monthly nurse-led outpatient HF clinic for 6 months post-discharge, including
education, clinical examination and indices monitoring, and starting of new
therapeutic drugs where appropriate
Control group: usual care
• explanation of condition
• prescribed medications by the ward nurse
• referral to appropriate post-discharge support as required).
• participants given an outpatient department appointment 6-8 weeks post
discharge
Outcomes Primary:
• event-free survival from either death or recurrent hospitalisation for any reason
during the 6-month follow-up
Secondary (6 months):
• rate of recurrent hospital stay
• treatment adherence (NR here)
• health-related quality of life
Notes Data source: published data only
Funding: ”SS is supported by the National Heart Foundation and theNational Health
andMedical Research Council of Australia. This study was supported by a research grant
from MerckPharmaceuticals UK.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”a random number allocation was
used to allocate equal numbers of small and
large clinics to either post dischargeHBI+C
or UC.”
Allocation concealment (selection bias) Unclear risk No information in paper
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Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Data on recurrent hospital stay
and/or death were also collated (in a
blinded manner) via the local area hospital
record system and death registry.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for in primary
outcome analysis.High risk of attrition bias
for QoL as only 46/106 (overall) partici-
pants completed a questionnaire at base-
line, and 41 completed it at 6 months
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Quote: “Data on recurrent hospital stay
and/or death were also collated (in a
blinded manner) via the local area hospital
record system and death registry.”
Tsuchihashi-Makaya 2013
Methods Multicentre RCT (3 centres)
Recruiting: participants were enrolled fromDecember 2007-March 2010 at 3 cardiology
hospitals
Follow-up: 12 months
Intervention category: case management
Person delivering the intervention: specialist nurse
Participants Country: Japan
Participants: N = 161 (intervention, N = 79; usual care, N = 82)
Mean ± SD age: intervention, 76.9 ± 10.9; usual care, 75.8 ± 12.1
Male sex N (%): intervention, 42 (53.2); usual care, 49 (59.8)
Ethnicity: NR, assumed to be predominantly Japanese
Actual severity of HF in study participants at recruitment, NYHA class, N (%):
• intervention: class I, N = 8 (10.1%); class II, N = 67 (84.8%); class III, N = 4 (5.
1%); class IV, N = 0
• control: class I, N = 14 (17.1%); class II, N = 63 (76.8%); class III, N = 5 (6.1%);
class IV, N = 0
Median EF%: NR
Inclusion criteria:
• hospital admission for HF with symptoms and signs of HF
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• pre-existing history of chronic HF, NYHA II-IV
• ≥ 18 years of age
Exclusion criteria:
• end-stage HF, defined as requiring mechanical support or continuous i/v
inotropic support
• a serious life-threatening illness with a life-expectancy of < 6 months
• stroke within the last 3 months
• cognitive dysfunction
• substance abuse or psychotic disorder
• participants whose physician or nurses refused access
Interventions Median duration of intervention: 2 months of home visits, 6 months of phone calls
• all enrolled participants received comprehensive discharge education by
cardiologist, nurse, dietitian, and pharmacist using a booklet that provided information
on pathophysiology, medical treatment, diet, physical activity, lifestyle modification,
self-measurement of body weight, self-monitoring of worsening HF, and emergency
contact methods.
Intervention: home-based disease management programme
• a home visit was made within 14 days after discharge from hospital
• nurses visited each participant’s home to assess how the participant was coping in
the home environment, HF status, general health status, adherence to medication,
lifestyle modification, daily activity, and social support needs
• home visits were made once every 2 weeks until 2 months after discharge
• telephone follow-up by nurses in addition to routine follow-up by cardiologists
• at the conclusion of home visiting, nurses conducted monthly telephone follow-
up until 6 months after discharge
• nurses monitored HF symptoms, participant’s general health status, and
requirement for other health and social support
• nurses consulted a multidisciplinary team (cardiologist, dietitian, pharmacist, and
social worker) during the intervention period to optimise the advice given to each
participant
Comparator: usual care
• comprehensive discharge education as detail above
• after hospital discharge, participants assigned to the usual-care group continued to
receive routine management by the cardiologist.
• no extra follow-up by a HF nurse or multidisciplinary team was provided
Outcomes Primary outcome:
• participant’s psychological status, including depression and anxiety assessed by
HADS
secondary outcomes:
• QOL (Short Form-8)
• all-cause death
• hospitalisation for HF (analysed as time to first event; defined as an unplanned
overnight stay in a hospital because of progression in HF symptoms or directly related
to HF)
Notes Data source: published data only
Funding: ”This work is supported by the grants from the Japanese Ministry of Health,
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Labour and Welfare, the Japan Heart Foundation, and Pfizer Health Research Founda-
tion.“
CoI: Hiroyuki Tsutsui has received research support from Novartis and honoraria for
lectures from Shionogi, Daiichi Sankyo, Tanabe-Mitsubishi, Novartis, MSD, Pfizer, and
Takeda.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized on a 1:1 basis, no further de-
tails given
Allocation concealment (selection bias) Unclear risk No information given
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Quote: “Prognostic data were reported
based on medical records or follow-up by
telephone.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 79/84 (94%) intervention group analysed,
82/84 (97.6%) control group analysed.
The analysis of primary and secondary end-
points was prespecified to be performed
in the per-protocol population, which in-
cluded all participants who received usual
care or home-based intervention, i.e. was
not ITT
Selective reporting (reporting bias) High risk NCT 01284400 outcomes registered in
January 2011, after enrollment ended and
2 months before final data collection.
Published protocol (Tsuchihashi-Makaya
2011) states that the secondary endpoint
is the time to the first event (all-cause
death, cardiac death, sudden cardiac death,
or hospitalization for HF). However,
Tsuchihashi-Makaya 2013 reports time to
first event for all-cause death and hospital-
isation (i.e. no mention of cardiac death)
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Other bias Unclear risk Hospitals were selected on the basis of their
organisational capability and enthusiasm
for participating in the study. The interven-
tionuses a booklet for the education section
and a checklist for follow-up, which could
minimise bias if delivered consistently
Tsuyuki 2004
Methods Multicentre, 2-stage RCT (only 2nd stage randomised)
Recruitment dates: September 1999-April 2000
Follow-up: 6 months
Intervention category: case management
Person delivering the intervention: other
Participants Country: Canada
Number randomised: 276 (intervention N = 140; usual care N = 136)
NYHA (%):
• intervention: class I, 12%; class II, 48%; class III, 35%; class IV, 5%
• control: class I, 14%; class II, 52%); class III, 30%; class IV, 3%
Age: intervention: 71 (SD 12); control: 72 (SD 12)
Percentage male: intervention: 58; control: 58
Ethnicity: NR
Inclusion criteria:
• consecutive patients aged > 18 years, admitted to a hospital with a most
responsible, primary, secondary, or complicating diagnosis of HF
Exclusion criteria:
• known secondary causes of HF (i.e. correctable causes as anaemia or
hyperthyroidism)
• preserved systolic function
• were taking an angiotensin-II antagonist because of known intolerance or
contraindication to ACE inhibitors
• had a terminal illness with a life expectancy < 6 months
• cognitive impairment
• were unable to communicate because of language barriers
• were attending a specialised HF clinic for medical management
• were participating in a HF clinical trial
• absolute contraindication to ACE inhibitors
• participants residing outside the region of the participating hospital
• those discharged to a setting where patients were not responsible for own
medication administration
Interventions Duration of intervention: 6 months
Intervention: patient support program
• 5 key areas: salt and fluid restriction, daily weighing, exercise alternating with rest
periods, proper medication use, and early recognition of worsening symptoms
• 1-1 education with research co-ordinator prior to discharge using written
educational package covering information on HF (definition, causes, symptoms),
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nondrug treatment, medication information (with special emphasis on proven benefits
of therapies), and self-monitoring
• adherence aids provided prior to discharge (medication organiser, medication
administration schedule, and daily weight log)
• participants encouraged to contact co-ordinator for ongoing community support
• community follow-up to reinforce education and adherence: telephone contact by
the local research co-ordinator at 2 weeks, 4 weeks,and monthly thereafter for up to 6
months post discharge (i.e. 7 calls)
• monthly newsletter “Living with Congestive HF”, featuring articles on 5 key
components, participant success stories, salt content of foods, low-salt recipes, and
compliance tips
• research co-ordinator could also recommend that participant consult physician
for ACE inhibitor dosage titration as appropriate, or if a problem arose which required
further investigation
Usual care:
• participants received a general heart disease pamphlet before discharge, but no
formal counselling beyond routine hospital procedure
• monthly telephone contact to check for clinical events
Outcomes Primary (6 months):
• medication adherence, as measured by pharmacy records
Secondary (6 months):
• clinical events
Notes Data source: published data only
Funding/CoI: ”Dr Johnson is a Population Health Investigator with Alberta Heritage
Foundation forMedical Research and holds a Canada Research Chair in Diabetes Health
Outcomes. Funded by an unrestricted educational grant from Parke Davis Canada (now
Pfizer Canada) and the University of Alberta Hospital Foundation.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomization was conducted
by a computer-generated sequence using
block randomisation (block size of 4), strat-
ified by study site (hospital).”
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Quote: “Clinical events, the secondary out-
come, were recorded by patient report and
through examination of hospital records.”
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk QoL NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All analyses were by intention to
treat”
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Noother apparent sources of bias, although
monthly follow-up calls to usual-care group
could have provided more contact than
would otherwise be expected
Wierzchowiecki 2006
Methods Single-centre RCT
Recruiting: dates NR
Follow-up: 12 months
Intervention category: multidisciplinary
Person delivering the intervention: multidisciplinary
Participants Country: Poland; setting: secondary care
Participants: N = 160 (intervention, 80 (50%); usual care, 80 (50%))
Mean ± SD age: intervention, 67.3 ± 10.2; usual care, 69.5 ± 10.7
Male sex: 48 (60%) in intervention group, 47 (59%) in control group
Ethnicity: NR
Actual severity of HF in study participants at recruitment NYHA class, N (%):
• intervention group class I, N = 0; class II, N = 13 (16%); class III, N = 35 (44%);
class IV, N = 32(40%)
• control group class I, N = 0; class II, N = 10 (12.5%); class III, N = 40 (50%);
class IV, N = 30 (37.5%)
Median EF%: NR
Inclusion criteria:
• hospitalised patients with HF
• established diagnosis
• on optimal medical treatment
Exclusion criteria: NR
Interventions Duration of intervention: 12 months
Multidisciplinary care:
• follow-up 1:1 visits of 30-40 min duration at the HF Clinic (HFC) 14 days and
1, 3, 6, and 12 months post-discharge included consultation with cardiologist, HF
nurse, physiotherapist and psychologist. Participants with advanced HF who were
unable to come to the clinic were visited at home by HF nurse, visits lasting about 1 h.
• between visits to the clinic, participants were under the care of their primary care
physicians. Participants and their GPs could access telephone counselling by HF nurse
and cardiologist during working hours
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• cardiologist determined underlying disease, reasons for any deterioration,
prognostic evaluation and assessment of current treatment, qualifying patients for
exercise rehabilitation and psychological referrals
• HF nurse informed participant about multidisciplinary care programme, disease,
symptoms, medication side effects and triggers for contact with clinic or emergency
care. HF nurse checked adherence to the drug regimen and gave advice about salt,
fluids and alcohol intake, sexual activity, necessity of vaccinations, capabilities of a
participant to travel or work, etc. He/she also familiarised participant with techniques
for blood pressure/BMI measurement etc. and mentioned potential of self-adjustment
in drug titration, i.e. furosemide (after telephone call)
• participants received a diary in which to record measurement data and an
educational booklet on HF
• participants received education sessions in the form of a lecture from hospital
physicians and HF clinic cardiologists, regarding the nature, aetiology, diagnosis and
therapy of HF
• physiotherapist, along with cardiologist, set up and monitored the exercise
rehabilitation programme
• psychologist presented advice on “how to cope with disease” and performed
psychotherapy in participants in whom a high level of trait anxiety was observed
(depressive syndrome) by cardiologists.
Comparator: usual care
• participants were cared for by their primary care physicians only
• did not participate in any educational or therapeutic activities
Outcomes Primary: NR
Outcomes:
• mortality
• rate of rehospitalisation
• QoL (MLHFQ) and self-care (the European Heart Failure Self-Care Behaviour
Scale)
Notes Funding: “This Programmewas in part financially supported by the Pozna Department
of Health and Welfare.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information in paper
Allocation concealment (selection bias) Unclear risk No information in paper
Blinding of participants and personnel
(performance bias)
High risk Not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Low completion rate for QoL question-
naire that was unbalanced between treat-
ment groups (56/80 (70%) in intervention
group, 35/80 (43.8%) in usual-care group)
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Unclear risk No other issues identified
Yu 2015a
Methods Single-centre RCT
Recruiting: October 2008-January 2010
Duration of follow-up: 9 months
Intervention category: case management
Person delivering intervention: specialist nurse
Participants Country: Hong Kong, China
Participants: randomised N = 178 (intervention N = 90; control N = 88)
Mean ± SD age: intervention 78.6 (7.1); control 78.7 (6.7)
Male sex N (%): intervention 59 (53.3); control 32 (36.4)
Ethnicity: 100% Chinese
Actual severity of HF in study participants at recruitment NYHA class, N (%):
• intervention: class II, N = 53 (58.9%); class III, N = 34 (37.8%); class IV, N = 3
(3.3%);
• control: class II, N = 50 (56.8%); class III, N = 36 (40.9%); class IV, N = 2 (2.3%)
LVEF, mean (SD) %: intervention 41.1 (16.1); control 39.0 (14.3)
Diabetes, N (%): intervention 36 (40.0%); control 43 (48.9%)
Inclusion criteria:
• aged ≥ 60 years
• diagnosed with HF according to the Framingham criteria
• Chinese
• able to communicate
• accessible by telephone at home
• cognitively intact, as indicated by an Abbreviated Mental Test score (Hong Kong
version) of 6 or more out of 10
Exclusion criteria:
• discharged to long-term care settings
• scheduled for cardiac surgery
Interventions Intervention: cardiac nurse implemented transitional care model, with:
• predischarge visit to assess health status, cultural beliefs, practices of self-care, and
post-discharge needs
• 2 weekly home visits to assess HF status and self-care implementation at home.
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Customised educational and supportive interventions;
• personal self-care goals and action plan to enable effective self-care.
• identification of appropriate community care services (including self-help groups,
social activities)
• phone call 1 week after 2nd home visit, then every 2 weeks for 3 months and then
every 2 months for 6 months. Call was to review self-care goal attainment, identify
barriers, give relevant advice, and modify action plan accordingly. Cardiac nurse
monitored symptom severity and provided prompt advice on self-care decision-making
(including when to seek medical consultation).
• further home visits offered to participants who had unfulfilled self-care and post-
discharge needs
• participants had telephone access to cardiac nurse during office hours
Comparator: usual care
• pharmacy dispensers gave brief instructions when participants collected
prescribed medications on hospital discharge.
• a regular medical consultation at the specialist clinic was arranged for 4 to 6 weeks
after discharge.
• no structured educational or supportive postdischarge care was offered
Outcomes • All-cause mortality
• All-cause readmissions
• HRQoL (MLHFQ)
Notes Funding: Hong Kong Jockey Club Charities Trust. No CoI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted block randomisation (block size
= 4, allocation ratio = 1:1), using a com-
puter-generated random number sequence
Allocation concealment (selection bias) Unclear risk Computer-generated, but known block
size could mean last in block can be pre-
dicted
Blinding of participants and personnel
(performance bias)
High risk Blinding not possible
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Another research nurse, who had
no information about subjects’ group sta-
tus, conducted face-to-face interviews at
participants’ homes to collect post-test
data...”
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk QoL self-reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Unbalanced dropout (24%usual care, 12%
intervention), particular impact onQoLas-
sessment.
Main analyses followed ITT principle. For
the survival analysis, people lost to follow-
up were censored, with no readmission or
mortality in the remaining period. Because
of an imbalance in dropout rates, 2 sensi-
tivity analyses were conducted: 1) per-pro-
tocol (only those who completed interven-
tion and outcome evaluation); 2) worst case
scenario analysis - those lost to follow-up
assumed to have died or had readmission
Selective reporting (reporting bias) Unclear risk No protocol found
Other bias Low risk Nothing identified
ACEI: angiotensin converting enzyme inhibitor; AP(R)N: Advanced Practice (Registered) Nurse; BDI: Beck Depression Inventory;
BMI: body mass index; CABG: coronary artery bypass graft; CAS: Control Attitude Scale; CoI: conflicts of interest; COPD:
chronic obstructive pulmonary disease; CV: cardiovascular; DM: diabetes mellitus; DMP: disease management programme; ECG:
electrocardiogram; ED: Emergency Department; EF: ejection fraction; EHFscBS: European Heart Failure Self-Care Behaviour
Scale; ESC: European Society of Cardiology; GP: general practitioner; HADS: Hospital Anxiety and Depression Scale; HF: heart
failure;HRQL: health related quality of life; i/v: intravenous; IQR: interquartile range; ITT: intention-to-treat; KCCQ:Kansas City
Cardiomyopathy Questionnaire; LOS: length of stay; LV: left ventricle;LVEF: left ventricular ejection fraction; LVSF: left ventricular
systolic function;MI:myocardial infarction;MLHFQ:Minnesota Living withHeart Failure questionnaire;NIH:National Institutes
of Health;NIHR:National Institute forHealth Research;NINR:National Institute of Nursing Research;NR: not reported;MMSE:
Mini-Mental State Examination; NYHA: New York Heat Association functional class; PAM: patient activation measure; PVD:
peripheral vascular disease; Q: questionnaire; QoL: quality of life; RCT: randomised controlled trial; Rx: therapy; SD: standard
deviation; Tx: transplantation
*information obtained from personal communication with study author
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACTRN12609000442202 Terminated, no results
ACTRN12616000099426 Purely educational intervention
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ACTRN12616001627448 Wrong patient population
ACTRN12617001143314 Wrong intervention
Adair 2012 Wrong intervention
Agvall 2013 Hospital admission for HF not an inclusion criterion
Aiken 2006 Not HF disease-specific - participants had HF or COPD (palliative care programme)
Akosah 2002 Non-randomised study
Akosah 2004 Non-randomised study
Al-Mobammad 2015 Wrong study design
Andryukhin 2010 Hospital admission for HF not an inclusion criterion
Angermann 2012 Focus on structured phone-based intervention
Anonymous 2016 Follow-up too short
Artinian 2003 Non-randomised study
Ashton 2014 Wrong study design
Austin 2007 Described as cardiac rehab. Hospital admission for HF not an inclusion criterion
Azad 2008 Hospital admission for HF not an inclusion criterion
Azevedo 2002 Non-randomised study
Balaban 2017 Wrong intervention
Baptiste 2016 Wrong study design
Barth 2001 Very small RCT, limited data presented, statistical analyses appear incorrect
Basoor 2011 Wrong intervention
Bekelman 2014 Wrong comparator
Bekelman 2018 Wrong patient group (hospital admission not an inclusion criterion)
Bell 2016 Wrong follow-up
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Benatar 2003 RCT both arms received an intervention
Blaha 2000 Paper discusses methodology of the intervention and is not a study or trial
Bocchi 2004 This reference was identified in an earlier version of this review. We screened the Abstract in this latest
update, and found that it did not meet the inclusion criteria, since it is a review of HF clinics in Brazil
Bocchi 2008 Hospital admission for HF not an inclusion criterion
Bondmass 2007 Secondary analysis of data from a previously excluded study
Boutwell 2014 Wrong study design
Bouvy 2003 Hospital admission for HF not an inclusion criterion
Brannstrom 2013 Wrong intervention
Brannstrom 2014 Wrong intervention
Bucci 2003 Hospital admission for HF not an inclusion criterion, and intervention is HF clinic with pharmacy
intervention for some
Byrnes 2012 Hospital admission for HF not an inclusion criterion
Capomolla 2004 Wrong intervention
Chen 2017 Wrong study design
Cleland 2005 Pure telemonitoring intervention
Comin-Colet 2016 Wrong intervention
Cordisco 1999 Non-randomised study
Costantini 2001 Mixed before and after and parallel-group study
de la Porte 2007 Hospital admission for HF not an inclusion criterion
de Lusignan 1999 Hospital admission for HF not an inclusion criterion
Deek 2016 Wrong intervention
Deek 2017 Wrong intervention
Delaney 2013 < 6 months’ follow-up
Dewalt 2006 Hospital admission for HF not an inclusion criterion
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DeWalt 2012 Control arm received a self-management education session, and hospital admission for HF not an
inclusion criterion
Dickson 2015 Wrong follow-up
Discher 2003 Non- randomised study
Dracup 2012 Wrong intervention
Dracup 2014 Primarily educational focus
Duffy 2005 Description of development of telephone mediated intervention - no evaluative data
Ekman 1998 < 6 months’ follow-up
ElGuindy 2013 Wrong intervention
Evans 1993 “Generic intervention” (i.e. not exclusively designed for, or directed at, peoples with CHF)
Fabbri 2007 Not an RCT. This refers to theDIAL study but is an opinion article on the need for disease management
programs in Italy
Farag 1967 Non-randomised study
Feldman 2004 Hospital admission for HF not an inclusion criterion. Nurse-based CRT
Fermann 2017 Wrong participants
Fitzgerald 1994 ’Generic’ intervention
Flynn 2005 Not an RCT
Foley 2008 Comment on an included study
Fonarow 2004 Editorial
Freund 2011 Wrong patient population
Galbreath 2004 Hospital admission for HF not an inclusion criterion
Gattis 1999 Hospital admission for HF not an inclusion criterion
GESICA 2005 Phone-based
Goldberg 2003 Purely telemonitoring intervention
Goodyer 1995 Hospital admission for HF not an inclusion criterion
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Grancelli 2003 Hospital admission for HF not an inclusion criterion
Gregory 2006 Cost data fromKimmelstiel 2004, but only reported in relation to 90-day data so not meeting 6-month
minimum follow-up inclusion criterion for this review
Grustam 2015 Wrong intervention
Guder 2015 Wrong study design
Hanchett 1967 Hospital admission for HF not an inclusion criterion
Hancock 2012 Hospital admission for HF not an inclusion criterion
Hansen 1992 ’Generic’ intervention
Harrison 2002 < 6 months’ follow-up
Harter 2016 Wrong participants (confirmed by email with author 16 April 2018)
Haruka 2014 Wrong participants
Heidenreich 1999 Non-randomised study
Heisler 2013 Control cipantss recieved more than usual care
Howlett 2011 Wrong participants
Huffman 2011 Not predominantly people with HF
Huffman 2014 Wrong intervention
Hughes 2000 ’Generic’ intervention
Hui-Ling 2014 Wrong participants
Inglis 2006 Long-term follow-up of 2 Stewart RCTs, only 1 of which was included in this review. Combined data
from the 2 studies presented, so not possible to separate out data from the included and excluded studies
Iraurgui 2007 Primarily educational intervention
ISRCTN18285541 Trial was abandoned for recruitment problems
ISRCTN71548370 Follow-up too short (1 month)
Jaarsma 2003 Methodology paper, no outcome data
Jain 2005 Not an RCT
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Jerant 2001 Small RCT with 3 arms: 13 participants receiving home telecare; 12 participants received telephone
care; 12 received usual care. An interesting paper but excluded form this review because the presentation
and analyses of these data do not allow either of the 2 interventions to be compared with the control
treatment
Johnson 2000 ’Generic’ intervention
Kakutani 2014 Wrong follow-up
Kalter-Leibovici 2017 Wrong participants (email clarification with study author (1May 2018) confirmed that data on hospital
admission were not collected)
Karhula 2015 Wrong participants
Kato 2013 Purely educational intervention
Khunti 2007 Not all participants had a previous hospital admission for HF
Laramee 2003 < 6 months’ follow-up
Ledwidge 2003 Cost study of participants in the excluded study by McDonald 2002
Liljeroos 2017 Wrong participants
Lin 2001 Non-randomised study
Linden 2005 Non-randomised study
Luttik 2009 Comparator not usual care
Luttik 2014 Wrong intervention
Martensson 2005 Hospital admission for HF not an inclusion criterion
Martín-Lesende 2013 Wrong intervention
Matassini 2016 Wrong study design
McClintock 2014 Wrong study design
McCoy 2007 Non-randomised study
McDonald 2002 < 6 months’ follow-up
Melin 2014 Wrong follow-up
Menon 2015 Wrong intervention
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Moser 2000 Conference poster, no full publication identified at 2012 update. Conference abstract no longer available
online, unable to contact study author by email (10 September 2018)
Murray 2007 Hospital admission for HF not an inclusion criterion
Nahlen 2016 Wrong intervention
Naylor 1994 “Generic”’ intervention
Naylor 1999 “Generic”’ intervention
NCT00202150 Intervention not HF-specific
NCT00300261 Intervention is focussed on telemonitoring
NCT01014884 Intervention not HF-specific
NCT01141907 Intervention is focussed on telemonitoring
NCT01342276 Wrong intervention
NCT01698242 Active control
NCT01820780 Intervention is focussed on medication management
NCT01878630 Intervention is focussed on telecare
NCT01886534 Follow-up too short (3 months)
NCT02110433 Intervention is focussed on telemedicine
NCT02425488 Intervention is educational in focus
NCT03035474 Active control
NCT03220204 Not H- specific
NCT03246035 Follow-up too short (90 days)
NCT03317951 Intervention is focussed on telemonitoring
Nguyen 2007 Hospital admission for HF not an inclusion criterion
O’Riordan 2014 Wrong intervention
Ojeda 2005 Non-randomised study. Contacted study author for clarification, who clarified that this is a non-
randomised follow-up of subgroup of participants from the PRICE RCT by Atienza 2004
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Oldland 2014 Wrong study design
Oliveira 2017 Wrong follow-up
Otsu 2011 Hospital admission for HF not an inclusion criterion
Palmer 2003 Narrative review
Panella 2005 Not an RCT of the appropriate intervention
Pascual 2011 Generic intervention
Patel 2008 Hospital admission for HF not an inclusion criterion
Pedone 2015 Wrong intervention
Peters-Klimm 2007 Hospital admission for HF not an inclusion criterion
Philbin 2000 Wrong intervention - a quality improvement programme targetted at hospital level
Piamjariyakul 2015 Wrong participants
Powell 2010 No usual-care comparison group
Hospital admission for HF not an inclusion criterion
Powers 2014 Wrong follow-up
Quinn 2006 Non-randomised study
Ramachandran 2008 Hospital admission for HF not an inclusion criterion. Contact with study author indicated some may
have only been clinic outpatients
Rao 2007 Hospital admission for HF not an inclusion criterion
RBR-9c3ssc Follow-up too short (90 days)
Reed 2017 Wrong study design
Reeder 2014 Wrong study design
Rich 1993 < 6 months’ follow-up
Rich 1995 < 6 months’ follow-up
Riegel 2000 Non-randomised study
Riegel 2002 Purely telemonitoring intervention
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Riegel 2016 Wrong comparator
Rodriguez-Gazquez 2012 Hospitalisation for HF not an inclusion criterion
Rondinini 2008 Non-randomised study
Rosen 2017 Wrong study design
Rubens 2014 Wrong study design
Rubin 1992 ’Generic’ intervention
Sanchez 2015 Wrong study design
Santos 2014 Wrong comparator
Scalvini 2016 Wrong intervention
Schneider 1993 Non-randomised study
Schou 2014 Wrong participants
Serxner 1998 Purely educational intervention
Sezgin 2017 Wrong participants
Shepherd 2015 Wrong intervention
Shively 2005 Hospital admission for HF not an inclusion criterion
Sisk 2006 Hospital admission for HF not an inclusion criterion
Smeulders 2006 Hospital admission for HF not an inclusion criterion
Smeulders 2010 Not all participants previously hospitalised for HF
Smith 2005 Hospital admission for HF not an inclusion criterion
Smith 2014 Wrong comparator
Srisuk 2017 Wrong intervention
Stamp 2016 Wrong intervention
Stewart 1998a ’Generic’ intervention
Stewart 1998b Subgroup from a ’generic’ study
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(Continued)
Stewart 1999b Subgroup from a ’generic’ study
Stewart 2002 Follow-up data at 4.2 years combining data from included study (Stewart 1999a), and excluded study
(Stewart 1998a). Data on included study not presented separately
Stewart 2012 Active control arm, not usual care
Stewart 2014 Wrong comparator
TEC4 2016 Wrong intervention
Thompson 2014 Wrong study design
Tibaldi 2009 Active control arm, not usual care
Topp 1998 Non-randomised study
Townsend 1988 ’Generic’ intervention
Trochu 2003 Not an RCT
Umeda 2014 Wrong intervention
Vaillant-Roussel 2014 Wrong intervention
Valle 2004 < 6 months’ follow-up
Van der Kluit 2014 Wrong study design
Van Lieshout 2011 Comparator not usual care
Van Rossum 1993 ’Generic’ intervention
Villanueva 2015 Wrong intervention
Vorilhon 2016 Wrong intervention
Wagenaar 2015 Wrong intervention
Warber 2011 Not people with CHF
Weinberger 1996 ’Generic’ intervention
Welsh 2013 Purely educational intervention
Williams 1994 ’Generic’ intervention
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(Continued)
Wongpiriyayothar 2008 Majority of participants had valvular heart disease; not clear if all hospitalised for HF
Woodend 2008 Purely telemonitoring
Yallop 2006 Wrong intervention
Yeshchenko 2014 Wrong intervention
Young 2016 Wrong intervention
Yu 2015b Wrong follow-up
COPD: chronic obstructive pilmonary disease; HF: heart failure; RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Anguita 2005
Methods No information
Participants No information
Interventions No information
Outcomes No information
Notes This is a paper in a Spanish-language journal. It appears to be a cost-benefit analysis of the included study Atienza
2004. We have been unable to find even an abstract to this paper so cannot confirm any characteristics
Begrambekova 2013
Methods Prospective randomisation to usual care (N = 249) and to a management programme delivered by doctors/nurse
team (N = 288)
Participants 537 participants, included in the National Heart Failure Registry
Interventions Management programme consists of structured education and follow-up (phone calls)
Outcomes Primary endpoint
• NYHA functional class dynamic
• QoL outcomes
• economic outcomes (particularly: frequency of unplanned readmissions and emergency calls)
The mean MLHFQ score at baseline was 57.79 in the active group and 56.96 in the control group. In both groups
MLHFQ score significantly decreased at 6 months −11.1; (P < 0.001) and −9,33 (P < 0.001), respectively. The
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Begrambekova 2013 (Continued)
difference between 2 groups was not statistically significant. The HF emergency visits also decreased by 24% (P < 0.
001) in active group and by 9.5% (P < 0.015) in control group
Notes Study author contacted by email 10 April 2018 but no response
Begrambekova 2016
Methods Secondary analysis of an RCT (Congestive heart failure: a multidisciplinary non-pharmacological approach for
changing in re-hospitalisation and prognosis in patients (CHANCE))
Participants 745 people with HF and depressive symptoms
Interventions Disease management programme
• structured education
• regular follow-up (phone calls)
Outcomes • Russian version of HADS
• Composite of CV mortality and HF readmission
Notes Study author contacted by email for further details of CHANCE trial 10 April 2018 but no response
Linked conference abstract (Mareev 2010) is for the CHANCE-AND trial, but also mentions the CHANCE trial.
Study author not traceable
Chung 2014
Methods RCT of 24 patient-caregiver dyads
Participants 24 people with HF and their family caregivers
Interventions Family cognitive education therapy
• CBT
• educational self-care intervention
Outcomes • Depression (Patient Health Questionnaire)
• QoL (MLHFQ) at 6 months
Notes Study author contacted by email 23 April 2018 to clarify whether majority of participants had been admitted to
hospital for HF, and whether the intervention was tailored to HF or a ’generic’ intervention. No response
Fan 2010
Methods Not clear from abstract - “divided into groups”
Participants 145 hospitalised patients with HF
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Fan 2010 (Continued)
Interventions Education for participants:
• diets
• self-management
• surveillance of HF symptoms
• explanation of drugs or devices used for HF.
Follow-up phone calls for participants in stable condition:
• phone calls every 4 weeks.
Follow-up phone calls for participants in unstable condition:
• phone calls every week.
Visits to the heart clinic to see specialists who major in HF provided treatment:
• adjustment of drug doses
• change of drugs
• health consultation for participants and their family members
Outcomes • NYHA functional class
• LVEF
• Self-monitoring indicators
• Achievement of target doses of beta-blockers
• CV event rate
Notes We assessed this Chinese-language study as potentially meeting the inclusion criteria, but we have been unable to get
a data extraction done for this review
ISRCTN13668364
Methods Cluster-RCT
Participants People with HF
Interventions Specialised nurse clinic (intervention) versus conventional HF treatment (control)
Outcomes • ECHO utilisation
• Angiotensin convertin enzyme-inhibitor use
• Readmission rates
Notes Recruitment status: completed. Enrollment started in 2000, but no results or publications identified
Mizukawa 2014
Methods Multicentre RCT (pilot study), January 2013-April 2014
Participants 59 people with HF
Interventions 3 arms:
• tele-monitoring group
◦ participants had a device to measure noninvasive blood pressure, heart rate, body weight measurements
that automatically sent data to the monitor centre
◦ nurses gave participants teleconsultation when the data were out of the optimal values
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Mizukawa 2014 (Continued)
◦ participants also received a disease management programme to gain self-management skills
• disease management programme
◦ participants write the value of blood pressure, heart rate, and body weight to monitor their conditions.
• usual-care group
◦ standard self-management education once from a nurse
◦ participants visited the physicians as usual
Outcomes • Readmission for HF
Notes Emailed only traceable study author (toshirok@hiroshima-u.ac.jp) on 1 May 2018 to ask for further details on
whether hospitalisation for HF was an inclusion criterion and whether results published in full, but no response
NCT00166049
Methods Factorial RCT
Participants HF
Interventions 3 arms:
• patient family education (intervention 1)
• family partnership intervention (intervention 2)
• usual care (control)
Outcomes Primary:
• adherence to dietary sodium and medication-taking behaviour
• physical status
• psychological status
• HRQoL
Secondary:
• health resource utilisation
• autonomy support
• perceived family criticism
• knowledge
Notes Recruitment status: completed. Study completion date: May 2011. No results found
NCT00182182
Methods Cluster -RCT
Participants HF
Interventions Primary case-based disease management strategy
Outcomes Primary:
• process-of-care composite score,
• ACEI-inhibitor use
180Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00182182 (Continued)
Secondary:
• disease-specific QoL,
• NYHA functional class
• all-cause hospitalisation
• HF hospitalisation
• ED visits for HF
• referral to HF clinic
• quality-adjusted survival
• overall costs
Notes Recruitment status: unknown. Study completion date was October 2006. No results found and comparator unclear
NCT01378247
Methods RCT
Participants Adults with HF
Interventions Family-focused nursing vs treatment as usual
Outcomes Primary:
• HRQoL
Secondary:
• change in European Heart Failure Self-Care Behavior Scale
• change in Family Functioning, Health and Social Support Scale
• change in Self-Efficacy for Managing Chronic Disease 6-item scale
• change in Major Depression Inventory diagnostic scale
• re-admissions
• HF re-admissions
• mortality
Notes Recruitment status: completed. Study completion date: January 2017. No results published/posted
NCT01461681
Methods RCT
Participants Adults with HF
Interventions Symptom management service for HF versus usual cardiology care
Outcomes Primary:
• change in depression assessed at baseline, 3 months and 6 months
Secondary outcomes: NR
Notes Recruitment status: completed. Study completion date: December 2013. No results published/posted
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NCT02112227 PACT-HF
Methods Cluster-RCT
Participants Adults and children (≥ 16 years) with HF
Interventions Discharge planning services versus standard care
Outcomes Primary:
• time to composite of all-cause readmissions
• emergency department visits
• death at 30 days and 3 months
Secondary:
• preparedness for discharge
• QoL on admission, at 6 weeks and 6 months post-discharge
• healthcare costs
Notes Recruitment status: completed. Study completion date: June 2016. No results published/posted
NCT02251899
Methods RCT: “A disease management study targeted to reduce health care utilization for patients with congestive heart
failure”. Start date January 2010, estimated study completion date June 2016
Participants Estimated enrolment: 10,000 adults with ≥ 1 unplanned inpatient occasion with primary diagnosis of HF during
the last 12 months
Interventions Disease management intervention (DMI):
• nurse-managed
• regularly delivered by telephone or, when necessary, in person
Control - not receiving the DMI
Outcomes Primary outcomes (at 2 years)
• number of hospitalisations
• number of outpatient visits to medical doctor
Secondary outcomes (at 2 years)
• mortality
• length of hospital stays
• total health care cost
Notes Gustaf Edgren (gustaf@pheph.se) contacted 16 April 2018 to see if any results are available yet - no response
NCT02331524
Methods 3-arm RCT
Participants Adults > 40 years with HF
Interventions • Feedback with associated encouragement about daily activity (intervention 1)
• Health coaching with associated individualised home exercise programme (intervention 2)
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NCT02331524 (Continued)
• Usual care (control)
Outcomes Primary:
• change in Medtronic implanted device patient activity measure
Secondary:
• ActiGraph daily activity
• 6-min walk test
• 30 seconds timed chair rise
• QoL
• health care utilisation
Notes Recruitment status: completed. Study completion date: July 2016. No results published/posted
Ortiz 2017
Methods RCT
2011-2013, patients were prospectively randomly allocated (1: 2) to standard care or intervention
Participants 127 patients with reduced EF
Interventions • Nurse-led clinic cross intervention programme (health education and drug treatment optimisation)
• Standard care
Outcomes Primary composite endpoint
• mortality and hospital readmissions from any cause.
Secondary endpoints
• all-cause mortality
• all-cause hospital readmissions
• HF readmissions
• time to 1st admission
• QoL improvements (assessed by MLHFQ)
Notes Emailed study author for clarification of whether majority of participants had been admitted to hospital for HF (1
May 2018). No response
Shao 2014
Methods RCT
Participants 120 HF outpatients in the medical centre
Interventions Self-management intervention.
“Diet control” strategy focused on sodium and fluid restriction:
• appraisal
• goal setting
• self-monitoring of diet control, symptoms and daily weight.
Comparison
• did not receive this intervention
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Shao 2014 (Continued)
Outcomes • Self-efficacy for salt and fluid control
• HF self-management behavior
• HF symptoms
• Depressive symptoms
• Daily weight monitoring
• HF health services utilisation
Notes Emailed study author (1May 2018) for clarification of whethermajority of participants had been admitted to hospital
for HF, and whether the conference abstract was now published as a full paper. No response
ACEI: angiotensin converting enzyme inhibitor; CV: cardiovascular; ED: Emergency Department; EF: ejection fraction; HADS:
Hospital Anxiety and Depression Scale; HRQoL: health-related quality of life; MLHFQ: Minnesota Living with Heart Failure
questionnaire; NYHA: New York Heart Association; QoL: quality of life; RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Bendelac 2014
Trial name or title OSICAT
Methods Prospective, multicentre RCT
Participants People with chronic HF
Interventions Ttelecardiology programme:
• daily scale assessment
• a device asking the participants daily questions on the symptoms associated with their HF
• regular telephone calls made by nurses
Outcomes • All-cause mortality assessed at 6, 12 and 18 months
• Hospitalisation assessed at 6, 12 and 18 months
• Cost-utility study: the economic analysis will adopt the healthcare payer’s perspective and will take into
account direct costs, indirect costs and informal care costs.
• Social and organisational acceptability
Starting date 2014
Contact information Pro Galinier: galinier.m@chu-toulouse.fr
Notes Contact with Prof Galinier (16 April 2018) confirmed that this study has not yet been completed
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Ding 2017
Trial name or title Innovative telemonitoring enhanced care programme for chronic heart failure (ITEC-CHF) to improve
guideline compliance and collaborative care: protocol of a multicentre randomised controlled trial
Methods Mutlicentre RCT
Participants 300 people with chronic HF
Interventions Innovative telemonitoring enhanced care programme for HF (ITEC-CHF)
• usual care
• additional telemonitoring service
◦ remote weight monitoring
◦ structured telephone support
◦ nurse-led collaborative care
Comparator:
• usual care
Outcomes Primary outcomes:
• compliance rates with the best-practice guidelines for daily weight monitoring
Secondary outcomes:
• compliance with other guideline recommendations (health maintenance, medication, diet and
exercise),
• health (HRQoL, risk factors, functional capacity and psychological states)
• economic outcomes related to the use of healthcare resources such as hospital readmissions and GP/
ED visits
Starting date Recruitment started 20 January 2015, anticipated last enrolment was 31 March 2017
Contact information Trial registration number: registered with Australian New Zealand Clinical Trial Registry (AC-
TRN12614000916640)
Hang.Ding@csiro.au
Notes Email contact with study author (31 May 2018) confirmed that the trial is complete but the results paper is
being drafted so results not yet available
Hardman S
Trial name or title The evaluation of a nurse-led intervention to improve self-management for patients admitted to hospital with
a diagnosis of heart failure (due to left ventricular systolic dysfunction)
Methods RCT
Participants 250 participants (125 in intervention arm, 125 in control arm)
Interventions The intervention is designed to enhance participants’ sense of self efficacy (confidence) in their ability to
adhere to medication and other aspects of their treatment regime including:
• fluid restriction
• diet
• exercise
• self-monitoring for signs of deteriorating HF
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Hardman S (Continued)
• using a problem-solving approach
Outcomes Primary endpoints during 1st 3 months after discharge:
• all-cause hospital readmissions
• HF hospital readmissions
Numerous secondary endpoints including mortality and 12-month data
Starting date NA, study likely to be completed in 2005
Contact information Dr. Suzanna Hardman Consultant Cardiologist with an interest in Community Cardiology,
TheWhittington &UCLHospitals, Clinical & AcademicDepartment of CardiovascularMedicine, StMary’s
Wing, Whittington Hospital, Highgate Hill, London N19 5NF, UK
Notes Contacted study author July 2010, publication expected soon. Contacted 11 September 2018 for further
update as no publications identified, no update
Massie 2001
Trial name or title A controlled trial of heart failure management programs
Methods Controlled trial
Participants 147 patients with symptomatic HF at 5 VA facilities
Interventions 3 groups:
• usual care
• nurse manager
• home monitoring
Also in two sites patients randomised to HF clinic
Outcomes Death or hospitalisation for a cardiac cause
Starting date NA
Contact information NA
Notes Poster abstract only. Study author contacted, full trial not published. No further publications identified
NCT02044211
Trial name or title Blended collaborative care for heart failure and co-morbid depression
Methods RCT
Participants HF and depression
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NCT02044211 (Continued)
Interventions • Collaborative care for HF and depression (intervention 1)
• Collaborative care for HF only (intervention 2)
• Usual care for HF and depression (control)
Outcomes Primary:
• mental HRQoL
Secondary:
• HF-related QoL
• mood symptoms
• rehospitalisation
• mortality (all-cause and cardiovascular)
• costs
• employment
Starting date February 2014
Contact information Principal Investigator: Bruce L. Rollman, University of Pittsburgh
Notes Estimated study completion date: June 2019.
NCT02481921
Trial name or title MEDIC-HF
Methods RCT
Participants Adults with HF
Interventions • Group medical visits
• Usual care
Outcomes Primary:
• QoL
Secondary:
• time to hospitalisation or death
Starting date 1 June 2015
Contact information Contact: Wen-Chih H Wu (wen-chih.wu@va.gov), Tracey Taveira (tracey.taveira@va.gov)
Notes Recruitment status: recruiting
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NCT02894502
Trial name or title MOTIVATE-HF
Methods RCT
Participants Adults with HF
Interventions • Motivational interviewing only for participants (intervention 1)
• Motivational interviewing for participants and caregivers (intervention 2)
• No intervention (control)
Outcomes Primary:
• self-care in participants and care-givers
Secondary:
• burden of HF symptoms
• QoL
• participant hospitalisation
• use of emergency services
• death
Starting date June 2014
Contact information Contact: Ercole Vellone (ercole.vellone@uniroma2.it), Rosaria Alvaro (rosaria.alvaro@uniroma2.it)
Notes Estimated study completion date: December 2018
NCT03012256
Trial name or title DIVERT-CARE
Methods RCT
Participants Adults ≥ 19 years with HF and COPD
Interventions • Cardio-respiratory management model
• Standard care
Outcomes Primary:
• first unplanned ED visit
• total care costs
• changes in participant activation
• number of symptoms
Secondary:
• number of unplanned ED visits
• HRQoL
Follow-up: 6 months
Starting date 6 February 2018
Contact information Contact: Andrew Costa (acosta@mcmaster.ca), Graham Campbell (campbg4@mcmaster.ca)
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NCT03012256 (Continued)
Notes Recruitment status: recruiting. Estimated study completion date: December 2019
NCT03035123
Trial name or title EduStra-HF
Methods RCT
Participants HF
Interventions • Therapeutic education
• Usual care
Outcomes Primary:
• number of rehospitalisations for acute HF
Secondary:
• participants’ knowledge about illness
• QoL
• length of stay for HF and all-cause hospitalisations
• hospitalisation rate for CVDs except HF
• CV and all-cause mortality rate,
• BNP or NT pro-BNP levels
Other:
• cost-effectiveness
Follow-up: 1 year
Starting date 1 April 2017
Contact information
Notes Estimated study completion date: 30 June 2020
NCT03108235
Trial name or title HOM-HEMP
Methods RCT
Participants Adults ≥ 55 years with chronic HF
Interventions • Home-based self-management psychosocial educational programme (HOM-HEMP) (intervention 1)
• HOM-HEMP with smartphone app (intervention 2)
• Standard care (control)
Outcomes Primary:
• cardiac self-efficacy scale
Secondary:
• HADS,
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NCT03108235 (Continued)
• HRQoL
• Social Support Questionnaire
• Self-Care Heart Failure Index
Other:
• 6-minute walk test
• NYHA functional class
• LVEF
• unplanned health services use
• process evaluation
Starting date 1 January 2018
Contact information Contact: Wenru Wang (nurww@nus.edu.sg)
Notes Estimated study completion date: 30 December 2019
NCT03555318
Trial name or title Intervention by a cardiologist and geriatrician in elderly patients after admission due to heart failure
Methods RCT
Participants Patients > 75 years with a recent admission for HF (within the previous 10 days)
Interventions Intervention:
• participants randomised to a combined ambulatory follow-up with a cardiologist and a geriatrician
Comparator:
• participants randomised to usual care (ambulatory follow-up with a cardiologist)
Outcomes Primary:
• all-cause hospitalisation
Secondary:
• HF hospitalisation
• QoL
• functional capacity
• medication use
• number of outpatient visits
• ED visits
• hospitalisations
Starting date Not yet recruiting (as of June 13, 2018) Estimated study completion is June 14, 2020
Contact information Nuria Farre, NFarreLopez@parcdesalutmar.cat
Notes
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Oksman 2017
Trial name or title TERVA: Tele-based health coaching program for chronic disease in primary care (NCT00552903)
Methods RCT
Participants 1570 patients with type 2 diabetes, coronary artery disease or congestive HF
Interventions Intervention:
• monthly individual health coaching by telephone from a specially trained nurse for 12- months
• routine social and healthcare
Control:
• routine social and health care
Outcomes • HRQoL (15D instrument to measure utility)
• Cost-effectiveness ratios (ICER, QALY)
Starting date Unclear
Contact information NCT00552903 Kristiina Patja <kristiina.patja@promedico.fi>
Notes Contact with study author (14 May 2018) indicated that the full 8-year clinical outcome data are not yet
published or available for this study, nor the relevant clinical outcome data for the Patja 2012 reference. The
Oksman 2017 paper contains cost-effectiveness data and a measure of health utility
Pugh 1999
Trial name or title Nursing case management for elderly heart failure patients
Methods Not clear
Participants 200 patients aged ≥ 65 years hospitalised at 1 centre for the treatment of HF
Interventions Intervention:
• enhanced discharge planning
• taught to manage their HF within parameters set by their physician using a workbook for guidance
• receive participant-specific printed material
• ongoing assessment and follow-up by a nurse for a 6-month period through phone calls and visits
Outcomes • Morbidity
• Mortality
• QoL
• Functional status
At 6 months and 1 year after discharge
Starting date NA, in July 1998 57 participants had been recruited
Contact information NA
Notes No publications identified
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Taylor 2015
Trial name or title Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) facilitated self-care rehabilitation inter-
vention in heart failure patients and caregivers
Methods Multicentre, parallel, 2-group RCT
Participants 216 patients with systolic HF and their caregivers
Interventions Intervention:
• self-help manual delivered by specially trained facilitators over a 12-week period
• usual care
Control
• usual care alone (control)
Outcomes Primary:
• participants’ disease-specific HRQoL (MLHFQ) at 12 months’ follow-up.
Secondary:
• survival
• HF hospitalisation
• blood biomarkers
• psychological well-being
• exercise capacity
• physical activity
• other measures of QoL
• participant safety and QoL
• psychological well-being
• perceived burden of caregivers at 4, 6 and 12 months’ follow-up.
A cost-effectiveness evaluation will also be carried out.
Starting date 13 November 2014
Contact information Trial registration number: ISRCTN86234930
r.taylor@exeter.ac.uk
Notes Pilot paper by Greaves 2016 does not contain outcomes relevant to this review. Full publication expected
soon
Vellone 2017
Trial name or title MOTIVATE-HF; NCT02894502
Methods 3-arm, multicentre RCT
Participants 240 people with HF and their caregivers
Interventions Motivational interviewing; 3 arms:
• motivational interviewing intervention to only participants
• motivational interviewing intervention to participants and caregivers
• standard care to participants and caregivers
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Vellone 2017 (Continued)
Outcomes • Self-care maintenance; self-care management, self-care confidence,
• HF somatic symptom perception
• Generic and disease-specific QoL
• Anxiety and depression
• Cognition
• Sleep quality
• Mutuality with caregiver
• Hospitalisations
• Use of emergency services
• Mortality
Starting date June 2014, estimated study completion date December 2018
Contact information ercole.vellone@uniroma2.it
Notes Email from study author (1 May 2018) confirmed that data collection is now complete but the main article
is not yet ready for dissemination
COPD: chronic obstructive pulmonary disease;CV: cardiovascular; CVD: cardiovascular disease; ED: Emergency Department; GP:
General Practitioner; HADS: Hospital Anxiety and Depression Scale; HF: heart failure; HRQoL: health-related quality of life;
ICER: incremental cost effectiveness ratio LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; QALY:
quality-adjusted life year; RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Case management vs usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality - main
analysis
26 6903 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.68, 0.90]
2 All-cause mortality - subgroup
analysis by length of follow-up
26 6903 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.68, 0.90]
2.1 6 months’ follow-up 10 3253 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.70, 1.11]
2.2 More than 6 months’
follow-up
16 3650 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.62, 0.88]
3 All-cause mortality - subgroup
analysis by person delivering
the intervention
26 6903 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.68, 0.90]
3.1 Specialist nurse 13 2268 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.61, 1.01]
3.2 Nurse/community nurse 6 2645 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.69, 1.03]
3.3 Pharmacist/community
pharmacist
3 507 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.25, 1.67]
3.4 Multidisciplinary 2 869 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.50, 1.03]
3.5 Other 2 614 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.42, 1.71]
4 All-cause mortality - sensitivity
analysis with low risk of bias
10 3514 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.55, 0.82]
5 HF readmissions - main analysis 12 2528 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.53, 0.78]
6 HF readmissions - subgroup
analysis by length of follow-up
12 2528 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.53, 0.78]
6.1 6 months’ follow-up 4 778 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.58, 0.88]
6.2 More than 6 months’
follow-up
8 1750 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.45, 0.81]
7 HF readmissions - subgroup
analysis by person delivering
the intervention
12 2528 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.53, 0.78]
7.1 Specialist nurse 7 945 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.47, 0.70]
7.2 Nurse/community nurse 1 252 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.42, 1.16]
7.3 Pharmacist/community
pharmacist
1 34 Risk Ratio (M-H, Random, 95% CI) 0.4 [0.16, 1.03]
7.4 Multidisciplinary 1 683 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.84, 1.39]
7.5 Other 2 614 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.45, 0.88]
8 HF readmissions - sensitivity
analysis with low risk of bias
4 741 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.50, 0.77]
9 All-cause readmissions - main
analysis
14 4539 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.83, 1.01]
10 All-cause readmissions -
subgroup analysis by length of
follow-up
14 4539 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.83, 1.01]
10.1 6 months’ follow-up 5 2120 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.89, 1.11]
10.2 More than 6 months’
follow-up
9 2419 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.01]
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11 All-cause readmissions -
subgroup analysis by person
delivering the intervention
14 4539 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.83, 1.01]
11.1 Specialist nurse 6 853 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.73, 0.99]
11.2 Nurse/community nurse 4 2255 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.92, 1.09]
11.3 Pharmacist/community
pharmacist
1 134 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.45, 1.03]
11.4 Multidisciplinary 1 683 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.92, 1.21]
11.5 Other 2 614 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.57, 1.38]
12 All-cause readmissions -
sensitivity analysis with low
risk of bias
6 2217 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.74, 1.02]
13 Quality of life (MLHFQ mean
score at end of follow-up)
8 Mean Difference (Random, 95% CI) Totals not selected
14 Quality of life (subgroup by
length of intervention)
8 Mean Difference (Random, 95% CI) -5.76 [-10.64, -0.88]
14.1 Less than 6 months’
follow-up
6 Mean Difference (Random, 95% CI) -3.32 [-8.59, 1.96]
14.2 More than 6 months’
follow-up
2 Mean Difference (Random, 95% CI) -12.14 [-16.48, -7.
79]
15 Quality of life (subgroup by
person delivering intervention)
8 Mean Difference (Random, 95% CI) -5.76 [-10.64, -0.88]
15.1 Specialist nurse 6 Mean Difference (Random, 95% CI) -7.87 [-14.36, -1.39]
15.2 Nurse/community nurse 2 Mean Difference (Random, 95% CI) -0.91 [-8.48, 6.67]
15.3 Pharmacist/community
pharmacist
0 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
15.4 Multidisciplinary 0 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
15.5 Other 0 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Clinic-based intervention vs usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality - main
analysis
7 1686 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.68, 1.10]
2 All-cause mortality - subgroup
analysis by length of follow-up
7 1686 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.68, 1.10]
2.1 6 months’ follow-up 2 306 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.32, 1.27]
2.2 More than 6 months’
follow-up
5 1380 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.67, 1.17]
3 All-cause mortality - subgroup
analysis by person delivering
the intervention
7 1686 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.68, 1.10]
3.1 Specialist nurse 4 1081 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.53, 1.15]
3.2 Nurse/community nurse 1 208 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.83, 1.73]
3.3 Pharmacist/community
pharmacist
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Multidisciplinary 2 397 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.47, 1.17]
195Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4 All-cause mortality - sensitivity
analysis with low risk of bias
2 296 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.23, 1.88]
5 All-cause mortality - sensitivity
analysis without cluster-RCT
6 1489 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.66, 1.15]
6 HF readmissions - main analysis 2 887 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
7 HF readmissions - subgroup
analysis by person delivering
the intervention
2 887 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
7.1 Specialist nurse 1 679 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.77, 1.30]
7.2 Nurse/community nurse 1 208 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
7.3 Pharmacist/community
pharmacist
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Multidisciplinary 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 HF readmissions - subgroup
analysis by length of follow-up
2 887 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
8.1 6 months’ follow-up 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 More than 6 months’
follow-up
2 887 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
9 All-cause readmissions 4 1129 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.72, 1.12]
10 All-cause readmissions -
subgroup analysis by length of
follow-up
4 1129 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.72, 1.12]
10.1 6 months’ follow-up 1 106 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.29, 0.91]
10.2 More than 6 months’
follow-up
3 1023 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.85, 1.16]
11 All-cause readmissions -
subgroup analysis by person
delivering the intervention
4 1129 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.72, 1.12]
11.1 Specialist nurse 3 921 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.52, 1.19]
11.2 Nurse/community nurse 1 208 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
Comparison 3. Multidisciplinary vs usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HF mortality - main analysis 2 277 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.23, 0.95]
2 All-cause mortality - main
analysis
8 1764 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.54, 0.83]
3 All-cause mortality - subgroup
analysis by length of follow-up
8 1764 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.54, 0.83]
3.1 6 months’ follow-up 2 478 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.47, 1.49]
3.2 More than 6 months’
follow-up
6 1286 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.49, 0.81]
4 All-cause mortality - sensitivity
analysis with low risk of bias
2 342 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.34, 1.25]
5 HF readmissions - main analysis 5 1108 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.50, 0.92]
6 HF readmissions - subgroup
analysis by length of follow-up
5 1108 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.50, 0.92]
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6.1 6 months’ follow-up 2 478 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.55, 1.40]
6.2 More than 6 months’
follow-up
3 630 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.44, 0.75]
7 All-cause readmissions - main
analysis
5 1152 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.71, 1.01]
8 All-cause readmissions -
subgroup analysis by length of
follow-up
5 1152 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.71, 1.01]
8.1 6 months follow up 2 478 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.54, 1.33]
8.2 more than 6 months
follow up
3 674 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.70, 1.02]
9 Quality of life - MLHFQ 2 140 Mean Difference (IV, Random, 95% CI) -12.21 [-16.43, -7.
99]
Analysis 1.1. Comparison 1 Case management vs usual care, Outcome 1 All-cause mortality - main analysis.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 1 All-cause mortality - main analysis
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aldamiz-Echevarria 2007 22/137 21/142 4.6 % 1.09 [ 0.63, 1.88 ]
Atienza 2004 30/164 51/174 6.8 % 0.62 [ 0.42, 0.93 ]
Berger 2010 21/96 35/90 5.8 % 0.56 [ 0.36, 0.89 ]
Blue 2001 25/84 25/81 5.7 % 0.96 [ 0.61, 1.53 ]
Brotons 2009 26/144 29/138 5.5 % 0.86 [ 0.53, 1.38 ]
de Souza 2014 10/123 18/129 3.0 % 0.58 [ 0.28, 1.21 ]
DeBusk 2004 21/228 29/234 4.8 % 0.74 [ 0.44, 1.26 ]
Dunbar 2014 2/70 2/64 0.5 % 0.91 [ 0.13, 6.30 ]
Holland 2007 30/169 24/170 5.3 % 1.26 [ 0.77, 2.06 ]
Jaarsma 2000 22/84 16/95 4.3 % 1.56 [ 0.88, 2.76 ]
Jaarsma 2008 (1) 83/344 99/339 10.1 % 0.83 [ 0.64, 1.06 ]
Kasper 2002 7/102 13/98 2.2 % 0.52 [ 0.22, 1.24 ]
Kimmelstiel 2004 11/103 14/97 2.9 % 0.74 [ 0.35, 1.55 ]
Krumholz 2002 9/44 13/44 2.9 % 0.69 [ 0.33, 1.45 ]
0.01 0.1 1 10 100
Favours case management Favours usual care
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(. . . Continued)
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kwok 2008 4/49 8/56 1.4 % 0.57 [ 0.18, 1.78 ]
Leventhal 2011 2/22 4/20 0.8 % 0.45 [ 0.09, 2.22 ]
Lopez 2006 9/70 19/64 3.1 % 0.43 [ 0.21, 0.89 ]
Mehralian 2014 2/55 4/55 0.7 % 0.50 [ 0.10, 2.62 ]
Naylor 2004 11/118 32/121 3.7 % 0.35 [ 0.19, 0.67 ]
Nucifora 2006 14/99 8/101 2.5 % 1.79 [ 0.78, 4.07 ]
Ong 2016 100/715 114/722 10.2 % 0.89 [ 0.69, 1.13 ]
Rainville 1999 1/17 4/17 0.4 % 0.25 [ 0.03, 2.01 ]
Stewart 1999a 18/100 28/100 4.9 % 0.64 [ 0.38, 1.08 ]
Tsuchihashi-Makaya 2013 8/79 8/82 2.0 % 1.04 [ 0.41, 2.63 ]
Tsuyuki 2004 16/140 12/136 3.1 % 1.30 [ 0.64, 2.64 ]
Yu 2015a 9/90 17/88 2.8 % 0.52 [ 0.24, 1.10 ]
Total (95% CI) 3446 3457 100.0 % 0.78 [ 0.68, 0.90 ]
Total events: 513 (Case management), 647 (Usual care)
Heterogeneity: Tau2 = 0.03; Chi2 = 35.94, df = 25 (P = 0.07); I2 =30%
Test for overall effect: Z = 3.39 (P = 0.00071)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Case management vs usual care, Outcome 2 All-cause mortality - subgroup
analysis by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 2 All-cause mortality - subgroup analysis by length of follow-up
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months’ follow-up
de Souza 2014 10/123 18/129 3.0 % 0.58 [ 0.28, 1.21 ]
Dunbar 2014 2/70 2/64 0.5 % 0.91 [ 0.13, 6.30 ]
Holland 2007 30/169 24/170 5.3 % 1.26 [ 0.77, 2.06 ]
Kasper 2002 7/102 13/98 2.2 % 0.52 [ 0.22, 1.24 ]
Kwok 2008 4/49 8/56 1.4 % 0.57 [ 0.18, 1.78 ]
Mehralian 2014 2/55 4/55 0.7 % 0.50 [ 0.10, 2.62 ]
Nucifora 2006 14/99 8/101 2.5 % 1.79 [ 0.78, 4.07 ]
Ong 2016 100/715 114/722 10.2 % 0.89 [ 0.69, 1.13 ]
Stewart 1999a 18/100 28/100 4.9 % 0.64 [ 0.38, 1.08 ]
Tsuyuki 2004 16/140 12/136 3.1 % 1.30 [ 0.64, 2.64 ]
Subtotal (95% CI) 1622 1631 33.7 % 0.88 [ 0.70, 1.11 ]
Total events: 203 (Case management), 231 (Usual care)
Heterogeneity: Tau2 = 0.02; Chi2 = 11.00, df = 9 (P = 0.28); I2 =18%
Test for overall effect: Z = 1.09 (P = 0.28)
2 More than 6 months’ follow-up
Aldamiz-Echevarria 2007 22/137 21/142 4.6 % 1.09 [ 0.63, 1.88 ]
Atienza 2004 30/164 51/174 6.8 % 0.62 [ 0.42, 0.93 ]
Berger 2010 21/96 35/90 5.8 % 0.56 [ 0.36, 0.89 ]
Blue 2001 25/84 25/81 5.7 % 0.96 [ 0.61, 1.53 ]
Brotons 2009 26/144 29/138 5.5 % 0.86 [ 0.53, 1.38 ]
DeBusk 2004 21/228 29/234 4.8 % 0.74 [ 0.44, 1.26 ]
Jaarsma 2000 22/84 16/95 4.3 % 1.56 [ 0.88, 2.76 ]
Jaarsma 2008 (1) 83/344 99/339 10.1 % 0.83 [ 0.64, 1.06 ]
Kimmelstiel 2004 11/103 14/97 2.9 % 0.74 [ 0.35, 1.55 ]
Krumholz 2002 9/44 13/44 2.9 % 0.69 [ 0.33, 1.45 ]
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(. . . Continued)
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Leventhal 2011 2/22 4/20 0.8 % 0.45 [ 0.09, 2.22 ]
Lopez 2006 9/70 19/64 3.1 % 0.43 [ 0.21, 0.89 ]
Naylor 2004 11/118 32/121 3.7 % 0.35 [ 0.19, 0.67 ]
Rainville 1999 1/17 4/17 0.4 % 0.25 [ 0.03, 2.01 ]
Tsuchihashi-Makaya 2013 8/79 8/82 2.0 % 1.04 [ 0.41, 2.63 ]
Yu 2015a 9/90 17/88 2.8 % 0.52 [ 0.24, 1.10 ]
Subtotal (95% CI) 1824 1826 66.3 % 0.74 [ 0.62, 0.88 ]
Total events: 310 (Case management), 416 (Usual care)
Heterogeneity: Tau2 = 0.04; Chi2 = 22.91, df = 15 (P = 0.09); I2 =35%
Test for overall effect: Z = 3.34 (P = 0.00083)
Total (95% CI) 3446 3457 100.0 % 0.78 [ 0.68, 0.90 ]
Total events: 513 (Case management), 647 (Usual care)
Heterogeneity: Tau2 = 0.03; Chi2 = 35.94, df = 25 (P = 0.07); I2 =30%
Test for overall effect: Z = 3.39 (P = 0.00071)
Test for subgroup differences: Chi2 = 1.48, df = 1 (P = 0.22), I2 =33%
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Analysis 1.3. Comparison 1 Case management vs usual care, Outcome 3 All-cause mortality - subgroup
analysis by person delivering the intervention.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 3 All-cause mortality - subgroup analysis by person delivering the intervention
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Specialist nurse
Blue 2001 25/84 25/81 5.7 % 0.96 [ 0.61, 1.53 ]
Brotons 2009 26/144 29/138 5.5 % 0.86 [ 0.53, 1.38 ]
Dunbar 2014 2/70 2/64 0.5 % 0.91 [ 0.13, 6.30 ]
Jaarsma 2000 22/84 16/95 4.3 % 1.56 [ 0.88, 2.76 ]
Kasper 2002 7/102 13/98 2.2 % 0.52 [ 0.22, 1.24 ]
Kimmelstiel 2004 11/103 14/97 2.9 % 0.74 [ 0.35, 1.55 ]
Krumholz 2002 9/44 13/44 2.9 % 0.69 [ 0.33, 1.45 ]
Leventhal 2011 2/22 4/20 0.8 % 0.45 [ 0.09, 2.22 ]
Naylor 2004 11/118 32/121 3.7 % 0.35 [ 0.19, 0.67 ]
Nucifora 2006 14/99 8/101 2.5 % 1.79 [ 0.78, 4.07 ]
Stewart 1999a 18/100 28/100 4.9 % 0.64 [ 0.38, 1.08 ]
Tsuchihashi-Makaya 2013 8/79 8/82 2.0 % 1.04 [ 0.41, 2.63 ]
Yu 2015a 9/90 17/88 2.8 % 0.52 [ 0.24, 1.10 ]
Subtotal (95% CI) 1139 1129 40.7 % 0.79 [ 0.61, 1.01 ]
Total events: 164 (Case management), 209 (Usual care)
Heterogeneity: Tau2 = 0.08; Chi2 = 19.85, df = 12 (P = 0.07); I2 =40%
Test for overall effect: Z = 1.85 (P = 0.064)
2 Nurse/community nurse
Aldamiz-Echevarria 2007 22/137 21/142 4.6 % 1.09 [ 0.63, 1.88 ]
de Souza 2014 10/123 18/129 3.0 % 0.58 [ 0.28, 1.21 ]
DeBusk 2004 21/228 29/234 4.8 % 0.74 [ 0.44, 1.26 ]
Kwok 2008 4/49 8/56 1.4 % 0.57 [ 0.18, 1.78 ]
Mehralian 2014 2/55 4/55 0.7 % 0.50 [ 0.10, 2.62 ]
Ong 2016 100/715 114/722 10.2 % 0.89 [ 0.69, 1.13 ]
Subtotal (95% CI) 1307 1338 24.6 % 0.84 [ 0.69, 1.03 ]
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(. . . Continued)
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 159 (Case management), 194 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.00, df = 5 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.088)
3 Pharmacist/community pharmacist
Holland 2007 30/169 24/170 5.3 % 1.26 [ 0.77, 2.06 ]
Lopez 2006 9/70 19/64 3.1 % 0.43 [ 0.21, 0.89 ]
Rainville 1999 1/17 4/17 0.4 % 0.25 [ 0.03, 2.01 ]
Subtotal (95% CI) 256 251 8.8 % 0.65 [ 0.25, 1.67 ]
Total events: 40 (Case management), 47 (Usual care)
Heterogeneity: Tau2 = 0.45; Chi2 = 7.16, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.90 (P = 0.37)
4 Multidisciplinary
Berger 2010 21/96 35/90 5.8 % 0.56 [ 0.36, 0.89 ]
Jaarsma 2008 (1) 83/344 99/339 10.1 % 0.83 [ 0.64, 1.06 ]
Subtotal (95% CI) 440 429 15.9 % 0.72 [ 0.50, 1.03 ]
Total events: 104 (Case management), 134 (Usual care)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.08, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 1.80 (P = 0.073)
5 Other
Atienza 2004 30/164 51/174 6.8 % 0.62 [ 0.42, 0.93 ]
Tsuyuki 2004 16/140 12/136 3.1 % 1.30 [ 0.64, 2.64 ]
Subtotal (95% CI) 304 310 9.9 % 0.85 [ 0.42, 1.71 ]
Total events: 46 (Case management), 63 (Usual care)
Heterogeneity: Tau2 = 0.18; Chi2 = 3.10, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.47 (P = 0.64)
Total (95% CI) 3446 3457 100.0 % 0.78 [ 0.68, 0.90 ]
Total events: 513 (Case management), 647 (Usual care)
Heterogeneity: Tau2 = 0.03; Chi2 = 35.94, df = 25 (P = 0.07); I2 =30%
Test for overall effect: Z = 3.39 (P = 0.00071)
Test for subgroup differences: Chi2 = 0.87, df = 4 (P = 0.93), I2 =0.0%
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Analysis 1.4. Comparison 1 Case management vs usual care, Outcome 4 All-cause mortality - sensitivity
analysis with low risk of bias.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 4 All-cause mortality - sensitivity analysis with low risk of bias
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aldamiz-Echevarria 2007 22/137 21/142 9.2 % 1.09 [ 0.63, 1.88 ]
Berger 2010 21/96 35/90 11.8 % 0.56 [ 0.36, 0.89 ]
Brotons 2009 26/144 29/138 11.3 % 0.86 [ 0.53, 1.38 ]
de Souza 2014 10/123 18/129 6.0 % 0.58 [ 0.28, 1.21 ]
Kasper 2002 7/102 13/98 4.4 % 0.52 [ 0.22, 1.24 ]
Kwok 2008 4/49 8/56 2.8 % 0.57 [ 0.18, 1.78 ]
Lopez 2006 9/70 19/64 6.2 % 0.43 [ 0.21, 0.89 ]
Naylor 2004 11/118 32/121 7.5 % 0.35 [ 0.19, 0.67 ]
Ong 2016 100/715 114/722 21.0 % 0.89 [ 0.69, 1.13 ]
Stewart 1999a 18/100 28/100 9.9 % 0.64 [ 0.38, 1.08 ]
Stewart 1999a 18/100 28/100 9.9 % 0.64 [ 0.38, 1.08 ]
Total (95% CI) 1754 1760 100.0 % 0.67 [ 0.55, 0.82 ]
Total events: 246 (Case management), 345 (Usual care)
Heterogeneity: Tau2 = 0.03; Chi2 = 14.64, df = 10 (P = 0.15); I2 =32%
Test for overall effect: Z = 3.90 (P = 0.000094)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Case management vs usual care, Outcome 5 HF readmissions - main analysis.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 5 HF readmissions - main analysis
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Atienza 2004 39/164 79/174 13.0 % 0.52 [ 0.38, 0.72 ]
Blue 2001 12/84 26/81 6.7 % 0.45 [ 0.24, 0.82 ]
de Souza 2014 20/123 30/129 8.5 % 0.70 [ 0.42, 1.16 ]
Jaarsma 2008 (1) 92/344 84/339 14.9 % 1.08 [ 0.84, 1.39 ]
Kasper 2002 26/102 35/98 10.2 % 0.71 [ 0.47, 1.09 ]
Krumholz 2002 9/44 17/44 5.7 % 0.53 [ 0.27, 1.06 ]
Lang 2018 0/25 4/25 0.5 % 0.11 [ 0.01, 1.96 ]
Leventhal 2011 1/22 2/20 0.7 % 0.45 [ 0.04, 4.64 ]
Naylor 2004 40/118 72/121 13.8 % 0.57 [ 0.43, 0.76 ]
Rainville 1999 4/17 10/17 3.5 % 0.40 [ 0.16, 1.03 ]
Tsuchihashi-Makaya 2013 16/79 28/82 8.1 % 0.59 [ 0.35, 1.01 ]
Tsuyuki 2004 53/140 70/136 14.5 % 0.74 [ 0.56, 0.96 ]
Total (95% CI) 1262 1266 100.0 % 0.64 [ 0.53, 0.78 ]
Total events: 312 (Case management), 457 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 22.42, df = 11 (P = 0.02); I2 =51%
Test for overall effect: Z = 4.42 (P = 0.000010)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Case management vs usual care, Outcome 6 HF readmissions - subgroup
analysis by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 6 HF readmissions - subgroup analysis by length of follow-up
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months’ follow-up
de Souza 2014 20/123 30/129 8.5 % 0.70 [ 0.42, 1.16 ]
Kasper 2002 26/102 35/98 10.2 % 0.71 [ 0.47, 1.09 ]
Lang 2018 0/25 4/25 0.5 % 0.11 [ 0.01, 1.96 ]
Tsuyuki 2004 53/140 70/136 14.5 % 0.74 [ 0.56, 0.96 ]
Subtotal (95% CI) 390 388 33.7 % 0.72 [ 0.58, 0.88 ]
Total events: 99 (Case management), 139 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.70, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 More than 6 months’ follow-up
Atienza 2004 39/164 79/174 13.0 % 0.52 [ 0.38, 0.72 ]
Blue 2001 12/84 26/81 6.7 % 0.45 [ 0.24, 0.82 ]
Jaarsma 2008 (1) 92/344 84/339 14.9 % 1.08 [ 0.84, 1.39 ]
Krumholz 2002 9/44 17/44 5.7 % 0.53 [ 0.27, 1.06 ]
Leventhal 2011 1/22 2/20 0.7 % 0.45 [ 0.04, 4.64 ]
Naylor 2004 40/118 72/121 13.8 % 0.57 [ 0.43, 0.76 ]
Rainville 1999 4/17 10/17 3.5 % 0.40 [ 0.16, 1.03 ]
Tsuchihashi-Makaya 2013 16/79 28/82 8.1 % 0.59 [ 0.35, 1.01 ]
Subtotal (95% CI) 872 878 66.3 % 0.60 [ 0.45, 0.81 ]
Total events: 213 (Case management), 318 (Usual care)
Heterogeneity: Tau2 = 0.10; Chi2 = 20.53, df = 7 (P = 0.005); I2 =66%
Test for overall effect: Z = 3.39 (P = 0.00069)
Total (95% CI) 1262 1266 100.0 % 0.64 [ 0.53, 0.78 ]
Total events: 312 (Case management), 457 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 22.42, df = 11 (P = 0.02); I2 =51%
Test for overall effect: Z = 4.42 (P = 0.000010)
Test for subgroup differences: Chi2 = 0.94, df = 1 (P = 0.33), I2 =0.0%
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Analysis 1.7. Comparison 1 Case management vs usual care, Outcome 7 HF readmissions - subgroup
analysis by person delivering the intervention.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 7 HF readmissions - subgroup analysis by person delivering the intervention
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Specialist nurse
Blue 2001 12/84 26/81 6.7 % 0.45 [ 0.24, 0.82 ]
Kasper 2002 26/102 35/98 10.2 % 0.71 [ 0.47, 1.09 ]
Krumholz 2002 9/44 17/44 5.7 % 0.53 [ 0.27, 1.06 ]
Lang 2018 0/25 4/25 0.5 % 0.11 [ 0.01, 1.96 ]
Leventhal 2011 1/22 2/20 0.7 % 0.45 [ 0.04, 4.64 ]
Naylor 2004 40/118 72/121 13.8 % 0.57 [ 0.43, 0.76 ]
Tsuchihashi-Makaya 2013 16/79 28/82 8.1 % 0.59 [ 0.35, 1.01 ]
Subtotal (95% CI) 474 471 45.7 % 0.58 [ 0.47, 0.70 ]
Total events: 104 (Case management), 184 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.07, df = 6 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 5.48 (P < 0.00001)
2 Nurse/community nurse
de Souza 2014 20/123 30/129 8.5 % 0.70 [ 0.42, 1.16 ]
Subtotal (95% CI) 123 129 8.5 % 0.70 [ 0.42, 1.16 ]
Total events: 20 (Case management), 30 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
3 Pharmacist/community pharmacist
Rainville 1999 4/17 10/17 3.5 % 0.40 [ 0.16, 1.03 ]
Subtotal (95% CI) 17 17 3.5 % 0.40 [ 0.16, 1.03 ]
Total events: 4 (Case management), 10 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
4 Multidisciplinary
Jaarsma 2008 (1) 92/344 84/339 14.9 % 1.08 [ 0.84, 1.39 ]
Subtotal (95% CI) 344 339 14.9 % 1.08 [ 0.84, 1.39 ]
Total events: 92 (Case management), 84 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
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(. . . Continued)
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
5 Other
Atienza 2004 39/164 79/174 13.0 % 0.52 [ 0.38, 0.72 ]
Tsuyuki 2004 53/140 70/136 14.5 % 0.74 [ 0.56, 0.96 ]
Subtotal (95% CI) 304 310 27.5 % 0.63 [ 0.45, 0.88 ]
Total events: 92 (Case management), 149 (Usual care)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.60, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 2.73 (P = 0.0064)
Total (95% CI) 1262 1266 100.0 % 0.64 [ 0.53, 0.78 ]
Total events: 312 (Case management), 457 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 22.42, df = 11 (P = 0.02); I2 =51%
Test for overall effect: Z = 4.42 (P = 0.000010)
Test for subgroup differences: Chi2 = 16.54, df = 4 (P = 0.00), I2 =76%
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Analysis 1.8. Comparison 1 Case management vs usual care, Outcome 8 HF readmissions - sensitivity
analysis with low risk of bias.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 8 HF readmissions - sensitivity analysis with low risk of bias
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
de Souza 2014 20/123 30/129 18.1 % 0.70 [ 0.42, 1.16 ]
Kasper 2002 26/102 35/98 26.0 % 0.71 [ 0.47, 1.09 ]
Lang 2018 0/25 4/25 0.6 % 0.11 [ 0.01, 1.96 ]
Naylor 2004 40/118 72/121 55.3 % 0.57 [ 0.43, 0.76 ]
Total (95% CI) 368 373 100.0 % 0.62 [ 0.50, 0.77 ]
Total events: 86 (Case management), 141 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.34, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 4.30 (P = 0.000017)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Case management vs usual care, Outcome 9 All-cause readmissions - main
analysis.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 9 All-cause readmissions - main analysis
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Atienza 2004 68/164 101/174 9.6 % 0.71 [ 0.57, 0.89 ]
Blue 2001 47/84 49/81 8.0 % 0.92 [ 0.71, 1.20 ]
de Souza 2014 38/123 49/129 5.4 % 0.81 [ 0.58, 1.15 ]
DeBusk 2004 116/227 117/234 11.6 % 1.02 [ 0.85, 1.22 ]
Jaarsma 2000 31/85 47/94 5.4 % 0.73 [ 0.52, 1.03 ]
Jaarsma 2008 (1) 194/344 181/339 14.3 % 1.06 [ 0.92, 1.21 ]
Kwok 2008 23/49 32/56 4.8 % 0.82 [ 0.56, 1.19 ]
Lang 2018 4/25 7/25 0.7 % 0.57 [ 0.19, 1.71 ]
Leventhal 2011 10/22 6/20 1.3 % 1.52 [ 0.67, 3.41 ]
Lopez 2006 23/70 31/64 4.0 % 0.68 [ 0.45, 1.03 ]
Naylor 2004 53/118 67/121 8.1 % 0.81 [ 0.63, 1.05 ]
Ong 2016 363/715 355/722 16.4 % 1.03 [ 0.93, 1.15 ]
Tsuyuki 2004 59/140 51/136 6.9 % 1.12 [ 0.84, 1.50 ]
Yu 2015a 25/90 27/88 3.5 % 0.91 [ 0.57, 1.43 ]
Total (95% CI) 2256 2283 100.0 % 0.92 [ 0.83, 1.01 ]
Total events: 1054 (Case management), 1120 (Usual care)
Heterogeneity: Tau2 = 0.01; Chi2 = 22.78, df = 13 (P = 0.04); I2 =43%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Case management vs usual care, Outcome 10 All-cause readmissions -
subgroup analysis by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 10 All-cause readmissions - subgroup analysis by length of follow-up
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months’ follow-up
de Souza 2014 38/123 49/129 5.4 % 0.81 [ 0.58, 1.15 ]
Kwok 2008 23/49 32/56 4.8 % 0.82 [ 0.56, 1.19 ]
Lang 2018 4/25 7/25 0.7 % 0.57 [ 0.19, 1.71 ]
Ong 2016 363/715 355/722 16.4 % 1.03 [ 0.93, 1.15 ]
Tsuyuki 2004 59/140 51/136 6.9 % 1.12 [ 0.84, 1.50 ]
Subtotal (95% CI) 1052 1068 34.2 % 0.99 [ 0.89, 1.11 ]
Total events: 487 (Case management), 494 (Usual care)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.42, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.12 (P = 0.91)
2 More than 6 months’ follow-up
Atienza 2004 68/164 101/174 9.6 % 0.71 [ 0.57, 0.89 ]
Blue 2001 47/84 49/81 8.0 % 0.92 [ 0.71, 1.20 ]
DeBusk 2004 116/227 117/234 11.6 % 1.02 [ 0.85, 1.22 ]
Jaarsma 2000 31/85 47/94 5.4 % 0.73 [ 0.52, 1.03 ]
Jaarsma 2008 (1) 194/344 181/339 14.3 % 1.06 [ 0.92, 1.21 ]
Leventhal 2011 10/22 6/20 1.3 % 1.52 [ 0.67, 3.41 ]
Lopez 2006 23/70 31/64 4.0 % 0.68 [ 0.45, 1.03 ]
Naylor 2004 53/118 67/121 8.1 % 0.81 [ 0.63, 1.05 ]
Yu 2015a 25/90 27/88 3.5 % 0.91 [ 0.57, 1.43 ]
Subtotal (95% CI) 1204 1215 65.8 % 0.89 [ 0.78, 1.01 ]
Total events: 567 (Case management), 626 (Usual care)
Heterogeneity: Tau2 = 0.02; Chi2 = 16.48, df = 8 (P = 0.04); I2 =51%
Test for overall effect: Z = 1.84 (P = 0.066)
Total (95% CI) 2256 2283 100.0 % 0.92 [ 0.83, 1.01 ]
Total events: 1054 (Case management), 1120 (Usual care)
Heterogeneity: Tau2 = 0.01; Chi2 = 22.78, df = 13 (P = 0.04); I2 =43%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Chi2 = 1.70, df = 1 (P = 0.19), I2 =41%
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(1) intensive intervention
Analysis 1.11. Comparison 1 Case management vs usual care, Outcome 11 All-cause readmissions -
subgroup analysis by person delivering the intervention.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 11 All-cause readmissions - subgroup analysis by person delivering the intervention
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Specialist nurse
Blue 2001 47/84 49/81 8.0 % 0.92 [ 0.71, 1.20 ]
Jaarsma 2000 31/85 47/94 5.4 % 0.73 [ 0.52, 1.03 ]
Lang 2018 4/25 7/25 0.7 % 0.57 [ 0.19, 1.71 ]
Leventhal 2011 10/22 6/20 1.3 % 1.52 [ 0.67, 3.41 ]
Naylor 2004 53/118 67/121 8.1 % 0.81 [ 0.63, 1.05 ]
Yu 2015a 25/90 27/88 3.5 % 0.91 [ 0.57, 1.43 ]
Subtotal (95% CI) 424 429 27.0 % 0.85 [ 0.73, 0.99 ]
Total events: 170 (Case management), 203 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.82, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
2 Nurse/community nurse
de Souza 2014 38/123 49/129 5.4 % 0.81 [ 0.58, 1.15 ]
DeBusk 2004 116/227 117/234 11.6 % 1.02 [ 0.85, 1.22 ]
Kwok 2008 23/49 32/56 4.8 % 0.82 [ 0.56, 1.19 ]
Ong 2016 363/715 355/722 16.4 % 1.03 [ 0.93, 1.15 ]
Subtotal (95% CI) 1114 1141 38.3 % 1.00 [ 0.92, 1.09 ]
Total events: 540 (Case management), 553 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.87, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
3 Pharmacist/community pharmacist
Lopez 2006 (1) 23/70 31/64 4.0 % 0.68 [ 0.45, 1.03 ]
Subtotal (95% CI) 70 64 4.0 % 0.68 [ 0.45, 1.03 ]
Total events: 23 (Case management), 31 (Usual care)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.81 (P = 0.070)
4 Multidisciplinary
Jaarsma 2008 (2) 194/344 181/339 14.3 % 1.06 [ 0.92, 1.21 ]
Subtotal (95% CI) 344 339 14.3 % 1.06 [ 0.92, 1.21 ]
Total events: 194 (Case management), 181 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
5 Other
Atienza 2004 68/164 101/174 9.6 % 0.71 [ 0.57, 0.89 ]
Tsuyuki 2004 59/140 51/136 6.9 % 1.12 [ 0.84, 1.50 ]
Subtotal (95% CI) 304 310 16.4 % 0.89 [ 0.57, 1.38 ]
Total events: 127 (Case management), 152 (Usual care)
Heterogeneity: Tau2 = 0.09; Chi2 = 5.92, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 0.53 (P = 0.60)
Total (95% CI) 2256 2283 100.0 % 0.92 [ 0.83, 1.01 ]
Total events: 1054 (Case management), 1120 (Usual care)
Heterogeneity: Tau2 = 0.01; Chi2 = 22.78, df = 13 (P = 0.04); I2 =43%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Chi2 = 8.00, df = 4 (P = 0.09), I2 =50%
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Analysis 1.12. Comparison 1 Case management vs usual care, Outcome 12 All-cause readmissions -
sensitivity analysis with low risk of bias.
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 12 All-cause readmissions - sensitivity analysis with low risk of bias
Study or subgroup Case management Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
de Souza 2014 38/123 49/129 14.8 % 0.81 [ 0.58, 1.15 ]
Kwok 2008 23/49 32/56 13.2 % 0.82 [ 0.56, 1.19 ]
Lang 2018 4/25 7/25 2.1 % 0.57 [ 0.19, 1.71 ]
Lopez 2006 23/70 31/64 11.2 % 0.68 [ 0.45, 1.03 ]
Naylor 2004 53/118 67/121 21.1 % 0.81 [ 0.63, 1.05 ]
Ong 2016 363/715 355/722 37.5 % 1.03 [ 0.93, 1.15 ]
Total (95% CI) 1100 1117 100.0 % 0.87 [ 0.74, 1.02 ]
Total events: 504 (Case management), 541 (Usual care)
Heterogeneity: Tau2 = 0.02; Chi2 = 8.64, df = 5 (P = 0.12); I2 =42%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Case management vs usual care, Outcome 13 Quality of life (MLHFQ mean
score at end of follow-up).
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 13 Quality of life (MLHFQ mean score at end of follow-up)
Study or subgroup case management usual care Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Brotons 2009 101 97 -12.54 (2.7546) -12.54 [ -17.94, -7.14 ]
Dunbar 2014 54 54 -6.3 (4.9366) -6.30 [ -15.98, 3.38 ]
Holland 2007 (1) 78 80 3.73 (3.7756) 3.73 [ -3.67, 11.13 ]
Kasper 2002 (2) 94 85 -12.6 (3.7659) -12.60 [ -19.98, -5.22 ]
Lang 2018 22 23 -9.5 (8.3455) -9.50 [ -25.86, 6.86 ]
Nucifora 2006 (3) 74 75 4 (2.9696) 4.00 [ -1.82, 9.82 ]
Ong 2016 (4) 383 413 -4.13 (1.7735) -4.13 [ -7.61, -0.65 ]
Yu 2015a 70 50 -11.4 (3.7316) -11.40 [ -18.71, -4.09 ]
-20 -10 0 10 20
Favours case management Favours usual care
(1) Data only reported as mean difference. Checked direction of effect in paper: ”Minnesota living with heart failurequestionnaire scores favoured controls”
(2) Change from baseline to 6 months in total score; SD imputed from p=0.001 using Revman Online Calculator
(3) Publication states that these are end of follow up (6 month) scores. Mean (SD) baseline scores were 36 (18) and 34 (19) for CM and UC, respectively
(4) SD imputed from reported p=0.02 using Revman Online Calculator
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Analysis 1.14. Comparison 1 Case management vs usual care, Outcome 14 Quality of life (subgroup by
length of intervention).
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 14 Quality of life (subgroup by length of intervention)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 Less than 6 months’ follow-up
Dunbar 2014 -6.3 (4.9366) 10.5 % -6.30 [ -15.98, 3.38 ]
Holland 2007 (1) 3.73 (3.7756) 12.7 % 3.73 [ -3.67, 11.13 ]
Kasper 2002 (2) -12.6 (3.7659) 12.7 % -12.60 [ -19.98, -5.22 ]
Lang 2018 -9.5 (8.3455) 5.9 % -9.50 [ -25.86, 6.86 ]
Nucifora 2006 (3) 4 (2.9696) 14.3 % 4.00 [ -1.82, 9.82 ]
Ong 2016 (4) -4.13 (1.7735) 16.4 % -4.13 [ -7.61, -0.65 ]
Subtotal (95% CI) 72.5 % -3.32 [ -8.59, 1.96 ]
Heterogeneity: Tau2 = 27.38; Chi2 = 16.69, df = 5 (P = 0.01); I2 =70%
Test for overall effect: Z = 1.23 (P = 0.22)
2 More than 6 months’ follow-up
Brotons 2009 -12.54 (2.7546) 14.7 % -12.54 [ -17.94, -7.14 ]
Yu 2015a -11.4 (3.7316) 12.8 % -11.40 [ -18.71, -4.09 ]
Subtotal (95% CI) 27.5 % -12.14 [ -16.48, -7.79 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.48 (P < 0.00001)
Total (95% CI) 100.0 % -5.76 [ -10.64, -0.88 ]
Heterogeneity: Tau2 = 34.62; Chi2 = 29.59, df = 7 (P = 0.00011); I2 =76%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Chi2 = 6.40, df = 1 (P = 0.01), I2 =84%
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(1) Data only reported as mean difference. Checked direction of effect in paper: ”Minnesota living with heart failurequestionnaire scores favoured controls”
(2) Change from baseline to 6 months in total score; SD imputed from p=0.001 using Revman Online Calculator
(3) Publication states that these are end of follow up (6 month) scores. Mean (SD) baseline scores were 36 (18) and 34 (19) for CM and UC, respectively
(4) SD imputed from reported p=0.02 using Revman Online Calculator
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Analysis 1.15. Comparison 1 Case management vs usual care, Outcome 15 Quality of life (subgroup by
person delivering intervention).
Review: Disease management interventions for heart failure
Comparison: 1 Case management vs usual care
Outcome: 15 Quality of life (subgroup by person delivering intervention)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 Specialist nurse
Brotons 2009 -12.54 (2.7546) 14.7 % -12.54 [ -17.94, -7.14 ]
Dunbar 2014 -6.3 (4.9366) 10.5 % -6.30 [ -15.98, 3.38 ]
Kasper 2002 (1) -12.6 (3.7659) 12.7 % -12.60 [ -19.98, -5.22 ]
Lang 2018 -9.5 (8.3455) 5.9 % -9.50 [ -25.86, 6.86 ]
Nucifora 2006 (2) 4 (2.9696) 14.3 % 4.00 [ -1.82, 9.82 ]
Yu 2015a -11.4 (3.7316) 12.8 % -11.40 [ -18.71, -4.09 ]
Subtotal (95% CI) 70.9 % -7.87 [ -14.36, -1.39 ]
Heterogeneity: Tau2 = 47.15; Chi2 = 21.39, df = 5 (P = 0.00068); I2 =77%
Test for overall effect: Z = 2.38 (P = 0.017)
2 Nurse/community nurse
Holland 2007 (3) 3.73 (3.7756) 12.7 % 3.73 [ -3.67, 11.13 ]
Ong 2016 (4) -4.13 (1.7735) 16.4 % -4.13 [ -7.61, -0.65 ]
Subtotal (95% CI) 29.1 % -0.91 [ -8.48, 6.67 ]
Heterogeneity: Tau2 = 22.19; Chi2 = 3.55, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.23 (P = 0.81)
3 Pharmacist/community pharmacist
Subtotal (95% CI) Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Multidisciplinary
Subtotal (95% CI) Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Other
Subtotal (95% CI) Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 100.0 % -5.76 [ -10.64, -0.88 ]
Heterogeneity: Tau2 = 34.62; Chi2 = 29.59, df = 7 (P = 0.00011); I2 =76%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Chi2 = 1.87, df = 1 (P = 0.17), I2 =47%
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(1) Change from baseline to 6 months in total score; SD imputed from p=0.001 using Revman Online Calculator
(2) Publication states that these are end of follow up (6 month) scores. Mean (SD) baseline scores were 36 (18) and 34 (19) for CM and UC, respectively
(3) Data only reported as mean difference. Checked direction of effect in paper: ”Minnesota living with heart failurequestionnaire scores favoured controls”
(4) SD imputed from reported p=0.02 using Revman Online Calculator
Analysis 2.1. Comparison 2 Clinic-based intervention vs usual care, Outcome 1 All-cause mortality - main
analysis.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 1 All-cause mortality - main analysis
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bohmer 2011 11/140 7/60 6.1 % 0.67 [ 0.27, 1.65 ]
Cline 1998 24/80 31/110 17.1 % 1.06 [ 0.68, 1.67 ]
Doughty 2002 19/100 24/97 13.7 % 0.77 [ 0.45, 1.31 ]
Jaarsma 2008 (1) 90/340 99/339 29.5 % 0.91 [ 0.71, 1.16 ]
Mejhert 2004 40/103 34/105 21.2 % 1.20 [ 0.83, 1.73 ]
Stromberg 2003 7/52 20/54 7.9 % 0.36 [ 0.17, 0.79 ]
Thompson 2005 5/58 7/48 4.4 % 0.59 [ 0.20, 1.74 ]
Total (95% CI) 873 813 100.0 % 0.87 [ 0.68, 1.10 ]
Total events: 196 (Clinic), 222 (Usual care)
Heterogeneity: Tau2 = 0.04; Chi2 = 9.58, df = 6 (P = 0.14); I2 =37%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Clinic-based intervention vs usual care, Outcome 2 All-cause mortality -
subgroup analysis by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 2 All-cause mortality - subgroup analysis by length of follow-up
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months’ follow-up
Bohmer 2011 11/140 7/60 6.1 % 0.67 [ 0.27, 1.65 ]
Thompson 2005 5/58 7/48 4.4 % 0.59 [ 0.20, 1.74 ]
Subtotal (95% CI) 198 108 10.5 % 0.64 [ 0.32, 1.27 ]
Total events: 16 (Clinic), 14 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
2 More than 6 months’ follow-up
Cline 1998 24/80 31/110 17.1 % 1.06 [ 0.68, 1.67 ]
Doughty 2002 19/100 24/97 13.7 % 0.77 [ 0.45, 1.31 ]
Jaarsma 2008 (1) 90/340 99/339 29.5 % 0.91 [ 0.71, 1.16 ]
Mejhert 2004 40/103 34/105 21.2 % 1.20 [ 0.83, 1.73 ]
Stromberg 2003 7/52 20/54 7.9 % 0.36 [ 0.17, 0.79 ]
Subtotal (95% CI) 675 705 89.5 % 0.89 [ 0.67, 1.17 ]
Total events: 180 (Clinic), 208 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 8.48, df = 4 (P = 0.08); I2 =53%
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 873 813 100.0 % 0.87 [ 0.68, 1.10 ]
Total events: 196 (Clinic), 222 (Usual care)
Heterogeneity: Tau2 = 0.04; Chi2 = 9.58, df = 6 (P = 0.14); I2 =37%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
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Analysis 2.3. Comparison 2 Clinic-based intervention vs usual care, Outcome 3 All-cause mortality -
subgroup analysis by person delivering the intervention.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 3 All-cause mortality - subgroup analysis by person delivering the intervention
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Specialist nurse
Cline 1998 24/80 31/110 17.1 % 1.06 [ 0.68, 1.67 ]
Jaarsma 2008 (1) 90/340 99/339 29.5 % 0.91 [ 0.71, 1.16 ]
Stromberg 2003 7/52 20/54 7.9 % 0.36 [ 0.17, 0.79 ]
Thompson 2005 5/58 7/48 4.4 % 0.59 [ 0.20, 1.74 ]
Subtotal (95% CI) 530 551 58.9 % 0.78 [ 0.53, 1.15 ]
Total events: 126 (Clinic), 157 (Usual care)
Heterogeneity: Tau2 = 0.08; Chi2 = 6.33, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Nurse/community nurse
Mejhert 2004 40/103 34/105 21.2 % 1.20 [ 0.83, 1.73 ]
Subtotal (95% CI) 103 105 21.2 % 1.20 [ 0.83, 1.73 ]
Total events: 40 (Clinic), 34 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
3 Pharmacist/community pharmacist
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Clinic), 0 (Usual care)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Multidisciplinary
Bohmer 2011 11/140 7/60 6.1 % 0.67 [ 0.27, 1.65 ]
Doughty 2002 19/100 24/97 13.7 % 0.77 [ 0.45, 1.31 ]
Subtotal (95% CI) 240 157 19.8 % 0.74 [ 0.47, 1.17 ]
Total events: 30 (Clinic), 31 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 873 813 100.0 % 0.87 [ 0.68, 1.10 ]
Total events: 196 (Clinic), 222 (Usual care)
Heterogeneity: Tau2 = 0.04; Chi2 = 9.58, df = 6 (P = 0.14); I2 =37%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 3.52, df = 2 (P = 0.17), I2 =43%
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(1) basic intervention
Analysis 2.4. Comparison 2 Clinic-based intervention vs usual care, Outcome 4 All-cause mortality -
sensitivity analysis with low risk of bias.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 4 All-cause mortality - sensitivity analysis with low risk of bias
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cline 1998 24/80 31/110 54.4 % 1.06 [ 0.68, 1.67 ]
Stromberg 2003 7/52 20/54 45.6 % 0.36 [ 0.17, 0.79 ]
Total (95% CI) 132 164 100.0 % 0.65 [ 0.23, 1.88 ]
Total events: 31 (Clinic), 51 (Usual care)
Heterogeneity: Tau2 = 0.48; Chi2 = 5.66, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Clinic-based intervention vs usual care, Outcome 5 All-cause mortality -
sensitivity analysis without cluster-RCT.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 5 All-cause mortality - sensitivity analysis without cluster-RCT
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bohmer 2011 11/140 7/60 7.9 % 0.67 [ 0.27, 1.65 ]
Cline 1998 24/80 31/110 20.2 % 1.06 [ 0.68, 1.67 ]
Jaarsma 2008 (1) 90/340 99/339 31.7 % 0.91 [ 0.71, 1.16 ]
Mejhert 2004 40/103 34/105 24.3 % 1.20 [ 0.83, 1.73 ]
Stromberg 2003 7/52 20/54 10.1 % 0.36 [ 0.17, 0.79 ]
Thompson 2005 5/58 7/48 5.8 % 0.59 [ 0.20, 1.74 ]
Total (95% CI) 773 716 100.0 % 0.87 [ 0.66, 1.15 ]
Total events: 177 (Clinic), 198 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 9.17, df = 5 (P = 0.10); I2 =45%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Clinic-based intervention vs usual care, Outcome 6 HF readmissions - main
analysis.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 6 HF readmissions - main analysis
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jaarsma 2008 (1) 84/340 84/339 35.2 % 1.00 [ 0.77, 1.30 ]
Mejhert 2004 69/103 69/105 64.8 % 1.02 [ 0.84, 1.24 ]
Total (95% CI) 443 444 100.0 % 1.01 [ 0.87, 1.18 ]
Total events: 153 (Clinic), 153 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Clinic-based intervention vs usual care, Outcome 7 HF readmissions - subgroup
analysis by person delivering the intervention.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 7 HF readmissions - subgroup analysis by person delivering the intervention
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Specialist nurse
Jaarsma 2008 (1) 84/340 84/339 35.2 % 1.00 [ 0.77, 1.30 ]
Subtotal (95% CI) 340 339 35.2 % 1.00 [ 0.77, 1.30 ]
Total events: 84 (Clinic), 84 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 Nurse/community nurse
Mejhert 2004 69/103 69/105 64.8 % 1.02 [ 0.84, 1.24 ]
Subtotal (95% CI) 103 105 64.8 % 1.02 [ 0.84, 1.24 ]
Total events: 69 (Clinic), 69 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 Pharmacist/community pharmacist
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Clinic), 0 (Usual care)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Multidisciplinary
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Clinic), 0 (Usual care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 443 444 100.0 % 1.01 [ 0.87, 1.18 ]
Total events: 153 (Clinic), 153 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 2.8. Comparison 2 Clinic-based intervention vs usual care, Outcome 8 HF readmissions - subgroup
analysis by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 8 HF readmissions - subgroup analysis by length of follow-up
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months’ follow-up
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Clinic), 0 (Usual care)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 More than 6 months’ follow-up
Jaarsma 2008 (1) 84/340 84/339 35.2 % 1.00 [ 0.77, 1.30 ]
Mejhert 2004 69/103 69/105 64.8 % 1.02 [ 0.84, 1.24 ]
Subtotal (95% CI) 443 444 100.0 % 1.01 [ 0.87, 1.18 ]
Total events: 153 (Clinic), 153 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 443 444 100.0 % 1.01 [ 0.87, 1.18 ]
Total events: 153 (Clinic), 153 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Clinic-based intervention vs usual care, Outcome 9 All-cause readmissions.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 9 All-cause readmissions
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cline 1998 22/56 43/80 18.9 % 0.73 [ 0.50, 1.07 ]
Jaarsma 2008 (1) 192/340 181/339 37.4 % 1.06 [ 0.92, 1.21 ]
Mejhert 2004 69/103 69/105 32.7 % 1.02 [ 0.84, 1.24 ]
Thompson 2005 13/58 21/48 11.0 % 0.51 [ 0.29, 0.91 ]
Total (95% CI) 557 572 100.0 % 0.90 [ 0.72, 1.12 ]
Total events: 296 (Clinic), 314 (Usual care)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.59, df = 3 (P = 0.04); I2 =65%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Clinic-based intervention vs usual care, Outcome 10 All-cause readmissions -
subgroup analysis by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 10 All-cause readmissions - subgroup analysis by length of follow-up
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months’ follow-up
Thompson 2005 13/58 21/48 11.0 % 0.51 [ 0.29, 0.91 ]
Subtotal (95% CI) 58 48 11.0 % 0.51 [ 0.29, 0.91 ]
Total events: 13 (Clinic), 21 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
2 More than 6 months’ follow-up
Cline 1998 22/56 43/80 18.9 % 0.73 [ 0.50, 1.07 ]
Jaarsma 2008 (1) 192/340 181/339 37.4 % 1.06 [ 0.92, 1.21 ]
Mejhert 2004 69/103 69/105 32.7 % 1.02 [ 0.84, 1.24 ]
Subtotal (95% CI) 499 524 89.0 % 0.99 [ 0.85, 1.16 ]
Total events: 283 (Clinic), 293 (Usual care)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.19, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 557 572 100.0 % 0.90 [ 0.72, 1.12 ]
Total events: 296 (Clinic), 314 (Usual care)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.59, df = 3 (P = 0.04); I2 =65%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 2.11. Comparison 2 Clinic-based intervention vs usual care, Outcome 11 All-cause readmissions -
subgroup analysis by person delivering the intervention.
Review: Disease management interventions for heart failure
Comparison: 2 Clinic-based intervention vs usual care
Outcome: 11 All-cause readmissions - subgroup analysis by person delivering the intervention
Study or subgroup Clinic Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Specialist nurse
Cline 1998 22/56 43/80 18.9 % 0.73 [ 0.50, 1.07 ]
Jaarsma 2008 (1) 192/340 181/339 37.4 % 1.06 [ 0.92, 1.21 ]
Thompson 2005 13/58 21/48 11.0 % 0.51 [ 0.29, 0.91 ]
Subtotal (95% CI) 454 467 67.3 % 0.79 [ 0.52, 1.19 ]
Total events: 227 (Clinic), 245 (Usual care)
Heterogeneity: Tau2 = 0.10; Chi2 = 8.47, df = 2 (P = 0.01); I2 =76%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Nurse/community nurse
Mejhert 2004 69/103 69/105 32.7 % 1.02 [ 0.84, 1.24 ]
Subtotal (95% CI) 103 105 32.7 % 1.02 [ 0.84, 1.24 ]
Total events: 69 (Clinic), 69 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 557 572 100.0 % 0.90 [ 0.72, 1.12 ]
Total events: 296 (Clinic), 314 (Usual care)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.59, df = 3 (P = 0.04); I2 =65%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 1.23, df = 1 (P = 0.27), I2 =19%
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Analysis 3.1. Comparison 3 Multidisciplinary vs usual care, Outcome 1 HF mortality - main analysis.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 1 HF mortality - main analysis
Study or subgroup Multidisciplinary Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gonzalez-Guerrero 2014 3/59 10/58 33.5 % 0.29 [ 0.09, 1.02 ]
Wierzchowiecki 2006 7/80 12/80 66.5 % 0.58 [ 0.24, 1.41 ]
Total (95% CI) 139 138 100.0 % 0.46 [ 0.23, 0.95 ]
Total events: 10 (Multidisciplinary), 22 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Multidisciplinary vs usual care, Outcome 2 All-cause mortality - main analysis.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 2 All-cause mortality - main analysis
Study or subgroup Multidisciplinary Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bekelman 2015 8/187 19/197 7.5 % 0.44 [ 0.20, 0.99 ]
Bernocchi 2017 1/56 1/56 0.6 % 1.00 [ 0.06, 15.59 ]
Cavusoglu 2017 15/125 13/123 9.8 % 1.14 [ 0.56, 2.29 ]
Del Sindaco 2007 27/86 32/87 27.6 % 0.85 [ 0.56, 1.29 ]
Ducharme 2005 12/115 19/115 10.5 % 0.63 [ 0.32, 1.24 ]
Gonzalez-Guerrero 2014 13/59 22/58 14.2 % 0.58 [ 0.32, 1.04 ]
Mao 2015 15/165 36/175 15.1 % 0.44 [ 0.25, 0.78 ]
Wierzchowiecki 2006 15/80 23/80 14.7 % 0.65 [ 0.37, 1.16 ]
Total (95% CI) 873 891 100.0 % 0.67 [ 0.54, 0.83 ]
Total events: 106 (Multidisciplinary), 165 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.99, df = 7 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.61 (P = 0.00031)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Multidisciplinary vs usual care, Outcome 3 All-cause mortality - subgroup
analysis by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 3 All-cause mortality - subgroup analysis by length of follow-up
Study or subgroup Multidisciplinary Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months’ follow-up
Cavusoglu 2017 15/125 13/123 9.8 % 1.14 [ 0.56, 2.29 ]
Ducharme 2005 12/115 19/115 10.5 % 0.63 [ 0.32, 1.24 ]
Subtotal (95% CI) 240 238 20.3 % 0.84 [ 0.47, 1.49 ]
Total events: 27 (Multidisciplinary), 32 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.40, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.59 (P = 0.55)
2 More than 6 months’ follow-up
Bekelman 2015 8/187 19/197 7.5 % 0.44 [ 0.20, 0.99 ]
Bernocchi 2017 1/56 1/56 0.6 % 1.00 [ 0.06, 15.59 ]
Del Sindaco 2007 27/86 32/87 27.6 % 0.85 [ 0.56, 1.29 ]
Gonzalez-Guerrero 2014 13/59 22/58 14.2 % 0.58 [ 0.32, 1.04 ]
Mao 2015 15/165 36/175 15.1 % 0.44 [ 0.25, 0.78 ]
Wierzchowiecki 2006 15/80 23/80 14.7 % 0.65 [ 0.37, 1.16 ]
Subtotal (95% CI) 633 653 79.7 % 0.63 [ 0.49, 0.81 ]
Total events: 79 (Multidisciplinary), 133 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.60, df = 5 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.68 (P = 0.00023)
Total (95% CI) 873 891 100.0 % 0.67 [ 0.54, 0.83 ]
Total events: 106 (Multidisciplinary), 165 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.99, df = 7 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.61 (P = 0.00031)
Test for subgroup differences: Chi2 = 0.81, df = 1 (P = 0.37), I2 =0.0%
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Analysis 3.4. Comparison 3 Multidisciplinary vs usual care, Outcome 4 All-cause mortality - sensitivity
analysis with low risk of bias.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 4 All-cause mortality - sensitivity analysis with low risk of bias
Study or subgroup Multidisciplinary Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernocchi 2017 1/56 1/56 5.7 % 1.00 [ 0.06, 15.59 ]
Ducharme 2005 12/115 19/115 94.3 % 0.63 [ 0.32, 1.24 ]
Total (95% CI) 171 171 100.0 % 0.65 [ 0.34, 1.25 ]
Total events: 13 (Multidisciplinary), 20 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Multidisciplinary vs usual care, Outcome 5 HF readmissions - main analysis.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 5 HF readmissions - main analysis
Study or subgroup Multidisciplinary Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cavusoglu 2017 (1) 37/125 35/123 24.9 % 1.04 [ 0.70, 1.54 ]
Del Sindaco 2007 28/86 49/87 26.7 % 0.58 [ 0.40, 0.83 ]
Ducharme 2005 12/115 19/115 13.5 % 0.63 [ 0.32, 1.24 ]
Gonzalez-Guerrero 2014 14/59 18/58 15.9 % 0.76 [ 0.42, 1.39 ]
Mao 2015 18/165 41/175 19.0 % 0.47 [ 0.28, 0.78 ]
Total (95% CI) 550 558 100.0 % 0.68 [ 0.50, 0.92 ]
Total events: 109 (Multidisciplinary), 162 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.68, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 2.53 (P = 0.011)
Test for subgroup differences: Not applicable
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(1) Reported n. participants with > median number of HF-related readmissions, where median=0.
232Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.6. Comparison 3 Multidisciplinary vs usual care, Outcome 6 HF readmissions - subgroup analysis
by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 6 HF readmissions - subgroup analysis by length of follow-up
Study or subgroup Multidisciplinary Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months’ follow-up
Cavusoglu 2017 (1) 37/125 35/123 24.9 % 1.04 [ 0.70, 1.54 ]
Ducharme 2005 12/115 19/115 13.5 % 0.63 [ 0.32, 1.24 ]
Subtotal (95% CI) 240 238 38.4 % 0.88 [ 0.55, 1.40 ]
Total events: 49 (Multidisciplinary), 54 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.55 (P = 0.58)
2 More than 6 months’ follow-up
Del Sindaco 2007 28/86 49/87 26.7 % 0.58 [ 0.40, 0.83 ]
Gonzalez-Guerrero 2014 14/59 18/58 15.9 % 0.76 [ 0.42, 1.39 ]
Mao 2015 18/165 41/175 19.0 % 0.47 [ 0.28, 0.78 ]
Subtotal (95% CI) 310 320 61.6 % 0.58 [ 0.44, 0.75 ]
Total events: 60 (Multidisciplinary), 108 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 4.11 (P = 0.000039)
Total (95% CI) 550 558 100.0 % 0.68 [ 0.50, 0.92 ]
Total events: 109 (Multidisciplinary), 162 (Usual care)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.68, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 2.53 (P = 0.011)
Test for subgroup differences: Chi2 = 2.35, df = 1 (P = 0.13), I2 =57%
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(1) Reported as the number of participants with more than the median number of HF-related readmissions, where median=0. Interpreted as being the number of
participants with more than 0 HF-readmissions.
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Analysis 3.7. Comparison 3 Multidisciplinary vs usual care, Outcome 7 All-cause readmissions - main
analysis.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 7 All-cause readmissions - main analysis
Study or subgroup Multidisciplinary Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bekelman 2015 55/187 59/197 19.3 % 0.98 [ 0.72, 1.34 ]
Cavusoglu 2017 (1) 47/125 43/123 17.7 % 1.08 [ 0.77, 1.50 ]
Del Sindaco 2007 (2) 48/86 65/87 27.2 % 0.75 [ 0.60, 0.93 ]
Ducharme 2005 45/115 66/115 21.9 % 0.68 [ 0.52, 0.90 ]
Gonzalez-Guerrero 2014 26/59 28/58 14.0 % 0.91 [ 0.62, 1.35 ]
Total (95% CI) 572 580 100.0 % 0.85 [ 0.71, 1.01 ]
Total events: 221 (Multidisciplinary), 261 (Usual care)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.70, df = 4 (P = 0.15); I2 =40%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
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(1) Reported as the number of participants with more than the median number of readmissions, where median=0. Interpreted as being the number of participants with
more than 0 readmissions.
(2) 24 months follow up
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Analysis 3.8. Comparison 3 Multidisciplinary vs usual care, Outcome 8 All-cause readmissions - subgroup
analysis by length of follow-up.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 8 All-cause readmissions - subgroup analysis by length of follow-up
Study or subgroup Multidisciplinary Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 6 months follow up
Cavusoglu 2017 (1) 47/125 43/123 17.7 % 1.08 [ 0.77, 1.50 ]
Ducharme 2005 45/115 66/115 21.9 % 0.68 [ 0.52, 0.90 ]
Subtotal (95% CI) 240 238 39.6 % 0.85 [ 0.54, 1.33 ]
Total events: 92 (Multidisciplinary), 109 (Usual care)
Heterogeneity: Tau2 = 0.08; Chi2 = 4.32, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.72 (P = 0.47)
2 more than 6 months follow up
Bekelman 2015 55/187 59/197 19.3 % 0.98 [ 0.72, 1.34 ]
Del Sindaco 2007 (2) 48/86 65/87 27.2 % 0.75 [ 0.60, 0.93 ]
Gonzalez-Guerrero 2014 26/59 28/58 14.0 % 0.91 [ 0.62, 1.35 ]
Subtotal (95% CI) 332 342 60.4 % 0.84 [ 0.70, 1.02 ]
Total events: 129 (Multidisciplinary), 152 (Usual care)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.40, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.79 (P = 0.073)
Total (95% CI) 572 580 100.0 % 0.85 [ 0.71, 1.01 ]
Total events: 221 (Multidisciplinary), 261 (Usual care)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.70, df = 4 (P = 0.15); I2 =40%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.01 0.1 1 10 100
Favours multidisciplinary Favours usual care
(1) Reported as the number of participants with more than the median number of readmissions, where median=0. Interpreted as being the number of participants with
more than 0 readmissions.
(2) 24 months follow up
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Analysis 3.9. Comparison 3 Multidisciplinary vs usual care, Outcome 9 Quality of life - MLHFQ.
Review: Disease management interventions for heart failure
Comparison: 3 Multidisciplinary vs usual care
Outcome: 9 Quality of life - MLHFQ
Study or subgroup Multidisciplinary Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bernocchi 2017 (1) 45 -11 (12.63) 35 -0.5 (11.9) 61.2 % -10.50 [ -15.90, -5.10 ]
Chen 2018 (2) 31 19.4 (12.2) 29 34.3 (14.4) 38.8 % -14.90 [ -21.68, -8.12 ]
Total (95% CI) 76 64 100.0 % -12.21 [ -16.43, -7.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 5.67 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours multidisciplinary Favours usual care
(1) change from baseline, measured in 45/56 intervention group and 35/56 control group participants
(2) mean score at end of 6 months follow up
A D D I T I O N A L T A B L E S
Table 1. Intervention components
Study Phone fol-
low-up
Largely
educa-
tional
Self-man-
agement
Weight
monitor-
ing
Dietary
advice
Ex-
ercise pro-
motion
Med-
ication re-
view
So-
cial/ psy-
chological
support
Dura-
tion of in-
terven-
tion (may
be shorter
than study
follow-
up)
Agren
2012
Y Y 3 months
Aldamiz-
Echevarria
2007
Y Y Y Y Y 15 days
Atienza
2004
Y Y Y Y Y Y Median
duration
509 days
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Table 1. Intervention components (Continued)
Bekelman
2015
Y Y Y Y Y Y 12 months
Berger
2010
Y Y Y Y 12 months
Bernocchi
2017
Y Y Y Y Y 4 months
Blue 2001 Y Y Y Y Up to 12
months
Bohmer
2011
Y Y 6 months
Brotons
2009
Y Y Y Y Y 12 months
Capomolla
2002
Y Y Y Y Y Y Not clear
Cavusoglu
2017
Y Y Y Y Y Y Y 6 months
Chen
2018
Y Y Y Y Y Y Y 6 months
Clark
2015
Y Y Y Y Y Y Y Y 6 months
Cline 1998 Y Y Y 12 months
DeBusk
2004
Y Y Y Y Y Y 1 year
de Souza
2014
Y Y Y Y Y Y 4 months
Del
Sindaco
2007
Y Y 24 months
Doughty
2002
Y Y Y Y Y 12 months
Ducharme
2005
Y Y Y Y 6 months
Dunbar
2014
Y Y Y Y Y Y Y 4.5
months
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Table 1. Intervention components (Continued)
Gonzalez-
Guerrero
2014
Y Y Y Y Y 6 months
Holland
2007
Y Y Y Y 6-8 weeks
Jaarsma
2000
Y Y Around 1
week
Jaarsma
2008
Y (basic
and inten-
sive inter-
ventions)
Y (inten-
sive inter-
vention)
Y (inten-
sive inter-
vention)
18 months
Kasper
2002
Y Y Y Y 6 months
Kimmel-
stiel
2004
Y Y Y Y Y 90 days +
longer for
unsta-
ble partici-
pants
Krumholz
2002
Y Y 12 months
Kwok
2008
Y Y Y Y Y 6 months
Lang 2018 Y Y Y Y Y Y Y 12 weeks
Leventhal
2011
Y Y Y Y Y 12 months
Lopez
2006
Y Y Y 12 months
Mao 2015 Y Y Y Y Y Y Y Inten-
sive phase
6 months,
then
phone fol-
low-
up every 2-
3 months;
overall fol-
low-up 24
months
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Table 1. Intervention components (Continued)
Mehralian
2014
Y 6 months
Mejhert
2004
Y Y Y Y 18 months
Naylor
2004
Y Y Y Y Y Y Interven-
tion
3 months,
follow-up
1 year
Nucifora
2006
Y Y Y 6 months
Ong 2016 Y Y Y Y Y Y 6 months
Rainville
1999
Y Y Y 3 months
Salehitali
2009
Y Y Y Y Y Y Y 6 months
Shively
2013
Y Y Y Y Y 6 months
Stewart
1999a
Y Y Interven-
tion con-
centrated
in first 2
weeks but
some
phone
contact up
to end of
follow-up
(6months)
Stromberg
2003
Y Y Y Y Y Y Y Y Unclear
Thomp-
son
2005
Y Y Y 6 months
Tsuchi-
hashi-
Makaya
2013
Y Y Y Y Y Y 6 months
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Table 1. Intervention components (Continued)
Tsuyuki
2004
Y Y Y Y Y Y 6 months
Wierz-
chowiecki
2006
Y Y Y Y Y Y Y 12 months
Yu 2015a Y Y Y Y 9 months
Table 2. Metaregression results
All-cause mortality All-cause readmissions HF readmissions
Intervention
component
Ratio of RR P value Ratio of RR P value Ratio of RR P value
Phone follow-up 0.72 (0.37 to 1.
38)
0.31 n/a n/a n/a n/a
Largely
educational
1.16 (0.80 to 1.
68)
0.42 0.93 (0.71 to 121) 0.53 0.65 (0.46 to 0.93) 0.02
Self-
management
1.03 (0.72 to 1.
46)
0.87 1.05 (0.81 to 1.36) 0.68 0.72 (0.48 to 1.07) 0.09
Weight manage-
ment
0.96 (0.68 to 1.
35)
0.81 1.32 (1.09 to 1.60) 0.008 1.53 (1.07 to 2.18) 0.03
Dietary advice 0.95 (0.67 to 1.
35)
0.78 1.15 (0.89 to 1.48) 0.26 1.29 (0.76 to 2.18) 0.31
Exercise promo-
tion
0.93 (0.66 to 1.
30)
0.65 0.95 (0.75 to 1.19) 0.61 0.89 (0.55 to 1.45) 0.61
Medication
review
0.86 (0.62 to 1.
20)
0.36 0.86 (0.71 to 1.03) 0.09 0.78 (0.50 to 1.22) 0.25
Social/psycho-
logical support
0.98 (0.59 to 1.
61)
0.92 0.92 (0.68 to 1.26) 0.58 0.76 (0.40 to 1.43) 0.35
HF: heart failure; RR: risk ratio
Phone follow-up was dropped from the model for all-cause readmissions and HF readmissions due to collinearity, so we could not
calculate ratio of RR or P value.
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A P P E N D I C E S
Appendix 1. Search strategies January 2018
CENTRAL via CRS Web
#1MeSH descriptor: [Heart Failure] explode all trees
#2((heart* or cardiac* or myocard*) near2 (fail* or insuff*))
#3(heart* near2 decomp*)
#4#1 or #2 or #3
#5MeSH descriptor: [Disease Management] this term only
#6(disease* near5 manag*)
#7MeSH descriptor: [Patient Care Management] this term only
#8MeSH descriptor: [Medication Therapy Management] this term only
#9MeSH descriptor: [Patient Care Team] explode all trees
#10MeSH descriptor: [Patient-Centered Care] this term only
#11(patient* near3 manag*)
#12(patient* near4 (care or caring))
#13(deliver* near2 care)
#14(manag* near5 care)
#15(management near5 program*)
#16(case near5 manag*)
#17MeSH descriptor: [Home Care Services] this term only
#18MeSH descriptor: [Home Care Services, Hospital-Based] this term only
#19(home near5 (intervention* or care))
#20(home near visit*)
#21homecare
#22MeSH descriptor: [Ambulatory Care] this term only
#23(ambulatory near2 (care or caring))
#24MeSH descriptor: [Patient Discharge] this term only
#25(discharg* near5 program*)
#26(practice next guideline*)
#27MeSH descriptor: [Practice Guidelines as Topic] this term only
#28(comprehensive* near5 (care or caring))
#29multidisciplinary
#30(treatment* near5 plan*)
#31(nurse* next led)
#32(discharg* near5 plan*)
#33#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32
#34#4 and #33
MEDLINE Ovid
1. exp Heart Failure/
2. ((heart* or cardiac* or myocard*) adj2 (fail* or insuff*)).tw.
3. (heart* adj2 decomp*).tw.
4. or/1-3
5. disease management/
6. (disease* adj5 manag*).tw.
7. Patient Care Management/
8. Medication Therapy Management/
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9. exp Patient Care Team/
10. Patient-Centered Care/
11. (patient* adj3 manag*).tw.
12. (patient* adj4 (care or caring)).tw.
13. (deliver* adj2 care).tw.
14. (manag* adj5 care).tw.
15. ((management or care) adj5 program*).tw.
16. (case adj5 manag*).tw.
17. Home Care Services/
18. Home Care Services, Hospital-Based/
19. (home adj5 (intervention* or care)).tw.
20. (home adj visit*).tw.
21. homecare.tw.
22. Ambulatory Care/
23. (ambulatory adj2 (care or caring)).tw.
24. Patient Discharge/
25. (discharg* adj5 program*).tw.
26. (practice adj guideline*).tw.
27. Practice Guidelines as Topic/
28. (comprehensive* adj5 (care or caring)).tw.
29. multidisciplinary.tw.
30. (treatment* adj5 plan*).tw.
31. (nurse* adj5 led).tw.
32. (discharg* adj5 plan*).tw.
33. or/5-32
34. 4 and 33
35. randomized controlled trial.pt.
36. controlled clinical trial.pt.
37. randomized.ab.
38. placebo.ab.
39. clinical trials as topic.sh.
40. randomly.ab.
41. trial.ti.
42. 35 or 36 or 37 or 38 or 39 or 40 or 41
43. exp animals/ not humans.sh.
44. 42 not 43
45. 34 and 44
Embase Ovid
1. exp heart failure/
2. ((heart* or cardiac* or myocard*) adj2 (fail* or insuff*)).tw.
3. (heart* adj2 decomp*).tw.
4. or/1-3
5. disease management/
6. (disease* adj5 manag*).tw.
7. patient care/
8. medication therapy management/
9. (patient* adj3 manag*).tw.
10. (patient* adj4 (care or caring)).tw.
11. (deliver* adj2 care).tw.
12. (manag* adj5 care).tw.
13. ((management or care) adj5 program*).tw.
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14. (case adj5 manag*).tw.
15. home care/
16. (home adj5 (intervention* or care)).tw.
17. (home adj visit*).tw.
18. homecare.tw.
19. ambulatory care/
20. (ambulatory adj2 (care or caring)).tw.
21. hospital discharge/
22. (discharg* adj5 program*).tw.
23. (practice adj guideline*).tw.
24. (comprehensive* adj5 (care or caring)).tw.
25. multidisciplinary.tw.
26. (treatment* adj5 plan*).tw.
27. (nurse* adj5 led).tw.
28. (discharg* adj5 plan*).tw.
29. or/5-28
30. 4 and 29
31. random$.tw.
32. factorial$.tw.
33. crossover$.tw.
34. cross over$.tw.
35. cross-over$.tw.
36. placebo$.tw.
37. (doubl$ adj blind$).tw.
38. (singl$ adj blind$).tw.
39. assign$.tw.
40. allocat$.tw.
41. volunteer$.tw.
42. crossover procedure/
43. double blind procedure/
44. randomized controlled trial/
45. single blind procedure/
46. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45
47. (animal/ or nonhuman/) not human/
48. 46 not 47
49. 30 and 48
50. limit 49 to embase
CINAHL
S53 S51 AND S52
S52 EM 20140212-20180109
S51 S32 AND S50
S50 S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49
S49 TX cross-over*
S48 TX crossover*
S47 TX volunteer*
S46 (MH “Crossover Design”)
S45 TX allocat*
S44 TX control*
S43 TX assign*
S42 TX placebo*
S41 (MH “Placebos”)
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S40 TX random*
S39 TX (doubl* N1 mask*)
S38 TX (singl* N1 mask*)
S37 TX (doubl* N1 blind*)
S36 TX (singl* N1 blind*)
S35 TX (clinic* N1 trial?)
S34 PT clinical trial
S33 (MH “Clinical Trials+”)
S32 S4 AND S31
S31 S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20
OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30
S30 (discharg* N5 plan*)
S29 (nurse* N2 led)
S28 (treatment* N5 plan*)
S27 multidisciplinary
S26 (comprehensive* N5 (care or caring))
S25 (practice N2 guideline*)
S24 (discharg* N5 program*)
S23 (MH “Patient Discharge”)
S22 (ambulatory N2 (care or caring))
S21 (MH “Ambulatory Care”)
S20 homecare
S19 (home N4 visit*)
S18 (home N5 (intervention* or care))
S17 (MH “Shared Services, Health Care”)
S16 (MH “Home Health Care”)
S15 (case N5 manag*)
S14 ((management or care) N5 program*)
S13 (manag* N5 care)
S12 (deliver* N2 care)
S11 (patient* N4 (care or caring))
S10 (patient* N3 manag*)
S9 (MH “Patient Centered Care”)
S8 (MH “Multidisciplinary Care Team”)
S7 (MH “Patient Care Plans+”)
S6 (disease* N5 manag*)
S5 (MH “Disease Management”)
S4 S1 OR S2 OR S3
S3 (heart* N2 decomp*)
S2 ((heart* or cardiac* or myocard*) N2 (fail* or insuff*))
S1 (MH “Heart Failure+”)
DARE via Cochrane Library
#1MeSH descriptor: [Heart Failure] explode all trees
#2((heart* or cardiac* or myocard*) near/2 (fail* or insuff*))
#3(heart* near/2 decomp*)
#4#1 or #2 or #3
#5MeSH descriptor: [Disease Management] this term only
#6(disease* near/5 manag*)
#7MeSH descriptor: [Patient Care Management] this term only
#8MeSH descriptor: [Medication Therapy Management] this term only
#9MeSH descriptor: [Patient Care Team] explode all trees
244Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#10MeSH descriptor: [Patient-Centered Care] this term only
#11(patient* near/3 manag*)
#12(patient* near/4 (care or caring))
#13(deliver* near/2 care)
#14(manag* near/5 care)
#15(management near/5 program*)
#16(case near/5 manag*)
#17MeSH descriptor: [Home Care Services] this term only
#18MeSH descriptor: [Home Care Services, Hospital-Based] this term only
#19(home near/5 (intervention* or care))
#20(home near visit*)
#21homecare
#22MeSH descriptor: [Ambulatory Care] this term only
#23(ambulatory near/2 (care or caring))
#24MeSH descriptor: [Patient Discharge] this term only
#25(discharg* near/5 program*)
#26(practice next guideline*)
#27MeSH descriptor: [Practice Guidelines as Topic] this term only
#28(comprehensive* near/5 (care or caring))
#29multidisciplinary
#30(treatment* near/5 plan*)
#31(nurse* next led)
#32(discharg* near/5 plan*)
#33#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32
Clinicaltrials.gov
Condition or disease: “heart failure”
Other: randomized
Intervention/treatment: (“disease management” OR “self care”) AND (other OR behavioral)
Applied filters: interventional, adult, older adult
ICTRP
heart failure AND disease management AND random*
WH A T ’ S N E W
Date Event Description
3 October 2018 New citation required but conclusions have not changed 22 new studies added. Conclusions unchanged but find-
ings now more robust due to increased number of stud-
ies and participants
2 October 2018 New search has been performed We re-ran the searches on 9 January 2018.
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H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 2, 2005
Date Event Description
23 December 2011 New citation required and conclusions have changed Updated with results of new searches. 16 new studies
included, and 10 from the original review removed as
not meeting revised inclusion criteria
Change in authorship reflects changes in team over
time
8 September 2008 Amended Converted to new review format
1 February 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
AT is guarantor of the review.
ST, and AT conceived and designed this update.
ST, NM and AT screened search results against inclusion criteria and carried out data extraction.
AT and NM appraised the risk of bias and GRADE rating of included studies.
AT wrote to authors of papers for additional information.
AT managed the data for the review, entered the data into Review Manager 5 (Review Manager 2014) and analysed the data.
AT and NM wrote the review, with ST and RT providing methodological perspective, clinical perspective and general advice.
D E C L A R A T I O N S O F I N T E R E S T
AT: none known
NM: none known
RT: none known
ST: none known
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane
Heart. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic
Reviews Programme, NIHR, NHS or the Department of Health, UK.
• This research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied
Health Research and Care North Thames at Bart’s Health NHS Trust (NIHR CLAHRC North Thames). The views expressed in this
article are those of the review author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social
Care, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
No protocol was published for this update, so we are including differences between the last update (Takeda 2012) and the current
update.
Changes in authorship have taken place since the protocol was registered, since two new researchers (AT, NM) joined the team and
others have moved on to other fields.
• The title of this review has been changed from ’Clinical Service Organisation for Heart Failure’ to reflect changes in terminology,
with an emphasis on disease management programmes rather than organisation of services.
• The objective of the review has been simplified by merging the original primary and secondary objectives into one.
• The original review contained four different mortality outcomes and four different readmission outcomes as primary outcomes,
and four secondary outcomes. For this update, we amended these to simplify the review and focus on user-important outcomes.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Aftercare [∗organization & administration]; Case Management [∗organization & administration]; Cause of Death; Chronic Disease;
Health Status; Heart Failure [mortality; ∗therapy]; Length of Stay; Patient Readmission [∗statistics & numerical data]; Practice Patterns,
Nurses’ [organization & administration]; Quality of Life; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
247Disease management interventions for heart failure (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
